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Abstract

Introduction: Mucosal human papillomavirus (HPV) infection is the most
common sexually transmitted infection (STI) and is associated with genitals warts,
anogenital cancers, and oropharyngeal cancers. Most sexually active persons will become
infected with HPV at some point in their lives, however few will develop HPV-related
diseases such as warts, lesions, or cancer as a result of the infection. It is unclear why a
minority of individuals fail to clear HPV infection and develop clinical disease. Due to
initial associations with cervical lesions, much research has focused on women. Th1 type
immune responses have been associated with successful response to HPV infection.
Factors such as psychological stress and sleep have been associated with immune
function. Stress has been associated with cervical lesions, however no study has
evaluated effects of stress or sleep on HPV infection. This research sought to examine the
associations between perceived stress and sleep problems with HPV prevalence,
incidence, and clearance among men.
Methods: Men were tested for 37 individual HPV genotypes every 6 months as
part of a large natural history study. A total of 426 men were followed over 1 to 4 visits.
Perceived stress was measured with a modified 4-item Perceived Stress Scale (PSS-4)
assessing stress in the past six months and was dichotomized into high (scores in the 4th
quartile) and low perceived stress. Self-reported sleep problems were measured by seven
likert-scale items and categorized as high (4th quartile of sleep problems scores),
vii

moderate (second and third quartiles; reference group), and low (first quartile). Three
HPV classifications were examined; men were categorized as positive for 'Any HPV' if
they tested positive for any of the 37 HPV genotypes in the study protocol, men were
categorized as positive for 'Oncogenic HPV' if they tested positive for any oncogenic
HPV type, and men were categorized as positive for 'Non-oncogenic HPV' if they tested
positive for any non-oncogenic HPV genotype.
In the prevalence analysis, men who had no detectable HPV infection with any of
the 37 types were the reference group in all analyses. Prevalence ratios and 95%
confidence intervals (95% CI) were calculated using Poisson regression with robust
variance. For HPV clearance and incidence, Cox regression with the robust sandwich
estimator was used to calculated hazard ratios and 95% confidence intervals.
Results: A total of 424 men had genotyping results available for the prevalence
analysis. High perceived stress was significantly associated with higher prevalence of any
HPV infection [PR =1.33 (95% CI: 1.06-1.68)] and oncogenic HPV infection [PR=1.53
(95% CI: 1.06-2.20)], adjusting for demographics, sexual behavior, and sleep problems.
High self-reported sleep problems was significantly associated with higher prevalence of
oncogenic HPV infection [PR=1.50 (95% CI:1.01-2.13)], adjusting for demographics,
sexual behavior, and perceived stress.
Perceived stress and self-reported sleep problems were not associated with
incidence of HPV infection. Perceived stress was not significantly associated with
clearance of HPV infection overall. Among men 50 and older however, men with high
stress were significantly less likely to clear any HPV infection than those with low stress
adjusting for demographics, HR=0.09 (95% CI: 0.02-0.49). Compared to men with
viii

moderate sleep problems, those with high sleep problems were significantly less likely to
clear an infection with any HPV type, HR=0.68 (95% CI: 0.49-0.94), or an oncogenic
HPV type, HR=0.51 (95% CI: 0.28-0.94), after adjustment for demographics and
perceived stress.
Discussion: This is the first study to examine associations between HPV infection
with perceived stress and self-reported sleep problems. It is also the largest study to
examine associations between these exposures and an infection outcome. Results suggest
that perceived stress and self-reported sleep problems have independent effects on HPV.
Evaluation of perceived stress, biological indicators of stress, objective measures of
sleep, and measurement of immune parameters may aid in further elucidating how stress
and sleep disturbance are related to HPV infection. Determination of modifiable factors
that can influence HPV infection may aid in the prevention of adverse disease outcomes
related to infection with this virus. Examining the impact of factors such as perceived
stress and sleep problems on HPV infection may aid in risk stratification of patients and
allow more targeted interventions among those most at risk for developing disease.
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Chapter 1: Introduction

Background and Significance
Infection with one of the approximately 40 mucosal types of human
papillomavirus (HPV) causes genital warts and is a necessary cause of cervical cancer1.
These HPV types are also associated with 60-90% of other anogenital cancers and 2530% of oropharyngeal cancers2. Genital warts and lesions can be treated with medical
procedures once they develop, however there is no antiviral treatment available that can
cure HPV infection3. Although most individuals will be infected with HPV at some point
in their lifetime, few will develop genital warts or cancer as a result of infection with
HPV. It is persistent infection with an oncogenic strain of HPV which can lead to
neoplastic lesions and eventually invasive cancers1. Few factors associated with HPV
persistence have been identified thus far. Studies of HPV viral clearance and HPV-related
diseases in women have found associations between smoking, oral contraceptive use,
infection with other STIs, diet, and host factors with HPV persistence1. However, few
studies have examined HPV persistence in men and factors that influence persistence in
men remain to be elucidated4. Research is needed to advance the understanding of factors
that influence HPV persistence in order to design interventions among men and women
infected with HPV and decrease the risk of progression to clinical disease. Identification
of factors associated with HPV persistence may also be beneficial in predicting patients
at highest risk of progression.
1

Psychoneuroimmunology (PNI) is the study of the bidirectional links between the
central nervous system (CNS), immune system, and endocrine system and the
implications of these interactions for health and disease5,6. Psychological factors may
play a role in the development and course of a range of diseases including infectious
diseases and several cancers6,7. Psychosocial factors could effect HPV persistence
through moderation of host immune responses8. Regression of genital warts and cervical
lesions have been associated with increased cell-mediated or Th1 type immune
responses9,10 and psychological stress has been associated with a decrease in Th1 type
immune responses and a shift towards a Th2 type immune response11. Thus, stress may
influence immunity and HPV persistence through this Th1 to Th2 shift. Sleep has also
been shown to modify immune response, possibly through shared regulatory molecules12.
Several studies have found an association between psychological stress and
cervical lesions. While results of the small number of studies examining stress and
cervical disease indicate an association, no study has examined the relationship between
stress and HPV infection. A single study reported an association between sleep quality
with number and percentage of helper T cells and percentage of cytotoxic T cells in
women with cervical disease3, however the effect of sleep on HPV infection has not been
evaluated.
Specific Aims
In order to further understand the possible role of stress and sleep on HPV
infection, this research builds on two prospective cohort studies of HPV in men to
examine the effect of self-reported perceived stress and sleep problems on HPV
prevalence and clearance in men. HPV-positive men are compared to HPV-negative men
2

at the baseline visit to examine associations between perceived stress and self-reported
sleep problems with prevalence of any HPV infection, oncogenic HPV infection, and
non-oncogenic HPV infection. Among HPV-positive men, those who have the same HPV
type detected at a following visit (type-specific persistent infection) are compared to men
who test HPV-negative (HPV clearance) to examine associations between perceived
stress and self-reported sleep problems with HPV clearance. Clearance of infection was
defined as two consecutive negative visits following testing positive for a specific HPV
type. Incidence of new type-specific HPV infection is also examined among HPV
negative men. Whereas many previous studies used standard Cox proportional hazards
models to evaluate HPV persistence, these methods do not allow all individual HPV
types to be modeled simultaneously. This study utilized an extended Cox model13 to
simultaneously model all HPV types individually, accounting for the correlation within
individual subjects, and calculated a common HR across all HPV types, all oncogenic
types, and all nononcogenic types.
Perceived stress was measured with a modified version of the 4 item perceived
stress scale (PSS-4)14 developed by Cohen et al. (1983)15. This scale attempts to measure
the degree to which situations are appraised as stressful and determine how
unpredictable, uncontrollable, and overloaded subjects consider their lives16. The threeitem version of the Jenkins Sleep Problems Scale (JSPS)17, which assess trouble falling
asleep, trouble staying asleep, and waking up feeling tired was included as wells as 4
items which assessed subjective sleep quality, sleep duration, ability to concentrate
during the day, and sleep problem distress.
The specific aims of this research were:
3

Aim 1: Examine associations between perceived stress and self-reported sleep problems
in the past 6 months with prevalence of HPV among all participants.
Aim 2: Evaluate the association between perceived stress and self-reported sleep
problems with clearance of HPV infection in a cohort of HPV-positive men and
incidence of HPV infection among HPV-negative men.
This study is the largest to evaluate the effect of perceived stress or self-reported
sleep problems with an infection outcome. Much of the previous research on perceived
stress and sleep disturbance has focused on effects of certain immune system measures
such as number and activity of NK cells and cytokines, however there is debate as to how
these changes could affect clinical outcomes such as clearance of an infection. This study
draws on multiple fields including epidemiology, biostatistics, PNI, and social science to
contribute to further understanding factors associated with HPV infection.

4

Chapter 2: Self-reported perceived stress and sleep problems are associated with
prevalence of Human Papillomavirus infection in U.S. men

Abstract
Human Papillomavirus (HPV) is a common sexually transmitted infection
associated with genital warts and ano-genital and oropharyngeal cancers. Th1 type
immune responses are associated with successful response to HPV infection; however
this does not occur for all people. Factors such as psychological stress and sleep have
been associated with immune function. Stress has been associated with cervical disease;
however no study has evaluated effects of stress or sleep on HPV infection. This study
examined associations between perceived stress, self-reported sleep problems, and HPV
prevalence in 426 men tested for 37 HPV genotypes. Perceived stress was measured with
a modified 4-item Perceived Stress Scale (PSS-4) assessing stress in the past six months
and was dichotomized into high (scores in the 4th quartile) and low perceived stress.
Self-reported sleep problems were measured by seven likert-scale items and categorized
as high (4th quartile of sleep problems scores), moderate (second and third quartiles;
reference group), and low (first quartile). High perceived stress was significantly
associated with higher prevalence of any HPV infection [PR =1.33 (95% CI: 1.06-1.68)]
and oncogenic HPV infection [PR=1.53 (95% CI: 1.06-2.20)] adjusting for
demographics, sexual behavior, and sleep problems. High self-reported sleep problems
were significantly associated with higher prevalence of oncogenic HPV infection
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[PR=1.50 (95% CI:1.01-2.13)] adjusting for demographics, sexual behavior, and
perceived stress. Results suggest that perceived stress and self-reported sleep problems
have independent effects on HPV. Further research is needed to examine whether
perceived stress and sleep problems are associated with HPV acquisition or duration of
infection.
Introduction
Ano-genital Human Papillomavirus (HPV) infection is the most common sexually
transmitted infection (STI). Most individuals who are sexually-active will become
infected in their lifetime18 with an estimated 6.2 million incident infections annually in
the US. There are approximately 40 HPV types which infect mucosal tissues such as the
anogenital and aerodigestive tracts1. These types are classified as high-risk types, those
associated with intraepithelial neoplasias and invasive carcinomas, or low-risk types,
those associated with non-cancerous lesions such as genital warts19. Infection with
multiple HPV types concurrently is common due to the shared route of sexual
transmission1.
Despite the high prevalence of HPV, most of those infected with HPV will mount
a successful immune response and clear the infection. Persistence of HPV infection
increases the risk of intraepithelial lesions and invasive carcinoma. In women the average
time to clearance of high risk types ranges from 8 to 14 months for oncogenic infection
and 5 to 6 months for non-oncogenic infection20. Few studies have examined HPV
incidence and clearance in men. In a large, longitudinal study conducted in Brazil,
Mexico, and the US, oncogenic types had a slightly lower incidence per 1000 person
months, 22.2 (95% CI: 19.8-24.9), compared to non-oncogenic types, 27.8 (95% CI:
6

24.8-31.0). Median time to clearance of oncogenic HPV was 7.2 months (95% CI: 6.79.5) compared to 7.6 (95% CI: 6.8-9.3) for non-oncogenic HPV types4.
Previous studies have found that stress can increase the severity and duration of
infectious diseases, promote reactivation of latent viruses, and affect vaccine response21.
Effects of stress on components of immunity including B and T cells, Natural Killer cells,
and cytokines have been observed. The immune response may differ depending on the
duration of the stress with brief stressors causing a shift from specific immunity to natural
immunity and chronic stressors leading to a shift from a Th1 towards a Th2 weighted
immune response7,11. Cytokines produced by these two subsets of T cells negatively
regulate each other and the development of one can suppress the other subset. Th1 cells
are involved in cell-mediated immunity, secreting interleukin (IL)-2, interferon (IFN)-γ,
and tumor necrosis factor (TNF)-β and activating macrophages. Th2 cells support
humoral immunity, activating B cell antibody responses and secreting IL-4, IL-5, IL-10,
and IL-1322. Although the exact mechanism of a successful immune response to HPV
infection is unknown Th1 immune responses have been associated with resolution of
HPV infection10, genital warts9, and cervical intraepithelial lesions and cancer23-25. Thus,
stress may impact HPV infection by suppressing Th1 immune responses. Although no
studies examined the association between stress and HPV infection associations of stress
with Herpes simplex virus type 2 (HSV-2), a viral STI, and cervical intraepithelial lesions
and cancer have been studied. A meta-analysis of 11 prospective studies found a
significant association between psychological stress and symptomatic genital HSV-2
recurrence26. A more recent study also found significant associations between daily
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distress and HSV-2 genital lesion frequency and onset27. Several studies report
associations between measures of stress and cervical lesions in women28-32.
Another factor which may be related to both stress and HPV infection is sleep
disturbance. Short sleep duration (less than five hours per night) and poor sleep quality
have been associated with increased risks of obesity, diabetes, hypertension, coronary
heart disease, and mortality33,34. Previous research suggests that partial sleep deprivation
(PSD) increases markers of systemic inflammation, TNF-α and IL-1β production, and
secretion of IL-634. In several observational studies where participant's regular sleep
patterns were measured via self-report or electroencephalograph (EEG), significant
associations with NK cell activity35,36 and NK cell number37 were found. In human
experimental studies of exposure to rhino virus38,39 sleep efficacy and duration were
associated with cold symptoms. The bi-directional communication between the brain and
immune system suggests a route by which sleep has the ability to influence the immune
system34.
In addition, correlations between stress and sleep have been found40, and it has
been suggested that sleep may mediate the relationship between stress and immunity37. If
stress and sleep have an effect on immunity this could have implications for the host's
ability to successfully respond to an HPV infection and subsequently influence disease
development. No study has previously evaluated the association between stress and HPV
infection or sleep and HPV infection. This study sought to examine the association
between measures of perceived stress and self-reported sleep problems with prevalence
of genital HPV infection among men.

8

Methods
Participants
This research is part of two larger studies of HPV in men, The Natural History of
HPV in Men (HIM) Study and the Cognitive and Emotional Responses (CER) Study.
Details of the parent studies have been reported previously. In brief, the HIM study is a
prospective natural history study of HPV in men from the Central Florida area, Sao
Paulo, Brazil and Morelos, Mexico4,41. Men are followed for 10 visits scheduled every six
months. At each visit a sexual history computer-assisted self interview (CASI)
questionnaire is administered, a visual inspection of the skin and external genitalia is
conducted, external genital skin samples are collected for HPV testing (current HPV
status), and participants are told results of the HPV test of their study visit 6 months prior
(previous HPV status). Men are recruited regardless of their HPV status and both HPVpositive and HPV-negative men were enrolled in the study. Because of the transient
nature of HPV infection men can transition from positive to negative and negative to
positive throughout the study.
A subset of HIM study participants in the US were invited to also participate in
the CER study. This is the behavioral arm of the larger HIM Study conducted among the
US cohort of men42, and assesses men’s cognitive and emotional responses to receiving
an HPV test result. At their first HIM study follow-up visit men are invited to participate
in the CER study. After providing informed consent men complete the CER CASI
approximately two to four weeks after completing their follow-up HIM study visit
(current HIM study visit). At the time men complete the CER questionnaire, they are
aware of their previous HPV status from approximately 6 months ago, but do not know
9

their current HPV status collected at the HIM visit 2-4 weeks prior to the CER visit.
Figure 1 presents a timeline of the HIM and CER studies.
As part of the CER study protocol men were followed over a total of 2 years and
completed the CER survey after each of 4 HIM visits. Items concerning perceived stress
and sleep problems were added to the CER CASI in June 2009. This was approximately
midway through CER participant recruitment and 55 participants had already completed
data collection of all 4 study visits. CER participants who completed the additional stress
and sleep items at least one time and within 45 days of their corresponding current HIM
visit were eligible for this analysis. Only data from participant’s first eligible CER visit
are included in this cross-sectional analysis of HPV prevalence. The study was approved
by the University of South Florida Institutional Review Board.
Measures
Perceived Stress
A modified version of the 4-item Perceived Stress Scale (PSS-4)16 was used to
assess self-reported perceived stress on the CER questionnaire. The PSS-4 was designed
to determine how unpredictable, uncontrollable, and overloaded individuals consider
their lives. Response categories are on a 5-point likert scale ranging from never to very
often16. Because participants in the HIM study are assessed every six months, yet the
original scale assesses stress in the previous month, PSS-4 items were modified to assess
stress in the past six months as reported in a comparison study of the 1-month and 6month PSS and a life events scale by43. Responses were summed to create a perceived
stress score with higher scores indicating higher perceived stress. Cronbach's alpha was
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0.65 for the stress scale. This is similar to 0.60, which was reported by the original
authors for the 4 item version of the scale16.
A previous study of stress and HSV in women found that only high levels of
stress were associated with lesion onset and stress was dichotomized as 'high' or 'low'27.
In the present study continuous stress scale scores ranged from 0 to 15 and were divided
into quartiles as follows; first quartile: 0 to 2, second quartile: 3 and 4, third quartile: 5
and 6, fourth quartile: 7 to 15. Inspection of the association between HPV prevalence and
perceived stress indicated that the relationship may not be linear. The highest prevalence
of HPV was observed among men in the highest quartile of perceived stress; men in the
lower three quartiles had a similar prevalence of HPV. Therefore, the perceived stress
exposure variable was categorized as high if participants scored in the highest quartile of
stress, and low if the perceived stress score was in the lower three quartiles.
Self-reported Sleep Problems
Seven items concerning subjective sleep problems were added to the CER
questionnaire. The three-item version of the Jenkins sleep problems scale (JSPS), a brief
reliable scale17, assessed trouble falling asleep, trouble staying asleep, and waking up
feeling tired. Four additional items assessed sleep duration, subjective sleep quality,
daytime functioning, and sleep distress. The subjective sleep quality item asks
participants to rate their sleep quality overall and is on a four point likert-scale ranging
from very good to very bad. The sleep duration item asks participants how many hours
and minutes of sleep they get at night. Duration of sleep time was divided into four
categories; ≥ 7 hours per night, 6 to <7 hours per night, 5 to <6 hours per night, and <5
hours per night, as in the coding for the Pittsburg Sleep Quality Index (PSQI)44. Two
11

four-point likert items: “Does not sleeping affect your ability to concentrate or get things
done during the day?”, and “How bothered are you by your sleep problems?” assessed
daytime functioning and sleep distress. Responses to the seven sleep items were summed
to create a sleep problems scale with higher scores indicating more sleep problems and
shorter sleep duration. Sleep problems items had good internal consistency (Cronbach's
alpha=0.79) and a factor analysis indicated all seven items loaded on a single factor.
Sleep problems scores demonstrated a different association with HPV prevalence
than perceived stress; men with scores in the second and third quartiles of the sleep
problems scale had the lowest prevalence of HPV. A follow-up study of weight gain and
sleep problems measured via the four-item JSPS found a similar pattern with men who
had the lowest summary sleep problems having the highest proportion of weight gain
(27% gained 5 kg or more) followed by those with the highest sleep problems (26%), and
men in the two middle categories (24% and 23%)45. Continuous sleep problems scale
scores ranged from 0 to 21 and were divided into quartiles as follows; first quartile: 0 to
4, second quartile: 5 and 6, third quartile: 7 to 10, fourth quartile: 11 to 21. The selfreported sleep problems exposure variable was categorized as low if participants scored
in the bottom 25% of sleep problems scores and high if participants scored in the top 25%
of sleep problems scores. Men in the middle 50% were categorized as moderate and
were selected as the reference group in all analyses because this group had the lowest
prevalence of HPV. Models using the four quartiles as separate groups were also
examined; the second quartile was the reference group as this group had the lowest HPV
prevalence. These models yielded the same results as the categorized sleep variable;
therefore we only present results of the categorized models.
12

Demographics and Sexual Behaviors
Single items assessed race, ethnicity, marital status, education, and health
insurance status. Age was calculated using the participant's date of birth and date of study
visit. Consistent with research among HIV-positive individuals46,47, men aged 50 and
older were categorized as 'older men.' Men younger than 50 were divided into four
approximately equal groups. At each study visit, participants are asked whether they had
sex in the past six months. Men who had sex were then asked about the number of
vaginal sex partners they had in the past six months. Number of vaginal sex partners was
categorized as zero (men who had not had sex in the past six months), one vaginal sex
partner, and two or more vaginal sex partners. Lifetime number of sex partners was
calculated by summing the number of female partners and male partners reported at each
study visit.
HPV Status
HPV status from participant's HIM study visit 2-4 weeks prior to assessing
perceived stress and sleep problems was the outcome for this analysis. Exfoliated penile
cell samples were tested for HPV DNA using polymerase chain reaction (PCR)
amplification of a fragment of the HPV L1 gene. Samples were tested for 37 individual
HPV genotypes41. Thirteen HPV types were categorized as oncogenic: 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, and 6848. The remaining HPV types were categorized as nononcogenic: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 66, 69, 70, 71, 72, 73, 81, 82, 83,
84, 89, and IS39.

13

Statistical Analysis
Three HPV classifications were examined. Men were categorized as positive for
'Any HPV' if they tested positive for any of the 37 HPV genotypes in the study protocol.
Men were categorized as positive for 'Oncogenic HPV' if they tested positive for any
oncogenic HPV type, regardless of also testing positive for a non-oncogenic HPV type.
Men were categorized as positive for 'Non-oncogenic HPV' if they only tested positive
for one or more non-oncogenic HPV genotypes. Samples that were positive for HPV on
PCR but failed to hybridize with a specific HPV type were considered unclassified. It is
unclear whether these were true HPV infections or coamplification of other genes41.
Among men in this sample those with only unclassified infections reported similar sexual
behaviors to men with no detectable HPV infection, therefore men with unclassified
infections were grouped with men who had no detectable HPV infection and formed the
reference group in all analyses. This approach has been used previously in the analysis of
HPV infection data49 and if considering men with unclassified HPV types as negative
were a misclassification of the outcome this would only attenuate associations.
A total of 426 men completed the study questionnaire; 425 completed all four of
the stress items of which 423 had HPV genotyping available for data analysis and 418
completed all of the sleep problems items of which 416 had HPV genotyping available.
Prevalence ratios and 95% confidence intervals (95% CI) were calculated using Poisson
regression with robust variance50 to examine associations between perceived stress, selfreported sleep problems, and HPV prevalence.
The majority of men in this sample reported their race as white (68%), their
ethnicity as non-Hispanic (82%), and were circumcised (79%) as determined by the study
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clinician. These factors were not significantly associated with HPV status in this sample
and were not included in multivariable models. Multivariable log-linear analyses for
perceived stress were adjusted for age in years, health insurance status, education, marital
status, and number of vaginal sex partners in the past six months. Smoking and alcohol
were not adjusted for in the stress multivariable model as we hypothesized that these
factors would likely be in the causal pathway from perceived stress to HPV status; i.e.
stress can affect smoking and alcohol which can then affect HPV status. A second
multivariable model also adjusted for sleep problems.
Multivariable analyses for self-reported sleep problems were adjusted for age in
years, health insurance status, education, marital status, lifetime number of sex partners,
smoking status, and alcohol consumption. A second multivariable model also adjusted for
perceived stress. The genmod procedure in SAS version 9.3 (Cary, NC) was used to
conduct statistical analyses.
Results
Characteristics of the Study Sample
Demographic variables by perceived stress and self-reported sleep problems can
be found in Table 2.1 and by HPV status in Table 2.4. Study participants ranged in age
from 18 to 70 (Mean = 31.2 ±13.4); 58 (14%) were aged 50 or older. Most men had
health insurance (74%), were single (59%), and had at least some college education
(88%). Of the participants, 234 were HPV negative, 99 were positive for an oncogenic
HPV type, and 91 men were positive for only a non-oncogenic HPV type (Table 2.1).
Among men with an oncogenic HPV infection, 67 were also positive for a non-oncogenic
type (data not shown). One hundred one men (24%) were categorized as having high
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stress and 324 were categorized as low stress. One hundred eleven men (27%) were
categorized as having low sleep problems, 208 as moderate sleep problems (50%), and 98
as high sleep problems (24%).
Table 2.1 presents demographic characteristics by perceived stress and selfreported sleep problems categories. There were significant differences in perceived stress
only by education and smoking. Self-reported sleep problems differed significantly by
age group, marital status, smoking status, and lifetime number of sexual partners.
Associations between Perceived Stress and HPV Prevalence
The prevalence of any HPV, oncogenic HPV, and non-oncogenic HPV was
higher among men with high stress compared to men with low stress (55% vs. 42% for
any HPV; 39% vs. 27% for oncogenic HPV; and 36% vs. 26% for non-oncogenic HPV).
High perceived stress was significantly associated with higher prevalence of any HPV
type (PR=1.31, 95% CI: 1.05-1.63), and any oncogenic HPV type (PR=1.45, 95% CI:
1.02-2.05). The association between perceived stress and prevalence of any HPV type
and any oncogenic HPV type remained significant after adjusting for demographics
(model 1: PR=1.37 (95% CI: 1.10-1.70) and PR=1.60 (95% CI: 1.14-2.24), respectively
and sleep problems (model 2: PR=1.33 ( 95% CI: 1.06-1.68) and PR=1.53 ( 95% CI:
1.06-2.20), respectively). Men with high perceived stress did not have a significantly
higher prevalence of any non-oncogenic HPV type (Table 2.3).
Adjustment for smoking and alcohol attenuated estimates slightly, but
associations between any HPV and oncogenic HPV remained significant (data not
shown). When stratified by previous HPV status from the prior 6 month study visit (data
not shown) the point estimates for high perceived stress were elevated for men who were
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previously positive (PR=1.11 for any HPV type and PR=1.21 for oncogenic HPV), and
for men who were previously negative (PR=1.73 for any HPV type and PR=2.07 for
oncogenic HPV) after adjusting for demographic factors.
Associations between Sleep Problems and HPV Prevalence
The prevalence of any HPV, oncogenic HPV, and non-oncogenic HPV was
higher among men with high sleep problems vs. moderate sleep problems (55% vs. 48%
for any HPV type; 43% vs. 33% for oncogenic HPV; and 32% vs. 28% for nononcogenic HPV). Corresponding prevalence ratios in univariate analysis were: any HPV
PR=1.40, (95% CI= 1.09-1.79), oncogenic HPV PR=1.89 (95% CI: 1.29-2.77), and nononcogenic HPV PR=1.34 (95% CI: 0.72-2.49). In multivariable analyses significance
persisted only for oncogenic HPV prevalence [model 1 PR=1.60 (95% CI:1.10-2.34) and
model 2 PR=1.50 (95% CI: 1.01-2.13)]. Low sleep problems were significantly
associated with prevalence of any HPV in model 1 [PR=1.27 (95% CI: 1.003-1.60)] and
model 2 [PR=1.27 (95% CI: 1.01-1.60)]. Low sleep problems were also associated with
oncogenic HPV in model 1 [PR=1.54 ( 95% CI: 1.04-2.26)] and Model 2 [PR=1.57
(95% CI: 1.07-2.30)]. Non-oncogenic HPV was not significantly associated with sleep
problems (Table 2.3).
Discussion
This study found a significantly higher prevalence of HPV infection among men
who reported high perceived stress and high self-reported sleep problems in the past 6
months compared to those reporting low perceived stress or moderate sleep problems.
The association with perceived stress and sleep problems was higher for oncogenic HPV
types than non-oncogenic types. Although relatively small this is the largest study to
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examine the association between perceived stress, self-reported sleep problems, and an
infection outcome.
In the present study a higher prevalence of HPV was only apparent in men scoring
in the upper quartile of PSS-4 scale scores. This is similar to a report by Strachan et al.
(2011)27, which found a non-linear association between daily psychological distress and
genital lesions due to HSV in a study of 19 women assessed daily. High stress predicted
HSV lesion development five days later compared to low stress and was associated with
frequency of lesion episodes in this group of women.
Associations with perceived stress were significant for any HPV infection and
oncogenic HPV infection. Although the point estimate for non-oncogenic HPV was
elevated (1.38 in the adjusted model) it did not reach statistical significance. Associations
between sleep problems and non-oncogenic HPV were also lower than for oncogenic
HPV types. Failure to achieve significance for perceived stress could be related to the
smaller number of men who only had a non-oncogenic infection; 91 men compared to 99.
It is also possible that the association with perceived stress and sleep problems is stronger
for oncogenic HPV infection than for non-oncogenic HPV infection. Oncogenic and nononcogenic HPV types differ in rates of acquisition and duration, two factors that
contribute to estimates of prevalence.
We hypothesized that smoking and alcohol were likely to lie in the causal
pathway from stress to HPV status. Associations remained after including these factors,
thus we do not believe the effect of perceived stress on HPV status is significantly
mediated by these behavioral factors. Perceived stress remained significantly associated
with any HPV infection and oncogenic HPV infection after adjusting for sleep problems.
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Sleep remained significantly associated with oncogenic HPV infection after adjusting for
stress. This suggests these exposures may independently influence HPV infection.
In this sample men with both low and high self-reported sleep problems were
more likely to be HPV positive than those with moderate sleep problems. The low
category included men who reported sleeping longer than 9 hours per night. Previous
research has reported associations between both long and short sleep duration with allcause mortality51, body mass index, diabetes, hypertension, and heart disease33. PSD has
been associated with lower antibody titers following administration of influenza
vaccine52. Sleep satisfaction has been associated with number and percentage of helper T
cells and percentage of cytotoxic T cells in women with cervical disease3. However this
is the first study to examine the association between an STI and self-reported sleep
problems. Research in this area is needed to further evaluate possible associations
between measures of sleep and HPV infection.
There are several limitations to this research. The majority of participants reported
their race as white. Additionally, men participating in a longitudinal study are a select
group and results may not be representative of all men. The course of HPV infection and
types of disease caused by HPV differ in men in women, and we cannot generalize these
results to women. In a meta-analysis by Chida and Mao (2009)26, female populations
showed a higher effect size between psychological stress and HSV-2 recurrence than the
total sample. Perceived stress, sleep problems, demographic characteristics, and sexual
behavior were self-reported and there is the possibility of misclassification bias and social
desirability bias. Measures of immune parameters, biological indicators of stress, and
drug/medication use were not collected. The PSS-4 is one of many ways to measure
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stress and is an abbreviated version of the original 14 item PSS. Stress is a complex
process and other measures of psychological stress such as coping style, social support,
and emotional responses may also be relevant. Sleep was measured with 7 self-reported
items. The use of full-length validated questionnaires or objective measurement of sleep
such as EEG may be helpful in elucidating the relationship between sleep disturbance and
HPV infection.
Participants were given results of their previous HPV test from genital samples
collected approximately 6 months prior at each visit, however at the time of survey
completion participants were unaware of their current HPV status. Men are told whether
they were positive or negative for any HPV type, but are not given information on the
type(s) of HPV for which they tested positive. If receipt of previous results affected
perceived stress and sleep problems or the reporting of these factors, then we would
expect self-reported previous HPV test results to be the most strongly associated with
perceived stress and sleep problems as this is what men believe their HPV status to be.
However, both previous laboratory HPV test result and self-reported previous HPV test
result were not significantly associated with perceived stress (p=0.07 and 0.22,
respectively) or self-reported sleep problems (p=0.48 and 0.85, respectively), and point
estimates were elevated for men previously positive and previously negative. Therefore,
we do not believe receipt of HPV test results affected reporting of perceived stress or
sleep problems.
This study found significant associations between high self-reported perceived
stress and sleep problems in the prior six months and prevalence of HPV. The association
between both stress and sleep problems with HPV was not linear, which may also be true
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for other outcomes of interest. Results suggest that perceived stress and self-reported
sleep problems may have independent effects on HPV prevalence. Evaluation of
perceived stress, biological indicators of stress, and measures of immune parameters may
aid in determining how stress and sleep are related to HPV infection. Determination of
modifiable factors that can influence HPV infection may aid in the prevention of adverse
disease outcomes related to infection with this virus. Future research is needed to
evaluate whether perceived stress and sleep problems are associated with incidence or
duration of HPV infection.
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Table 2.1. Demographic characteristics of men tested for genital HPV infection
who completed the first visit from the parent (CER) study and men who completed
additional stress and sleep items and were eligible for inclusion into the present analysis.

Age
18 to 20
21 to 22
23 to 31
32 to 49
≥50
Education
HS Diploma/GED or less
Some college, no degree
2-yr/4-yr/Graduate
degree
Health Insurance
No
Yes
Marital Status
Unmarried, Single
Unmarried, living with a partner
Married
Separated/ Divorced, widowed
Smoking status
Never
Former
Current
Alcohol
No alcohol
≤1 drink per day
>1 drink per day
Number of vaginal sex partners in the past 6 months
0
1
≥2
Lifetime number of sex partners
0
1-3
4-9
10-20
≥21
Decline to answer
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CER Totala
n (%)

Eligible for
Analysisa
n (%)

149
94
107
119
67

(28%)
(18%)
(20%)
(22%)
(13%)

93
81
95
99
58

(22%)
(19%)
(22%)
(23%)
(14%)

70
257

(13%)
(48%)

49
195

(12%)
(46%)

209

(39%)

182

(43%)

130
394

(25%)
(75%)

109
312

(26%)
(74%)

351
44
80
59

(66%)
(8%)
(15%)
(11%)

250
51
75
49

(59%)
(12%)
(18%)
(12%)

295
131
109

(55%)
(24%)
(20%)

244
94
87

(57%)
(22%)
(20%)

105
205
208

(20%)
(40%)
40%)

76
172
164

(18%)
(42%)
(40%)

146
182
120

(33%)
(41%)
(27%)

120
194
103

(29%)
(47%)
(25%)

27
129
122
131
102
25

(5%)
(24%)
(23%)
(24%)
(19%)
(5%)

22
100
98
101
88
17

(5%)
(23%)
(23%)
(24%)
(21%)
(4%)

Table 2.1 continued
HPV Status
Negative for HPV
297 (55%)
234 (55%)
Positive for Any HPV type
239 (45%)
190 (45%)
Positive for Oncogenic HPVa
99 (30%)
Positive for Non-oncogenic HPV onlyb
91 (28%)
Perceived Stress
1st quartile (0 to 2)
NA
92 (22%)
2nd quartile (3 and 4)
NA
124 (29%)
3rd quartile (5 and 6)
NA
108 (25%)
4th quartile (7 to 15)
NA
101 (24%)
Sleep
1st quartile (0 to 4)
NA
111 (27%)
2nd quartile (5 and 6)
NA
92 (22%)
3rd quartile (7 to 10)
NA
116 (28%)
4th quartile (11 to 21)
NA
98 (24%)
a
Total number of men who completed the first visit of the parent study (Cognitive and Emotional
Responses Study), n=536
b

Total number of men who completed additional perceived stress and sleep items and were eligible for
inclusion into the present analysis, n=426
NA: Not Applicable
Note: Numbers may not add to 426 due to some participants' selecting "Decline to answer";
percentages calculated including those who did not decline to answer
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Table 2.2. Demographic characteristics of men tested for HPV by self-reported perceived stress and sleep problems.

n
Age
18 to 20
21 to 22
23 to 31
32 to 49
≥50
Education
HS Diploma/GED or less
Some college, no degree
2-yr/4-yr/Graduate degree
Health Insurance
No
Yes
Marital Status
Unmarried, Single
Unmarried, living with a partner
Married
Separated/ Divorced, widowed
Smoking status
Never
Former
Current
Alcohol
No alcohol
≤1 drink per day
>1 drink per day

Low
(%)

Perceived stress
High
n (%)

75
67
71
69
42

(81%)
(83%)
(76%)
(70%)
(72%)

18
14
23
30
16

(19%)
(17%)
(24%)
(30%)
(28%)

28
155
141

(57%)
(79%)
(78%)

21
40
40

(43%)
(21%)
(22%)

p-value
0.22

n

Low
(%)

Sleep problems
Moderate
High
n (%)
n (%)

25
21
24
24
17

(27%)
(26%)
(26%)
(25%)
(31%)

60
41
47
38
22

(65%)
(51%)
(51%)
(40%)
(40%)

8
18
22
34
16

(9%)
(23%)
(24%)
(35%)
(29%)

13
58
40

(29%)
(30%)
(22%)

18
98
92

(40%)
(51%)
(51%)

14
35
49

(31%)
(18%)
(27%)

<0.01

0.10

0.89
82
239

(76%)
(77%)

26
73

(24%)
(73%)

197
40
57
30

(79%)
(78%)
(76%)
(61%)

52
11
18
19

(21%)
(22%)
(24%)
(39%)

195
71
58

(80%)
(76%)
(67%)

48
23
29

(20%)
(24%)
(33%)

59
127
129

(78%)
(74%)
(79%)

17
44
35

(22%)
(26%)
(21%)

0.12
33
76

(31%)
(25%)

44
161

(41%)
(53%)

30
68

(28%)
(22%)

62
16
19
14

(25%)
(32%)
(26%)
(29%)

134
26
34
14

(54%)
(52%)
(47%)
(29%)

50
8
19
20

(20%)
(16%)
(26%)
(42%)

75
14
21

(32%)
(15%)
(25%)

120
52
36

(50%)
(55%)
(43%)

43
28
27

(18%)
(30%)
(32%)

26
48
35

(37%)
(28%)
(21%)

34
84
82

(49%)
(49%)
(50%)

10
38
46

(14%)
(22%)
(28%)

0.06

0.02

0.04

<0.01

0.62
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p-value
<0.01

0.07

Table 2.2 continued
Number of vaginal sex partners in the past 6 months
0.64
0.50
0
90 (75%)
30 (25%)
32 (28%)
55 (48%)
28 (24%)
1
145 (75%)
48 (25%)
52 (27%)
100 (53%)
38 (20%)
≥2
82 80%)
21 (20%)
25 (24%)
48 (47%)
30 (29%)
Lifetime number of sex partners
0.10
0.02
0
16 (73%)
6 (27%)
8 (38%)
11 (52%)
2 (10%)
1-3
83 (83%)
17 (17%)
30 (30%)
53 (53%)
17 (17%)
4-9
74 (78%)
21 (22%)
23 (24%)
55 (59%)
16 (17%)
10-20
79 (80%)
20 (20%)
27 (28%)
45 (46%)
26 (27%)
≥21
58 (67%)
29 (33%)
16 19%)
35 (42%)
32 (39%)
Decline to answer
11 (65%)
6 (35%)
6 (38%)
8 (20%)
2 (13%)
HPV Status
Negative for HPV
189 (81%)
45 (19%)
57 (25%)
126 (56%)
44 (19%)
Positive for Any HPV type
135 (71%)
54 (29%)
0.02c
53 (28%)
82 (43%)
54 (55%) 0.03c
Positive for Oncogenic HPVa
70 (71%)
29 (29%)
0.04c
28 (29%)
37 (38%)
33 (34%) 0.01c
Positive for Non-oncogenic HPV onlyb
65 (72%)
25 (28%)
0.09c
25 (27%)
45 (49%)
21 (23%) 0.60c
a
Number and percentage of men positive for an oncogenic HPV type regardless whether they were also positive for a non-oncogenic type, percentage of men
positive does not include participants with only an non-oncogenic HPV type
b

Number and percentage for men only positive for a non-oncogenic HPV type, percentage of men positive does not include participants with an oncogenic HPV
type
c

P-value calculated by comparing positive men to men negative for all HPV types
Note: Numbers may not add to 426 due to some participants' selecting "Decline to answer"; percentages calculated including those who did not decline to answer
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Table 2.3. Associations between perceived stress, sleep problems, and prevalence of any
HPV type, any oncogenic HPV type, and any non-oncogenic HPV type among men
tested for HPV.

Prev.
(%)
Perceived Stressa
Low
High

41.7
54.6

Sleep problemsb
Low
Moderate
High

48.2
39.4
55.1

Univariate
PR (95% CI)

1.31

1.00
(1.05-1.63)

Any HPV Type
Multivariable 1
PR (95% CI)

1.37

1.00
(1.10-1.70)

1.22

Prev.
(%)

(0.95-1.58)
1.27 (1.003-1.60)
1.00
1.00
1.40 (1.09-1.79)
1.21 (0.95-1.53)
Any Oncogenic HPV Type
Univariate
Multivariable 1
PR (95% CI)
PR (95% CI)

Perceived Stressa
Low
High

27.0
39.2

1.45

Sleep problemsb
Low
Moderate
High

32.9
22.7
42.9

1.00
(1.02-2.05)

1.60

1.00
(1.14-2.24)

Multivariable 2
PR (95% CI)

1.33
1.27
1.16

1.00
(1.06-1.68)
(1.01-1.60)
1.00
(0.91-1.48)

Multivariable 2
PR (95% CI)

1.53

1.00
(1.06-2.20)

1.45

Prev.
(%)

(0.96-2.20)
1.54 (1.04-2.26)
1.57 (1.07-2.30)
1.00
1.00
1.89 (1.29-2.77)
1.60 (1.10-2.34)
1.50 (1.01-2.13)
Any Non-oncogenic HPV Type
Univariate
Multivariable 1
Multivariable 2
PR (95% CI)
PR (95% CI)
PR (95% CI)

Perceived Stressa
Low
High

25.6
35.7

1.40

Sleep problemsb
Low
Moderate
High

30.5
26.3
32.3

1.23
1.34

1.00
(0.96-2.04)
(0.69-2.19)
1.00
(0.72-2.49)

1.40
1.38
1.01

1.00
(0.96-2.04)
(0.68-2.80)
1.00
(0.45-2.23)

1.38
1.16
1.23

1.00
(0.93-2.05)
(0.77-1.75)
1.00
(0.80-1.89)

a

Multivariable 1 model adjusted for age, insurance, education, marital status, and number of vaginal sex
partners in the past 6 months, Multivariable 2 model additionally adjusted for sleep category
b

Multivariable 1 model adjusted for age, insurance, education, marital status, smoking status, alcohol
consumption and lifetime number of sex partners, Multivariable 2 model additionally adjusted for
perceived stress category
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Table 2.4. Demographic characteristics of men tested for genital HPV infection by prevalence of any HPV type, oncogenic HPV type,
and non-oncogenic HPV type.
Total Sample
n
Age
18 to 20
21 to 22
23 to 31
32 to 49
≥50
Education
HS Diploma/GED or less
Some college, no degree
2-yr/4-yr/Graduate degree
Health Insurance
No
Yes
Marital Status
Unmarried, Single
Unmarried, living with a partner
Married
Separated/ Divorced, widowed
Smoking status
Never
Former
Current

(%)

Any HPVa
n

p-valueb

(%)

Oncogenicc
n

(%)

0.01
93
81
95
99
58

(22%)
(19%)
(22%)
(23%)
(14%)

31
31
46
56
26

(33%)
(38%)
(48%)
(57%)
(46%)

(12%)
(46%)
(43%)

27
80
83

15
17
25
31
11

(56%)
(41%)
(46%)

(26%)
(74%)

57
130

(59%)
(12%)
(18%)
(12%)

106
23
37
24

29
68

(42%)
(45%)
(50%)
(50%)

(57%)
(22%)
(20%)

98
40
52

0.09
28
62

(35%)
(26%)

(29%)
(28%)
(29%)
(37%)

0.29
47
12
22
10

(25%)
(30%)
(37%)
(29%)

0.03
49
24
26

27

(42%)
(21%)
(32%)

0.80
59
11
15
14

(40%)
(43%)
(60%)

0.02
15
30
46

(36%)
(27%)

<0.01
244
94
87

(21%)
(22%)
(30%)
(37%)
(33%)

0.13

0.59
250
51
75
49

0.14
16
14
21
25
15

(36%)
(30%)
(27%)

(25%)
(31%)
(43%)

p-valueb

(%)

0.59
12
50
37

(53%)
(42%)

n

(19%)
(25%)
(34%)
(42%)
(26%)

0.05
109
312

Non-oncogenicd

0.03

0.15
49
195
182

p-valueb

0.01
49
16
26

(25%)
(23%)
(43%)

Table 2.4 continued
Alcohol
0.38
0.36
0.69
No alcohol
76 (18%)
29 (39%)
15 (25%)
14 (23%)
≤1 drink per day
172 (42%)
76 (44%)
38 (28%)
38 (28%)
>1 drink per day
164 (40%)
79 (48%)
44 (34%)
35 (29%)
<0.01
Number of vaginal sex partners in the past 6 months
<0.01
0.01
0
120 (29%)
39 (33%)
16 (16%)
23 (22%)
1
194 (47%)
77 (40%)
35 (23%)
42 (27%)
≥2
103 (25%)
69 (67%)
43 (56%)
26 (43%)
Lifetime number of sex partners
<0.01
<0.01
<0.01
0
22 (5%)
4 (18%)
2 (10%)
2 (10%)
1-3
100 (23%)
11 (11%)
4 (4%)
7 (7%)
4-9
98 (23%)
43 (44%)
26 (32%)
17 (24%)
10-20
101 (24%)
66 (65%)
31 (47%)
35 (50%)
≥21
88 (21%)
56 (64%)
29 (48%)
27 (47%)
Decline to answer
17 (4%)
10 (63%)
7 (54%)
3 (33%)
Perceived Stress
0.10
0.13
0.27
1st quartile (0 to 2)
92 (22%)
38 (41%)
23 (30%)
15 (22%)
2nd quartile (3 and 4)
124 (29%)
56 (45%)
28 (29%)
28 (29%)
3rd quartile (5 and 6)
108 (25%)
41 (38%)
19 (22%)
22 (25%)
4th quartile (7 to 15)
101 (24%)
54 (55%)
29 (39%)
25 (36%)
Sleep
0.06
0.01
0.60
1st quartile (0 to 4)
111 (27%)
53 (48%)
28 (33%)
25 (30%)
2nd quartile (5 and 6)
92 (22%)
34 (37%)
17 (23%)
17 (23%)
3rd quartile (7 to 10)
116 (28%)
48 (41%)
20 (23%)
28 (29%)
4th quartile (11 to 21)
98 (24%)
54 (55%)
33 (43%)
21 (32%)
a
Men who were positive for any of the 37 HPV types, n=190 (45%)
b
Chi-square test compared to men HPV negative
c
Men positive for an oncogenic HPV type regardless whether they were also positive for a non-oncogenic type, n=99 (30%); percentage of men positive does not
include participants with only an non-oncogenic HPV type
d
Men only positive for a non-oncogenic HPV type, n=91 (28%); percentage of men positive does not include participants with an oncogenic HPV type
Note: Numbers may not add to 426 due to some participants' selecting "Decline to answer"; percentages calculated including those who did not decline to answer
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Figure 1.1. Timeline of HIM and CER study visits.
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Chapter 3: Self-reported Perceived Stress and Sleep Problems: Associations with
Incidence and Clearance of Human Papillomavirus Infection in U.S. Men

Abstract
The 40 types of Human Papillomavirus (HPV) which can infect mucosal tissue
are the most common sexually transmitted infection (STI) and are associated with anogenital warts and cancers. Most infected individuals will clear the infection and HPV
DNA of a specific type will no be longer detected, however the virus will persist in some.
We previously reported associations between perceived stress and self-reported sleep
problems with prevalence of HPV infection in men. Here we examined the association
between these factors and clearance and incidence of HPV infection. Cox regression
using a robust sandwich estimator was used to calculate hazard ratios (HR) and 95%
confidence intervals (95% CI). A total of 426 men completed 997 study visits. Neither
perceived stress nor self-reported sleep problems was significantly associated with
incidence of HPV infection. Perceived stress was not significantly associated with
clearance of infection. However, among men 50 and older, those with high stress were
significantly less likely to clear any HPV infection in adjusted models, HR=0.09 (95%
CI: 0.02-0.49). Compared to men with moderate sleep problems, those with high sleep
problems were significantly less likely to clear an infection with any HPV type, HR=0.68
(95% CI: 0.49-0.94), or an oncogenic HPV type, HR=0.51 (95% CI: 0.28-0.94), after
adjusting for demographics and perceived stress. Determining the impact of factors such
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as perceived stress and sleep problems on HPV infection may aid in risk stratification and
secondary prevention efforts among those HPV-positive.
Introduction
Over 100 types of human papillomavirus (HPV) have been identified, of which
approximately 40 can infect mucosal tissue such as the anogenital and aerodigestive
tracts. Together these mucosal HPV types are the most common sexually transmitted
infection (STI). Low risk, or non-oncogenic, HPV types are associated with genital warts.
High risk, or oncogenic, HPV types are a necessary, but insufficient cause of cervical
cancer. Although much research has focused on cervical cancer, these types have also
been associated with other anogenital cancers and cancers of the head and neck19.
The HPV virus has developed multiple strategies to evade the host's immune
system such as confining viral protein expression to keratinocytes and downregulation of
IFN-α gene expression. However, in most infected individuals HPV-specific immune
responses will eventually clear the infection to where HPV DNA of a specific type can no
longer be detected20,53. Although the exact mechanism remains to be elucidated54, a
successful immune response has been characterized by strong, local, cell-mediated
immune responses20.
HPV persistence is generally defined as detection of the same HPV type at least
two times over a specified time interval. However, there is no consensus on what time
interval should be considered “meaningful” persistence1. It is uncertain whether the
infection is entirely cleared by the host or the virus becomes latent and undetectable55.
Although infection with oncogenic HPV is necessary in the progression of cervical
cancer, studies of HPV viral clearance and HPV-related diseases in women have found
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several factors associated with HPV persistence including smoking, oral contraceptive
use, infection with other STIs, diet56, and host factors such as genes for HLA class I and
II. Viral factors such as HPV type, viral load, and viral integration are also associated
with disease outcomes1.
A few studies have examined HPV incidence and clearance in men. Factors
previously associated with HPV clearance in men include circumcision status, lifetime
number of sex partners, infection with multiple HPV types, age, and country of
residence4,49,57-61. We previously reported significant associations between perceived
stress and self-reported sleep problems with HPV prevalence in men.
The purpose of this report is to examine associations between perceived stress and
self-reported sleep problems with incidence and clearance of genital HPV infection in
men. We hypothesized that clearance, rather than incidence, would be associated with
perceived stress and self-reported sleep problems. Incidence of HPV infection in men has
previously been associated with sexual behaviors4,57-59 and exposure to the virus is likely
the most important factor in acquisition. Among men who become positive for HPV,
stress and sleep may impact clearance via a negative impact on immune responses11,34.
Methods
Participants
Men participating in the Natural History of HPV in Men (HIM) Study complete
study visits every 6 months where a sexual history computer-assisted self interview
(CASI) questionnaire is administered, a visual inspection of the skin and external
genitalia is conducted, and external genital skin samples are collected for HPV testing4. A
subset of HIM study participants in the Central Florida area were invited to also
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participate in The Cognitive and Emotional Responses (CER) Study42. This separate
study assessed additional behavioral factors among HIM study participants. Men
completed the CER CASI approximately 2-4 weeks after each HIM study visit. CER men
were recruited into this study at their third HIM study visit and completed the CER
questionnaire 4 times over approximately 2 years. Items concerning perceived stress and
self-reported sleep problems were added to the CER CASI in June 2009 (midway through
CER participant recruitment). All CER visits including the additional items which were
completed within 45 days of the corresponding HIM visit were eligible for the present
analysis. Additional details of this study can be found in the prevalence manuscript. This
study was approved by the University of South Florida Institutional Review Board.
Measures
Perceived Stress
Self-reported perceived stress in the past 6-months was assessed via a modified
version of the 4-item Perceived Stress Scale (PSS-4). This scale was designed to
determine how unpredictable, uncontrollable, and overloaded individuals consider their
lives with 5-point likert scale response categories ranging from never to very often for all
4 items16. Participants completed this scale at each CER study visit. Stress was
dichotomized and categorized as high if participants scored a 7 or above (top 25% of
stress scores) and low if the perceived stress score was from 0 to 6 (bottom 75%).
Self-reported Sleep Problems
Seven items assessed self- reported sleep problems with responses on a four-point
likert-scale. The three-item version of the Jenkins sleep problems scale (JSPS) assessed
trouble falling asleep, trouble staying asleep, and waking up feeling tired17. Four
33

additional items assessed sleep duration, subjective sleep quality, daytime functioning,
and sleep distress. Self-reported sleep problems were categorized as low if participants
scored between 0 and 4 (bottom 25%), moderate if they scored from 5 to10 (middle
50%), and high if they scored from 11 to 21 (top 25%). Men in the moderate category
formed the reference group in all analyses.
Demographics and Sexual Behaviors
Marital status, education, and health insurance status were assessed with single
items. Age was calculated using the date of birth and date of study visit. Men aged 50 and
older were categorized as 'older men' in this study. This categorization of men aged 50
and older is consistent with research conducted among HIV-positive persons46,47. Men
younger than 50 were categorized as 18 to 29 or 30 to 49. Men who reported having had
sex in the past 6 months were asked to report the number of vaginal sex partners during
this time. Number of vaginal sex partners was divided into three categories: zero (men
who had not had sex in the past six months), 1 vaginal sex partner, and 2 or more vaginal
sex partners. Lifetime number of sex partners was calculated by summing the total
number of female and male partners participants reported at each visit.
HPV Status
Polymerase chain reaction (PCR) amplification of a fragment of the HPV L1 gene
was used to test exfoliated penile cell samples for HPV DNA. Each penile sample was
tested for 37 individual HPV genotypes41. Thirteen HPV types were categorized as
oncogenic: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 6848. The remaining HPV
types were categorized as non-oncogenic: 6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67, 66,
69, 70, 71, 72, 73, 81, 82, 83, 84, 89, and IS39.
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Statistical Analysis
Men who tested positive for any of the 37 HPV genotypes in the study protocol
were categorized as positive for 'Any HPV.' Men who tested positive for any oncogenic
HPV type were categorized as positive for 'Oncogenic HPV' and men who tested positive
for non-oncogenic HPV genotypes were categorized as positive for 'Non-oncogenic
HPV.' Men could contribute to the oncogenic and non-oncogenic analyses if they were
positive for both types of HPV.
Clearance of an HPV infection was defined as two consecutive negative tests
following a positive test for a specific HPV type. Infections were considered prevalent if
they had been detected at any previous visit or if it was detected at the first HIM study
visit. If an infection was first detected at a participants final eligible visit it was not
analyzed for clearance. Incidence of an HPV infection was defined as a positive test for
an HPV type not detected at baseline or any previous follow-up visit.
Cox regression62 was used to calculate hazard ratios (HR) and 95% confidence
intervals (CI). Because it is possible for men to be infected with multiple HPV types,
type-specific HPV clearance and incidence was analyzed and all infections were included
in the analysis. To account for within-subject correlations, the robust sandwich estimator
was used for the covariance matrix13. Stratified analyses were conducted to assess
possible effect modification. The phreg procedure in SAS version 9.3 (Cary, NC) was
used to conduct statistical analyses. Schoenfeld residual plots did not indicate substantial
violation of the proportional hazards assumption.
Demographic and sexual behaviors included in our analysis of HPV prevalence
were also adjusted for in clearance and incidence multivariable models. Multivariable
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analyses for perceived stress were adjusted for age in years, health insurance status,
education, marital status, and number of vaginal sex partners in the past six months. A
second multivariable model also adjusted for sleep problems. Multivariable analyses for
self-reported sleep problems were adjusted for age in years, health insurance status,
education, marital status, lifetime number of sex partners, smoking status, and alcohol
consumption. A second multivariable model also adjusted for perceived stress. Most
participants were white (68%), non-Hispanic (82%), and were circumcised as determined
by a HIM study physician (79%). As in our previous analysis of HPV prevalence, these
factors were not significantly associated with clearance or incidence of an HPV infection
in this sample and were not included in multivariable models.
Results
Characteristics of the Study Sample
Data on perceived stress and self-reported sleep problems were collected from
June 2009 to July 2011. There were a total of 997 eligible visits among 426 men. Total
follow-up time per participant ranged from 4.4 to 32.1 months with a mean of 15.5
(SD=6.6) months. The mean age of participants was 31.2 (SD=13.4) with a range of 18 to
70. The majority of participants reported they had health insurance (74%), were single
(59%), and had at least some college education (88%). There were a total of 336 incident
infections detected among 163 men during follow-up (Table 3.1). Number of incident
infections ranged from 1 to 9 with a mean of 2.1 infections per person. There were 554
individual HPV infections detected at baseline or during follow-up among 222 men that
were analyzed for clearance. Number of infections per person ranged from 1 to 10 with a
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mean of 2.5 infections per person. Overall, 53% of HPV infections cleared during followup (Table 3.1).
Associations between Perceived Stress and HPV Incidence and Clearance
Perceived stress was not significantly associated with incidence of any HPV type,
oncogenic HPV, or non-oncogenic HPV (data not shown). Perceived stress was not
significantly associated with clearance of any HPV type (Table 3.2), oncogenic HPV
(Table 3.3), or non-oncogenic HPV (Table 3.4). However, among men 50 and older,
those with high stress were significantly less likely to clear any HPV infection, HR=0.09
(95% CI: 0.02-0.49) after adjusting for demographics.
Associations between Self-reported Sleep Problems and HPV Incidence and Clearance
Self-reported sleep problems were not significantly associated with incidence of
any HPV type, oncogenic HPV, or non-oncogenic HPV (data not shown). Men with high
sleep problems were significantly less likely to clear an infection with any HPV type
compared to men with moderate sleep problems, HR=0.68 (95% CI: 0.49-0.94) (Table
3.2), and significantly less likely to clear an oncogenic HPV infection compared to men
with moderate sleep problems after adjusting for demographics, HR=0.59 (95% CI: 0.360.98) (Table 3.3), and after additional adjustment for stress, HR=0.51 (95% CI: 0.280.94). New infections were more likely to clear among men with low or high selfreported sleep problems compared to men with moderate sleep problems with this
difference reaching statistical significance among men with low self-reported sleep
problems for non-oncogenic HPV infection, HR=1.89 (95% CI: 1.06-3.38). Among men
with prevalent infections, those with low or high sleep problems were less likely to clear
HPV however, these differences did not reach statistical significance.
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Discussion
We found significant associations between self-reported sleep problems and
clearance of HPV infection in this cohort of men. Perceived stress was only significantly
associated with reduced clearance of any HPV infection among men aged 50 and older.
Neither perceived stress or self-reported sleep problems were significantly associated
with incidence of HPV infection.
Associations between perceived stress and self-reported sleep problems could
differ by age group and prevalence of HPV infection. It is possible that the effects of
stress and sleep disturbance could differ depending on where a person is in the course of
HPV infection. Perceived stress and self-reported sleep problems many not affect HPV
clearance among those with new infections. If stress and sleep disturbance have a
negative impact on HPV clearance among prevalent infections then these factors may
also be associated with HPV-related diseases as it is persistent infection with oncogenic
HPV types that has been associated with cervical cancer in women1. A retrospective
cohort study conducted using national registers in Sweden found significant associations
between loss of a child and subsequent development of infection related cancers in
parents . Associations were particularly elevated for HPV-related and possibly HPVrelated cancers with the highest significant relative risk estimates obtained for cancers of
the cervix, larynx, and eye63. Future studies which include longer follow-up of HPVinfected persons may aid in determining how stress and sleep disturbance can effect HPV
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clearance among recently detected infection and infections of longer duration as well as
possible associations with HPV-related diseases.
Most men in this study were younger and the number of men in the 50 and older
age group was limited. Despite the small sample of older men, significance was reached
for any HPV infection. Among older men, participants with high stress were significantly
less likely to clear an HPV infection compared to those with low stress. Although there
has been little research which examined differences in the association between stress and
measures of immunity or disease by age, Kiecolt-Glaser et al. (2001)64 postulated that
ageing and stress could interact with the effect of stress on immunity greater among older
adults. A study of immune response to influenza vaccine found that the effect of chronic
stress in the form of caregiving for a spouse with dementia was more strongly associated
with non-response post vaccination among participants >70 compared to those younger
than 70 years of age65. A review of studies assessing associations between the stress of
caregiving with measures of endocrinological and immunologic dysregulation reported
more consistent findings among elderly populations than non-elderly caregivers66.
Although significant associations were observed, this study had several
limitations. There was not an inadequate sample size to determine associations within all
subgroups of age and prevalence of infection. Men participating in longitudinal studies
such as the HIM Study are a select group and the majority of participants were white,
therefore results may not be generalizable to all men with HPV infection. Immune
parameters, biological indicators of stress, and drug or medication use was not collected
and we cannot assess the impact of these factors. Measures of perceived stress, sleep
problems, demographics, and sexual behaviors were all self-reported. There is no single
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method for assessing patient reported stress or sleep disturbance. Stress is a complex
factor and the PSS-4 is one of many methods for measuring the concept of stress. Sleep
disturbance can also be measured through numerous aspects of sleep dysfunction. In the
present study, sleep problems was measured subjectively using participant self-report.
Objective measures of sleep such as electroencephalographic (EEG) assessment may aid
in exploring the relationship between infection and sleep disturbance.
This is the largest study to examine associations between perceived stress and
sleep problems with clearance of an infection. High self-reported sleep problems were
significantly associated with decreased clearance of HPV among this sample of men.
Stress may also be associated with clearance of HPV infection among certain groups of
men. The direction of the associations differed by age group and prevalence of infection,
which could be a consideration in future research to ensure adequate sample sizes of
specific subgroups. Further research is needed to confirm associations of these factors
with HPV infection among women. Future studies may examine associations of these
factors with HPV-related diseases such as cervical, anal, or penile lesions in men and
women. Determining modifiable behavioral factors associated with HPV clearance will
be important in secondary prevention efforts to decrease the burden of HPV-related
diseases among HPV-positive individuals. Examining the relationships between
participant reported perceived stress and sleep disturbance, objective measures of sleep,
salivary cortisol levels (widely used as a biomarker for psychological stress67), immune
parameters such Natural Killer cells and cytokines, and HPV infection could provide a
better understanding of the mechanisms by which these exposures influence HPV
infection. Examining the impact of factors such as perceived stress and sleep problems on
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HPV infection may aid in risk stratification of patients and allow more targeted efforts
among those at greatest risk of developing clinical disease.
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Table 3.1. Number of incident infections, total number of infections, and percent of
infections that cleared during follow-up.

Incidence
# Incident
Infections
Any HPV
Oncogenic
16
18
31
33
35
39
45
51
52
56
58
59
68
Non-oncogenic
6
11
26
40
42
53
54
55
61
62
64
66
67
69
70
71
72
73
81
82
83
84
89
139

336
136
22
8
5
1
4
20
8
23
11
6
3
21
4
200
17
2
1
8
5
14
13
7
12
21
1
24
3
2
4
1
4
10
3
4
6
21
16
1

Clearance
Total #
# (%) Cleared
Infections
Infections
n
n (%)
554
294 (53%)
212
135 (57%)
45
21 (47%)
12
7 (58%)
5
4 (80%)
3
2 (67%)
5
1 (20%)
27
15 (56%)
14
11 (79%)
30
18 (60%)
22
16 (73%)
7
5 (71%)
3
2 (67%)
29
15 (52%)
10
7 (70%)
342
159 (50%)
24
7 (29%)
4
2 (50%)
0
0%
7
6 (86%)
7
7 (100%)
31
13 (42%)
22
11 (50%)
9
5 (56%)
18
11 (61%)
38
17 (45%)
1
1 (100%)
35
18 (51%)
0
0%
0
0%
11
5 (45%)
3
3 (100%)
8
5 (63%)
10
7 (70%)
7
2 (29%)
8
3 (38%)
18
10 (56%)
40
19 (48%)
41
18 (44%)
0
0%
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Table 3.2. Associations between HPV clearance, perceived stress, and self-reported sleep
problems among men positive for any HPV type.

Any HPV Type
Univariate
Multivariable 1
HR (95% CI)
HR (95% CI)
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

New infection
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High
Prevalent infection
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

1.00
1.16 (0.86-1.56)

Multivariable 2
HR (95% CI)

1.00
1.09 (0.76-1.57)

1.00
1.23 (0.86-1.77)

0.85 (0.60-1.20)
0.97 (0.67-1.41)
1.00
1.00
0.79 (0.59-1.05)
0.77 (0.56-1.07)
Stratified Analyses
Prevalence of Infection

0.99 (0.68-1.44)
1.00
0.68 (0.49-0.94)

1.00
1.45 (0.95-2.24)

1.00
1.23 (0.67-2.24)

1.00
1.04 (0.63-1.73)

1.42 (0.89-2.28)
1.00
1.03 (0.64-1.65)

NC
1.00
NC

NC
1.00
NC

1.00
0.83 (0.52-1.32)

1.00
0.85 (0.53-1.36)

1.00
0.90 (0.56-1.44)

0.74 (0.43-1.27)
1.00
0.73 (0.46-1.18)

0.96 (0.49-1.88)
1.00
0.78 (0.46-1.32)

0.97 (0.50-1.90)
1.00
0.79 (0.47-1.34)
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Table 3.2 continued
Age Category
Aged 18 to 29
Perceived Stressa
Low
1.00
1.00
1.00
High
1.16 (0.69-1.96)
1.22 (0.72-2.06)
NC
Sleep problemsb
Low
0.70 (0.43-1.13)
0.71 (0.35-1.41)
0.79 (0.40-1.56)
Moderate
1.00
1.00
1.00
High
0.73 (0.46-1.15)
0.56 (0.33-0.93)
0.48 (0.29-1.82)
Aged 30 to 49
Perceived Stressa
Low
1.00
1.00
1.00
High
1.41 (0.88-2.27)
1.00 (0.41-2.40)
1.40 (0.53-3.68)
b
Sleep problems
Low
0.86 (0.45-1.65)
1.21 (0.58-2.50)
1.19 (0.59-2.41)
Moderate
1.00
1.00
1.00
High
0.77 (0.49-1.23)
0.92 (0.45-1.87)
0.65 (0.36-1.17)
Aged ≥50
Perceived Stressa
Low
1.00
1.00
1.00
High
0.28 (0.05-1.56)
0.09 (0.02-0.49)
NC
Sleep problemsb
Low
NC
NC
NC
Moderate
1.00
1.00
1.00
High
NC
NC
NC
a
Multivariable 1 model adjusted for age, insurance, education, marital status, number of
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable
2 model additionally adjusted for sleep category
b

Multivariable 1 model adjusted for age, insurance, education, marital status, smoking
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV
infection, Multivariable 2 model additionally adjusted for perceived stress category
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Table 3.3. Associations between HPV clearance, perceived stress, and self-reported sleep
problems among men positive for any oncogenic HPV type.

Any Oncogenic HPV Type
Univariate
Multivariable 1
HR (95% CI)
HR (95% CI)
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

New infection
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High
Prevalent infection
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

1.00
1.12 (0.75-1.68)

Multivariable 2
HR (95% CI)

1.00
1.03 (0.62-1.71)

1.00
1.39 (0.79-2.42)

0.74 (0.45-1.21)
0.77 (0.46-1.28)
1.00
1.00
0.68 (0.45-1.02)
0.59 (0.36-0.98)
Stratified Analyses
Prevalence of Infection

0.78 (0.46-1.32)
1.00
0.51 (0.28-0.94)

1.00
1.52 (0.84-2.76)

1.00
2.09 (0.92-4.74)

1.00
1.44 (0.70-2.99)

0.96 (0.48-1.95)
1.00
0.82 (0.43-1.56)

NC
1.00
NC

NC
1.00
NC

1.00
0.54 (0.26-1.13)

1.00
0.59 (0.29-1.23)

1.00
0.74 (0.31-1.72)

0.62 (0.27-1.42)
1.00
0.50 (0.22-1.16)

0.54 (0.22-1.35)
1.00
0.43 (0.18-1.05)

0.54 (0.22-1.36)
1.00
0.62 (0.23-1.65)
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Table 3.3 continued
Age Category
Aged 18 to 29
Perceived Stressa
Low
1.00
1.00
1.00
High
1.76 (0.90-3.41)
1.81 (0.76-4.28) NC
Sleep problemsb
Low
0.68 (0.33-1.39)
0.73 (0.26-2.07) NC
Moderate
1.00
1.00
1.00
High
0.91 (0.50-1.64)
0.55 (0.24-1.25) NC
Aged 30 to 49
Perceived Stressa
Low
1.00
1.00
1.00
High
0.97 (0.52-1.82)
0.55 (0.20-1.55)
0.51 (0.14-1.90)
b
Sleep problems
Low
0.51 (0.17-1.54)
0.23 (0.03-1.88)
Moderate
1.00
1.00
1.00
High
0.42 (0.20-0.88)
0.47 (0.08-2.60)
Aged ≥50
Perceived Stressa
Low
1.00
1.00
1.00
High
0.81 (0.10-6.96)
NC
NC
Sleep problemsb
Low
1.25 (0.32-4.89)
NC
NC
Moderate
1.00
1.00
1.00
High
2.84 (0.68-11.97) NC
NC
a
Multivariable 1 model adjusted for age, insurance, education, marital status, number of
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable
2 model additionally adjusted for sleep category
b

Multivariable 1 model adjusted for age, insurance, education, marital status, smoking
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV
infection, Multivariable 2 model additionally adjusted for perceived stress category
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Table 3.4. Associations between HPV clearance, perceived stress, and self-reported sleep
problems among men positive for any non-oncogenic HPV type.

Any Non-oncogenic HPV Type
Univariate
Multivariable 1
HR (95% CI)
HR (95% CI)
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

New infection
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High
Prevalent infection
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

1.00
1.19 (0.79-1.79)

Multivariable 2
HR (95% CI)

1.00
1.17 (0.76-1.81)

1.00
1.25 (0.79-1.97)

0.94 (0.61-1.45)
1.08 (0.65-1.80)
1.00
1.00
0.89 (0.61-1.29)
0.89 (0.59-1.35)
Stratified Analyses
Prevalence of Infection

1.10 (0.66-1.84)
1.00
0.77 (0.49-1.21)

1.00
1.41 (0.81-2.44)

1.00
1.07 (0.57-1.99)

1.00
1.28 (0.60-2.75)

1.89 (1.06-3.38)
1.00
1.25 (0.71-2.21)

1.19 (0.56-2.51)
1.00
0.85 (0.46-1.57)

1.24 (0.59-2.60)
1.00
0.63 (0.29-1.37)

1.00
1.04 (0.57-1.90)

1.00
1.00 (0.54-1.83)

1.00
0.99 (0.53-1.85)

0.83 (0.44-1.54)
1.00
0.96 (0.56-1.65)

1.24 (0.52-2.91)
1.00
1.09 (0.59-2.03)

1.23 (0.52-2.93)
1.00
1.08 (0.58-2.00)
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Table 3.4 continued
Age Category
Aged 18 to 29
Perceived Stressa
Low
1.00
1.00
1.00
High
0.82 (0.43-1.55)
0.82 (0.40-1.67)
NC
Sleep problemsb
Low
0.73 (0.38-1.38)
0.97 (0.37-2.52)
NC
Moderate
1.00
1.00
1.00
High
0.57 (0.30-1.07)
0.57 (0.28-1.16)
NC
Aged 30 to 49
Perceived Stressa
Low
1.00
1.00
1.00
High
1.78 (0.87-3.64)
1.13 (0.26-4.99)
1.53 (0.30-7.86)
b
Sleep problems
Low
1.07 (0.45-2.57)
1.94 (0.76-4.93)
NC
Moderate
1.00
1.00
1.00
High
1.11 (0.56-2.20)
1.07 (0.33-3.45)
NC
Aged ≥50
Perceived Stressa
Low
1.00
1.00
1.00
High
0.17 (0.03-1.17) NC
NC
Sleep problemsb
Low
NC
NC
NC
Moderate
1.00
1.00
1.00
High
NC
NC
NC
a
Multivariable 1 model adjusted for age, insurance, education, marital status, number of
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable
2 model additionally adjusted for sleep category
b

Multivariable 1 model adjusted for age, insurance, education, marital status, smoking
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV
infection, Multivariable 2 model additionally adjusted for perceived stress category
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Chapter 4: Discussion
Conclusions
This research identified two new factors significantly associated with HPV
infection in men. This is the largest study to measure perceived stress or self-reported
sleep problems in relation to an infection outcome. Study findings support research on the
association between stress and sleep disturbance with immunity, also contributing to the
field of psychoneuroimmunology. Results suggest new avenues for further research,
which could possibly lead to new prognostic factors or indicate a possible target for
interventions among individuals HPV-positive.
Over the past 30 years, many studies have been conducted to examine the
association between stress and the immune system. However, much of the previous
research examining stress has looked at associations with measures of the immune system
such as cytokines and Natural Killer cells. Whether these changes in immune function
can have implications for disease in healthy populations remains unclear11. Studies which
examine perceived stress, changes in immune parameters, and disease or infection
outcomes are needed to determine the effect of changes in immune parameters on clinical
outcomes and whether these changes in immune function are the mechanism by which
stress can influence disease.
This study adds to the psychoneuroimmunology literature by reporting on
associations between perceived stress and self-reported sleep problems with HPV
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prevalence, clearance, and incidence. Few studies have examined associations between
these factors and a clinical outcome such as HPV infection. This is also the largest study
to date to examine associations between perceived stress, sleep disturbance, and an
infection outcome.
Initial analyses examined the association between perceived stress and selfreported sleep problems with HPV prevalence using data from the baseline visit. This
analysis included a total of 426 men, although 2 did not have genotyping data available.
Due to the high prevalence of HPV infection in this population (44.8%), prevalence ratios
(PR) were calculated rather than odds ratios (OR). Logistic regression models have been
widely used to estimate ORs adjusting for covariates, however the OR will only
approximate the relative risk (RR) when the outcome of interest is rare (<10%). When the
outcome is common the OR will overestimate the RR68. Because the outcome of interest
in this study was common (45% of participants were HPV-positive), a Poisson regression
model with robust error variance was used estimate the prevalence ratio50.
The association between perceived stress and self-reported sleep problems with
HPV infection was not linear. A higher prevalence of HPV infection was only observed
among men scoring in the highest quartile of perceived stress. For self-reported sleep
problems, men in the middle 50% had the lowest prevalence of HPV and those with both
low and high self-reported sleep problems had a higher prevalence. To further explore
associations between HPV prevalence, marginal generalized estimating equation models
with an autoregressive correlation structure were used to calculate ORs including all
study visits when the full dataset was available69. Results of this analysis were formatted
as a brief for potential publication and can be found in Appendix D.
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For HPV clearance and incidence, Cox regression62 was used to examine
associations with perceived stress and self-reported sleep problems. There were several
issues with this dataset which required consideration for analyses. Items to assess the
exposures were added midway through the CER study, therefore participants could have
received the additional items for the first time at their 1st, 2nd, 3rd, or 4th study visit.
However, HPV test results were available for all visits, including those before the first
time exposure items were asked. To avoid bias, time was calculated as the time from the
first detection of an HPV type, not the first time participants tested positive after they
came under observation by the additional survey items. Thus, the data were left truncated.
Because men could be infected with multiple HPV types, there were multiple parallel
events per subject. To address these issues, the data set was put into a counting process
format. This format allows time-dependent covariates and strata, left truncation, and
multiple events per subject70. The robust sandwich estimator was used for the covariance
matrix 13 to account for with-in subject correlations.
In the baseline prevalence analyses, high perceived stress and both high and low
self-reported sleep problems were significantly associated with a higher prevalence of
any HPV infection and oncogenic HPV infection. Analyses using all study visits suggest
effect modification of the relationship between HPV prevalence and perceived stress by
age group and marital status and by age group, marital status, and education for selfreported sleep problems. Men with high perceived stress were significantly more likely to
be infected with oncogenic HPV in the total sample, among men 50 and older, and
among single men. Compared to men with moderate self-reported sleep problems, men
with low sleep problems were significantly more likely to be infected with any HPV type
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among the total sample, men aged 30 to 49, men aged 50 and older, men with a college
degree, and married men; significant associations with an oncogenic HPV type were
found among the total sample and men with a college degree; and significant associations
with a non-oncogenic HPV type were found among men aged 30 to 49 and married men.
Compared to men with moderate self-reported sleep problems, men with high sleep
problems were significantly more likely to be infected with oncogenic HPV among men
with a college degree.
In the prevalence analysis, men reporting low or high sleep problems had a higher
prevalence of HPV than men in the moderate category. In the clearance analysis, men
with low sleep problems were less likely to clear any HPV infection or an oncogenic
HPV infection compared to the moderate group although differences were not significant.
Men in the low sleep problems group could have reported sleeping longer than 9 hours
per night. Because both short and long sleep duration have been associated with other
disease outcomes in previous studies, additional analyses were conducted to examine
these associations. Table E.9 presents analyses of GEE prevalence and WLW clearance
estimates for 5 categorizations of sleep duration with 7 to 9 hours as the reference group.
Although only two point estimates were significant in all the analyses, it suggests that
men with long sleep duration may also be more likely to be HPV positive.
Factors associated with HPV clearance in prior research studies conducted among
men include circumcision status, lifetime number of sex partners, infection with multiple
HPV types, age, and country of residence4,49,57-61. Analyses of the follow-up data
examined perceived stress and self-reported sleep problems with incidence and clearance
of HPV infection. In the total sample, men high self-reported sleep problems were
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significantly less likely to clear any HPV type and oncogenic HPV types compared to
men with moderate sleep problems. Perceived stress was not significantly associated with
HPV clearance in the total sample. However among men aged 50 and older, those with
high stress were significantly less likely to clear an HPV infection.
Clearance analyses were also stratified by whether the infection was newly
detected or had been detected previously. Although results were not significant, among
men with new infections those with high perceived stress were more likely to clear an
infection compared to men with low perceived stress whereas among men with
previously detected infections those with high perceived stress were less likely to clear
and infection compared to men with low perceived stress. Due to the cross-sectional
nature of the prevalence analysis, men with longer lasting infections would be more
likely to be positive at the time of the study. If prevalent infections are negatively
affected by high stress, but new infections are not, this could explain the significant
results in the prevalence analysis that were not found in the overall sample in the
clearance analysis. As expected based on the prevalence analysis, men with high and low
sleep problems were less likely to clear HPV infections compared to men with moderate
sleep problems.
In the prevalence analyses and clearance analysis, adjustment for demographic
factors and sexual behavior increased the magnitude of associations between HPV
infection and both perceived stress and self-reported sleep problems. The prevalence
analysis of all study visits and the clearance analysis suggest that age may modify the
association between perceived stress and HPV infection, with effects more prominent
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among men 50 and older. Results of all analyses suggest that oncogenic HPV types are
affected by stress and sleep disturbance, but non-oncogenic types may not be.
Future Research
This is a relatively small study, however results suggest that further investigation
of these factors may prove useful. Although there is a vaccine to prevent infection and
treatments are available for HPV-related diseases such as topically applied creams,
surgical removal, cryotherapy, trichloroacetic acid, and 5-fluororacil, there is no antiviral
treatment that can cure HPV infection among patients HPV-positive19. Determining
modifiable behavioral factors associated with HPV clearance, such as perceived stress
and sleep problems, could be important in secondary prevention efforts to decrease the
burden of HPV-related diseases. Future studies could examine associations of these two
exposures with HPV infection among women. Gender may be an effect modifier of the
association between stress and immune function, thus these findings need to be
confirmed in female populations.
There are many ways to measure stress and additional stress measurements as
well as other psychosocial factors such as coping, social support, and emotional
responses may be examined. This study only measured self-reported perceived stress and
sleep problems. The use of full-length validated questionnaires or objective measures of
sleep such as wrist actigraphy or EEG may be helpful in elucidating the relationship
between sleep disturbance and HPV infection. Associations between both stress and sleep
disturbance with immune parameters such as NK cells, cytokine levels and Th1 to Th2
ratios could also be a focus of further studies. Salivary cortisol has been widely used as a
biomarker for psycholocial stress67. Examining the relationships between cortisol levels,
54

participant reported perceived stress and sleep disturbance, objective measures of sleep,
immune parameters, and HPV infection could provide a better understanding of the
mechanisms by which these exposures influence HPV infection and biologic plausibility.
This study looked at associations between perceived stress and sleep problems
only with HPV infection. Many HPV infections are transient and do not result in clinical
disease such as genital warts and lesions. Examining the associations of these factors with
HPV-related diseases among both men and women may be useful. Results of this study
suggest oncogenic, rather than non-oncogenic, HPV types may be affected by perceived
stress and sleep disturbance. Thus, diseases caused by oncogenic types such as precancerous cervical, penile, and anal lesions, as well as ano-genital cancers could also be
associated with these two behavioral factors. If these factors are associated with HPVrelated diseases, future research could examine behavioral interventions among these
patients.
Determining factors associated with HPV prevalence, clearance, and HPV-related
diseases may also aid in risk stratification of HPV-positive patients. Although HPV
infection is very common, most patients will not develop clinical disease due to the virus.
Combining information on stress, sleep, and other factors may allow identification of
patients at the highest risk of progressing to more severe disease and allow clinicians to
target them for closer follow-up. Patients with the lowest risk of progression may not
need to be followed closely, which could decrease the financial and psychological burden
of being HPV-positive among these patients.
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Appendix A. Literature Review

HPV
The Papillomaviridae are a family of DNA tumor viruses. Included in this family
are the human papillomaviruses (HPV) which comprise over 100 different types. These
viruses can cause genital warts and are a necessary cause of cervical cancer1. HPV
infections are also associated with other anogenital cancers and a portion of
oropharyngeal cancers2.
About 40 HPV types, members of the Alphapapillomaviruses1, can infect mucosal
tissues such as the anogenital and aerodigestive tracts. HPV types that infect the genital
tract are classified as high-risk types, associated with intraepithelial neoplasias and
invasive carcinomas, and low-risk types which are associated with condylomatas or
genital warts19. Specifically, HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68,
73,and 82 have been identified as high-risk types71.
Anogenital HPV infection is the most common sexually transmitted infection
(STI). Most individuals who are sexually-active will become infected in their lifetime18.
There are an estimated 6.2 million incident infections annually in the United States.
Infection with multiple HPV types is common due to the shared route of sexual
transmission1. Natural history studies find cumulative incidence rates of 13.6% to 41%
after 12 months of follow-up, 34% to 39% after 24 months, and 55% after 5 years72.
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HPV types 6 and 11 cause 90% of genital warts cases. Though infection is
common, only about 1% of adults have visible warts. Most incident infections (74%)
occur in individuals 15 to 24 years of age19. The incidence of genital warts has been
increasing in the US since the 1950s73. In addition to genital warts, HPV can also cause
papillomas in oral mucosa and recurrent respiratory papillomatosis (RRP), which can
interfere with breathing and may require surgical or laser removal19.
HPV Biology
The HPV genome encodes for early (E) and late (L) viral proteins. There are
seven E proteins, of which E6 and E7 are oncogenic and can interfere with the host’s cell
cycle control. E6 binds the oncosuppressor p53 and E7 binds the RB protein74. The
genomes of high risk types have been found to integrate into the host’s DNA in cases of
cervical neoplasia74. Integration leads to disruption of the E2 gene, a repressor of E6 and
E7, and upregulation of E6 and E753. L1 and L2 encode the structural and viral capsid
proteins74. The L1 gene is the most conserved and has been used for identification of
different HPV types. Differences greater than 10% define a type, 2% to 10% a subtype,
and less than 2% a variant75.
Cervical Cancer
The National Cancer Institute estimates that in 2010 there will be 12,200 incident
cases of cervical cancer (age-adjusted incidence rate=8.1 per 100,000 per year based on
2003-2007 SEER data) and 4,210 women will die of the disease (age-adjusted death
rate=2.4 per 100,000 annually). Cervical cancer affects women at younger ages then
other forms of cancer. From 2003 to 2007 the median age at diagnosis was 48 and the
median age at death was 57. Among incident cases, 14.5% were aged 20 to 34, 26.1%
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were 35 to 44 and 23.7% were 45 to 54. Of the deaths due to cervical cancer 5.1% were
aged 20 to 34, 16.0% were 35 to 44, and 23.2% were 45 to 54. Racial disparities exist,
with black and Hispanic women having higher age-adjusted incidence and a death rates
than white women76.
Most cervical cancers are squamous cell carcinoma (SCC) (85 to 90%), with
adenocarcinoma accounting for 10 to 15% of cases74. The vast majority of cervical
cancers (99%) occur within the cervical transformation zone where squamous metaplasia,
the replacement of columnar epithelium by squamous epithelium, takes place56. Nearly
all carcinomas of the cervix are caused by high-risk HPV1; HPV is detected in >99% of
cases72. HPV carcinogenesis can also occur in similar tissue located in the anus56.
Infection with HPV can lead to abnormal cervical cytology and histology.
Papanicolaou (Pap) tests are used to screen for abnormal cytology. The most common
cytology is atypical squamous cells (ASC). ASC includes two subcategories; ASC of
undetermined significance (ASCUS) and ASC cannot exclude high-grade squamous
intraepithelial lesions (ASC-H). Cytological diagnoses also consist of low-grade
squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions
(HSIL)1. The basis of Pap test guidelines are that lesions progress from low-grade
dysplasia to moderate and severe dysplasias, followed by pre-invasive lesions and
eventually develop into invasive cancers, although studies have shown that rapid
progression to HSIL can occur77,78. Having a low-grade pap smear (ASCUS or LSIL) is
the main risk factor for a high-grade smear (HSIL and ASC-H)79.
Histological diagnoses of biopsies include cervical intraepithelial neoplasia (CIN)
1 though 3, squamous cell carcinoma in situ (CIS), adenocarcinoma in situ (AIS) and
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invasive cancer. An estimated 1 million women will be diagnosed with CIN 1 annually
in the US and 500,000 will be diagnosed with high-grade lesions including CIN 2 and 3.
Most cases of CIN 1 (70 to 90%) will regress. There is debate about whether CIN 2
constitutes a low-grade or high-grade lesion. It is estimated that about 43% of untreated
CIN 2 lesions regress, 35% will persist, and 22% progress to become carcinoma. CIN 3
is considered cervical pre-cancer and is used as a surrogate for invasive cervical cancer1.
Most cases of cervical carcinomas (70%) are caused by HPV type 16 or 1819, with types
31 and 45 accounting for an additional 10% of cases72. Whereas HPV-16 is the most
common type detected in SCC (50% of cases) HPV-18 is the most common type detected
in cervical adenocarcinomas (55% of cases)72.
Infection with a high-risk type of HPV is a necessary, but not sufficient, cause of
nearly all cases of cervical cancer18. Though infections are very common, only a few of
those women who are infected will progress to cervical cancer. Many women who
become infected will clear the infection six to 12 months later. It is still unclear whether
the infection is entirely cleared by the host or the virus becomes latent and is not
detectable55. It remains unknown why in a minority of women HPV infections persist
and progress to cervical lesions and cancer56. Although infection with oncogenic HPV is
necessary, other factors may be important in the development of cancer such as host cellmediated immunity, smoking, oral contraceptive use, infection with other STIs,
inflammation, and parity56.
Other Cancers
Though cervical disease is the most researched, HPV can cause neoplasias in
several other anogenital sites including vulvar (VIN), vaginal (VAIN), anal (AIN), and
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penile (PIN) intraepithelial neoplasias19. About 60% to 90% of vaginal, anal and perianal
cancers are positive for HPV. Sexual practices, such as men having sex with men
(MSM) increase the risk of anal cancer2. The incidence of anal cancer and AIN is even
higher among immunocompromised populations80. The age adjusted incidence rate of
anal cancer in the general population is estimated to be 1.4 to 2 per 100,000. Studies of
HIV+ men have shown an incidence of 70 per 100,00080. Among established renal
transplant patients, the prevalence of anal HPV infection is 47% and the relative risk for
anal cancer is about 1080. HPV, particularly HPV-16, is also found in 50% of vulvar
cancers and 30% to 50% of penile cancers2.
More recently, HPV has also been implicated in causing carcinomas of the head
and neck. About 25% to 30% of these cancers have been associated with HPV infection.
The annual incidence of these cancers have been increasing in the US since the 1970’s,
possibly due to changes in sexual practices2.
Burden of HPV
HPV infections cause a substantial burden to the health care system. Women with
cytological diagnoses of ASCUS or SILs require monitoring with additional Pap smear
screenings and possible colposcopy and biopsy18. The annual estimated direct medical
costs of follow-up for abnormal cytology and treatment of neoplasias was $3.6 billion
and $146.4 million for treatment of invasive cervical cancer in the US in the year 200081.
The direct medical costs of treating anogenital warts is difficult to estimate due to
the wide range of incidence estimates. Assuming an incidence of 500,000, the costs are
approximated at $167.4 million annually81. Treatment of genital warts can be difficult.
No current treatment can offer a cure for the disease; removing genital warts, maintaining
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clearance, and clearing the virus. Warts may be removed via ablative therapies, however
rates of recurrence can be high73. The economic impact of non-cervical diseases due to
HPV-6, -11, -16, and -18 including anogential warts, juvenile-onset recurrent respiratory
papillomatosis (JORRP), and other genital cancers (anal, penile, vaginal, and vulval) and
mouth and oropharyngeal cancers in the US was estimated at $418 million (range $160
million to $1.6 billion) in 200382.
HPV infection also carries a psychlogical burden. The most commonly reported
emotions among HPV-positive women are depression, anxiety, and anger83. Women
with abnormal Pap smear results have reported feelings of stigma, fear, self-blame, anger,
stress, confusion, and embarrassment84. The emotional and psychological stress genital
warts can cause can be worse than the morbidity of the disease including sex life
impairments, fear of cancer, and negative affects on the emotional relationship with sex
partners73.
Brief Immunology Background
The human immune response can be divided into innate immunity and adaptive
immunity. Innate immune responses occur within minutes to hours of exposure to a
pathogen. The immune parameters of the innate immune system include; macrophages
and neutrophils which ingest and destroy pathogens; complement, plasma proteins that
induce inflammatory responses and mark pathogens for destruction by phagocytes; and
natural killer (NK) cells which can destroy infected cells. If a pathogen is able to breach
these immediate immune defenses, then adaptive immune responses become activated.
Adaptive immunity takes several days to develop, but can lead to long-lasting memory of
specific pathogens.
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Antibody-mediated, or humoral, immunity responds to extracellular pathogens,
clearing free virus particles and preventing reinfection. Foreign substances (antigens)
provoke the production of antibodies, proteins which combine with a specific antigen and
accelerate its destruction. Immunoglobulins (Ig) are the antigen recognition molecules on
B cells. There are five different types of Ig - IgM, IgD, IgG, IgA, and IgE - each with
distinctive functions. This immune response is the basis for the ability of vaccines to
induce immunity. Pathogens residing within the cell, such as viruses, do not encounter
antibodies and cannot be destroyed by an antibody response. Lymphocytes, cells that
recognize and respond to antigens, destroy cells infected with intracellular pathogens in a
process called cell-mediated immunity. T lymphocytes are important in cell-mediated
and humoral immunity. Immune cells secrete proteins that mediate signaling between
cells called cytokines. The main classes of cytokines are interleukins (IL), interferons,
(IFN), tumor necrosis factors (TNF), and chemokines22,85.
The two classes of lymphocytes are B and T cells. B cells originate within bone
marrow whereas T cells develop within the thymus. Lymphocytes carry clusters of
differentiation (CD) molecules on the cell surface. Two major subsets of T cells are
those that carry CD4, a major histocompatibility complex (MHC) class II receptor and
the receptor for HIV, and CD8, an MHC class I receptor. Maturing T cells carry CD4,
CD6, and CD8. Mature T cells will become CD4+CD8- (helper T cells) which promote
immune responses and CD4-CD8+ (cytotoxic T cells) which kill other cells and can
suppress the immune response. T cells are divided into two subsets, T helper 1 (Th1) and
T helper 2 (Th2), which are characterized by the lymphokines (cytokines released by
lymphocytes) they secrete. Th1 cells are involved in cell-mediated immunity and secrete
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IL-2 (an activation factor for T, B, and NK cells), IFN-γ (enhances B cell production of
Ig2a, production of MHC class I molecules, NK activity, and activates macrophages), and
TNF-β (can induce apoptosis, activate neutrophils, and enhance leukocyte adhesion and
procoagulant). IL-12 stimulates Th1 cells. Th2 cells support humoral immunity (aiding
B lymphocytes in differentiating into plasma cells and secreting antibodies) and secrete
IL-4, IL-5, IL-10, and IL-13. The activities of Th1 lymphokines have a tendancy to
counter the activities of Th2 lymphokines22,85. CD4+ T cells are Th1 type while CD8+
are Th2. Regulatory T cells (CD4+CD25+ Treg) secrete IL-10 and TGF-β and have been
implicated in chronic and immunopathologic viral infections. Antigen presenting cells
(APC) activate naïve T cells and determine whether they become Th1, Th2, or Treg20.
HPV and Immunity
In most infected individuals, HPV-specific humoral and cell-mediated immune
responses will eventually clear the infection to where HPV DNA of a specific type can no
longer be detected20,53. However, the exact mechanism of a successful immune response
remains to be elucidated54. HPV has evolved several mechanisms to avoid recognition by
the host immune system including replicating without inducing cell death and
suppression of proinflammatory cytokines, chemokines, and antiviral proteins54. A
suboptimal CD4+ T cell response along with induction of T reg cells may contribute to
persistence of an HPV infection54.
Despite the ability of HPV to evade immune response, a successful immune
response characterized by strong, local cell-mediated immunity, is mounted in most
individuals20. Regressing genital warts display a Th1 type immune response with large
infiltrates of CD4+, CD8+, macrophages in the stroma and epithelium and IL-12, TNF-α,
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and IFN-γ cytokines9. Though detailed prospective studies are not possible in humans,
animal models of mucosal HPV infection demonstrate a cellular infiltrate similar to that
seen in humans with regressing warts. In these animal models, systemic T cells responses
to HPV E2 and E6 peak during wart regression20.
HPV infection occurs in the lower genital tract in females, which is part of the
mucosal immune system. Therefore, local immunity may be significant in clearance or
persistence of an HPV infection74. Cervical anti-HPV immunoglobulin (Ig)A and IgG
have been inversely correlated with HPV DNA and cervical lesions86,87. In organ
transplant patients on immunosuppressive drugs the prevalence of viral warts increases
with increasing time since transplantation88.
Women who are HIV+, even those on highly active antiretroviral therapy
(HAART), clear HPV infections at a significantly lower rate than HIV- women89,90. CD4
cell count has been associated with HPV persistence in HIV+ women90. A study among
men who have sex with men (MSM) found that HIV+ MSMs may clear certain types of
HPV slower than HIV- MSMs. This study had few HIV+ participants and may have
been underpowered to detect differences for all HPV types91.
Cervical Neoplasia and Immunity
Host immune response plays a role in the development of cervical lesions and
cancers as evidenced by higher rates of cervical lesions and anogenital cancers among
HIV infected individuals89,92 and the immunocompromised.80,93 Use of HAART has been
shown to affect lesion development among HIV+ women by decreasing the risk of
progression and increasing regression92,94. Cervical cancer is usually found among
individuals who harbor HR-HPV infection for years or decades without an effective
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immune response. Cellular and humoral immune responses are necessary for clearance
of HPV-associated cervical lesions and prevention of progression to more advanced
disease states. Although it has not been well characterized, the cervical mucosal immune
response is thought to be important in viral clearance95.
Th1 type immune responses have been shown to significantly correlate with
regression of lesions in many studies. Compared to normal tissue, HSIL has a
significantly lower percentage of Th1 type cells and higher proportions of IL4+ and IL6+
cells95. Consistent with a reduced th1 type immunity, de Gruijl et al. (1998)96 found the
frequency of IFN-γ, IL-19, and IL-12 mRNA expression was significantly lower in
cervical cancer biopsies compared to biopsies from normal or CIN 1-3 women. In 30
women with CIN III and 10 healthy controls, women with CIN III who had more
extensive disease had lower production of IL-2 after mitogen stimulation and higher
production of IL-4 and IL-10 after PHA-stimulation97. Lymphoproliferative responses to
HPV 16 E6 and E7 peptides have been associated with clearance of HPV infection and
regression of CIN lesions98 and cell-mediated immune response to E7 peptides
significantly correlates with regression and resolution of infection within 12 months10.
HPV 16 E2 specific T-cell Th1 responses are associated with regression of
LSIL23,25. de Jong et al. (2004)99 found a strong CD4+ T-helper lymphoproliferative
response along with prominent IFN-γ and IL-5 secretion against HPV 16 antigens in
healthy women, whereas women with cervical cancer had absent or impaired HPV 16
specific immune responses. They theorize that this lack of HPV 16 specific T-cell
immunity could result in the development of cervical cancer. In a study by Steele et al.
(2005)100 the frequency of CD4+ T-cell response to HPV 16 proteins was higher in
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normal women (50%) and women with cancer (60%) compared to those with CIN 1
(37.5%) and CIN 2-3 (25%). In patients with regressing CIN 1, CD4+ cells
predominated within the stroma and epithelium. These patients with regressing CIN 1
had higher CD4/CD8 ratios than progressing CIN 1, CIN 3, and invasive cancer in the
stroma, although this difference was significant only for invasive cancer. Patients with
invasive carcinoma had significantly higher CD8+ and CD45RO+ cells compared to
regressing CIN 1101.
Th1 type CD4+ T-cell reactivity to HPV18 E6 have been detected in 20% of
healthy blood bank donors compared to 0% of patients with HPV 18+ CIN 3 or cervical
cancer102. In a follow-up study of 13 cervical cancer patients, production of IFN-γ by
HPV-18 E6 specific CD4+ T cells, total number of CD4+ T cells, and T-bet+ lymphoid
cells were significantly higher among those with a favorable outcome after surgery103.
A cross-sectional analysis of 140 women showed that the proportion of women
showing strong IL-2 production against HPV-16 peptides was greatest in women who
were cytologically normal, but had previously tested HPV positive (35%) and decreased
with increasing disease grade; 20% in LSIL, 17% in HSIL, and 7% in cancer patients104.
In multivariate analysis of cross-sectional data, higher levels of IFN-γ and IL-10 were
significantly associated with decreased odds of having CIN 2 or 3 compared to CIN 1 or
normal histology. Increased expression of Foxhead box P3 (Foxp3), a Treg transcription
factor, was significantly associated with having CIN 2 or 3105.
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Among women with cervical dysplasia followed for 7 to 52 months, cellular
immunity to HPV 16 E7, assessed via delayed-type hypersensitivity skin test, was
significantly associated with regression of CIN24. Secretory IgA (SIgA), IgG, and SIgM
contribute to mucosal immunity. IgA and IgG have been associated with cervical
lesions86,87.
Genetic factors affecting some immune system components have been associated
with clinical outcome of HPV infection. Genetic variation in HLA genes may play a role
in the immune response against HPV95. Polymorphisms in the TNF-α, a proinflammatory Th1 cytokine gene, have been associated with CIN 1 or invasive cervical
cancer in case-control studies106,107.
It is estimated that HIV+ women have a 2 to 12 folder higher risk of developing
cervical lesions and a significantly lower mean age of invasive cervical cancer (ICC).
ICC was added to the CDC list of AIDS-defining illnesses108. Renal transplant patients
have a significantly higher prevalence of cervical neoplasia than non-immunosuppressed
controls109. A prospective study that followed HIV+ and HIV- women for up to 5.5 years
found that the risk of incident SIL was significantly higher among HPV+ women, rate
ratio=4.5, 95% CI: 3.1 to 6.492. The cumulative incidence of ASCUS among women
normal at study entrance was 78% among HIV+ compared to 38% among HIV- women.
Among women who had ASCUS diagnosed by Pap smear, significantly more HIV+
women progressed to SIL (60% of HIV+ and 25% of HIV-, p<0.01). HIV+ women with
lower CD4+ lymphocyte counts were more likely to develop SIL, OR=1.7, 95% CI: 0.8
to 3.692. Table A.1 presents a summary of immune parameters that have been associated
with HPV-related disease outcomes.
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Table A.1. Immune Parameters Associated with HPV Infection and Cervical Lesions
Immune parameter
IgA
IgG
HPV-specific cytotoxic T lymphocytes
(CTL)
lymphoproliferative response to HPV 16
HPV 16 E2 specific T-cell response
INF-γ
INF-γ transcripts
production of IFN-γ by HPV-18 E6
specific CD4+ T cells
IL-10
IL-10 transcripts
IL-12 transcripts
Foxp3 (T reg transcription factor)
T-lymphocytes
macrophages
CD4+ T-cell reactivity to HPV 18 E6 and
E7
CD4+ T-cell response to HPV 16
total number of CD4+ T cells

Increase associated with
↓ cervical disease and HPV DNA
↓ cervical disease and HPV DNA
↑ cervical disease

Sources
Bierl (2005)86
Bierl (2005)
Sheu (2007)95

clearance of HPV and regression
cervical lesions
↑ regression of LSIL
↓ prevalence of CIN 2 r 3
premalignant disease vs invasive
carcinoma
favorable clinical outcome after
surgery
↓ prevalence of CIN 2 or 3
premalignant disease vs invasive
carcinoma
premalignant disease vs invasive
carcinoma
↑ prevalence of CIN 2 or 3
regression of genital warts
regression of genital warts
healthy control status vs CIN 3 or
cancer
normal or cancer vs CIN 1-3
favorable clinical outcome after
surgery

Sheu (2007)

80

Woo (2010)25
Scott (2009)105
de Gruijl (1998)96
Seresini (2007)103
Scott (2009)
de Gruijl (1998)
de Gruijl (1998)
Scott (2009)
Coleman (1994)9
Coleman (1994)
Welters (2006)102
Steele (2005)100
Seresini (2007)

Table A.1 continued
total number of T-bet+ lymphoid cells
delayed-type hypersensitivity to HPV 16
E7
CD8+ cell count

favorable clinical outcome after
surgery
regression of CIN

Seresini (2007)

invasive cancer

Monnier-Benoit
(2006)101
Monnier-Benoit
(2006)
Monnier-Benoit
(2006)
Coleman (1994)

CD45RO+

invasive cancer

CD4+/CD8+ ratio

regressing CIN 1 vs invasive cancer

CD4+ cell count
HAART use

regression of genital warts
HIV Positive Populations
↑ HPV clearance
↓ SIL
↑ lesion regression
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Hopfl (2000)24

Moscicki (2004)90
Duerr (2006)92
Minkoff (2001)94

Treatment
There is no antiviral treatment available that can cure HPV infections.
Podophyllotoxin and imiquimod can be applied by patients at home to treat genital warts.
Podophyllotoxin arrests cell division and induces cell death. Imiquimod induces
production of a Th1 weighted immune response. Other therapies include surgical
removal of lesions, cryotherapy, trichloroacetic acid, and 5-fluororacil19.
Recently, two vaccines have been developed using virus-like particles (VLPs) to
prevent HPV infection. Gardasil protects against types 6, 11, 16, and 18 while Cervarix
protects against types 16 and 18. Both vaccines are up to 100% effective and could
prevent 70% of cervical cancers and 90% of genital warts (Gardasil only) in women and
men not already infected with these types of HPV. The high cost of these vaccines may
be a barrier to vaccine uptake19. There has also been considerable controversy
surrounding the HPV vaccine itself and enactment of compulsory vaccination for school
attendance in the U.S., which has been shown to achieve high rates of vaccine
coverage110.
Factors Associated with HPV Clearance
HPV persistence is generally defined as detection of the same HPV type at least
two times over a specified time interval. There is no consensus on what time interval
should be considered “meaningful” persistence. Studies have shown that the longer an
HPV infection persists the more likely it is to remain persistent. Studies of HPV viral
clearance and HPV-related diseases in women have found several factors which are
associated with HPV persistence; smoking, oral contraceptive use, infection with other
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STIs such as Chlamydia trachomatis, diet including fruit and vegetable and alcohol
intake, and host factors such as genes for HLA class I and II. Viral factors such as HPV
type, viral load, and viral integration are also associated with disease outcomes1. Few
studies have examined HPV persistence in men. Factors that influence HPV persistence
in men remain to be elucidated.
Kjaer et al. (2005)57 examined persistence of HPV in male soldiers aged 18 to 29
years. After a baseline visit, men were examined approximately 6.6 months later (range
5.4 to 7.8 months). Of the 374 men enrolled, 114 were HPV-positive at their baseline
visit. Data for 73 to 77 men were reported in the analysis of HPV persistence. In
univariate analysis, multiple HPV types at baseline, high risk type at baseline, and current
smoking were associated with persistence. Multiple HPV types at baseline was the only
factor examined which was significant in multivariate analysis, adjusted OR=4.2, 95%
CI: 1.3-12.7. High-risk type, current smoking, Chlamydia DNA, age (≥21 versus ≤20)
and number of sex partners (0-1 versus ≥2) were not significantly associated with HPV
persistence in multivariate analysis.
In this analysis HPV infection was considered to be persistent if any of the HPV
types detected at baseline was subsequently detected at the follow-up visit. Therefore,
men with multiple HPV infections would need to clear all of them in order to be included
in the clearance group. Thus, the finding that multiple HPV types at baseline is related to
clearance of HPV could be an artifact of the method of analysis.
Lajous et al. (2005)58 evaluated HPV persistence in male soldiers in Mexico.
Three hundred thirty six men were sampled at a baseline visit and at a one year followup. There were 105 men who were HPV-positive at baseline and had a follow-up visit.
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Higher median number of baseline infections was significantly associated with increased
risk of persistence, adjusted OR=1.84, 95% CI:1.24-2.90, and men who self-reported they
were circumcised had a significantly decreased risk of persistence, adjusted OR=0.12,
95% CI: 0-0.87. Age (<20, 21-25, and >25), religion (Catholic, Other, None), intercourse
with prostitutes, and anal intercourse with females were not significantly associated with
HPV persistence.
The definition of persistence in this analysis was defined as "having the same
HPV type at both times; these participants were compared with those who were
positive at baseline and negative at follow-up." Thus, it appears that in this analysis men
with multiple HPV types would have to clear all of them in order to be considered as
having HPV clearance.
A prospective cohort study by Giuliano et al. (2008)49 examined 290 men every 6
months for HPV infection; mean duration of follow-up of was 15.5 months. Median time
to clearance (the amount of time for 50% of infections to clear) was 5.9 months for any
HPV infection, 5.8 months for oncogenic HPV types, and 6.0 months for nononcogenic
types. The percent of participants who remained HPV positive at 6 months was 44.5%
for any HPV, 41.7% for oncogenic HPV, and 46.5% for nononcogenic HPV. At 12
months, 25.5%, 19.0%, and 29.3% remained positive for any HPV, oncogenic HPV, and
nononcogenic HPV, respectively with 10.7%, 0%, and 14.4% remaining positive at 18
months. Age was not significantly associated with HPV persistence.
In another analysis of this cohort, Lu et al. (2009)59 examined HPV clearance in
285 men followed for average of 18 months. In univariate analyses, circumcision was
positively significantly associated with HPV clearance for any HPV type and oncogenic
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HPV, but not for nononcogenic HPV types. Age, education, marital status, cigarette
smoking, age at first sexual intercourse, lifetime number of sex partners, history of STI,
having a steady sex partner in the past 3 months, having a sex partner with an STI in the
past 3 months, having new a sex partner in the past 3 months, and condom use during the
past 3 months were not associated with HPV clearance. In multivariate analyses,
clearance of any HPV infection was significantly higher in circumcised men (HR=3.1,
95% CI: 1.2-8.2) adjusting for cigarette smoking and lifetime number of sex partners.
For oncogenic HPV types, clearance of any HPV infection was significantly higher in
circumcised men (HR=6.5, 95% CI: 2.1-19.7) and men with a higher lifetime number of
sex partners (HR=4.9, 95% CI: 1.2-19.8 comparing >16 partners to 0-4 partners)
adjusting for age at first sexual intercourse. Nononcogenic HPV persistence was not
associated with any sociodemographic and behavioral factors examined in univariate or
multivariate analyses.
More recently, results of a clinical trial of circumcision among 650 HIV-negative
men in Rakai, Uganda were reported60. Men were randomized to an intervention group
(immediate circumcision) or control group (circumcision at the end of the 24 month
follow-up) and were assessed for HPV at enrollment, six months, 12 months, and 24
months. Men in the intervention group had a significantly higher rate of clearance
compared to men in the control group, adjusted RR=1.39, 95% CI: 1.17-1.64. Rates were
adjusted for age, education, number of sex partners, and condom use, however the risk
ratio for these variables was not reported.
Hernandez et al. (2010)61 followed 357 men for a mean of 431 days, range = 2 to
9 visits. Men were assessed every two months. Adjusting for age, race/ethnicity,
85

birthplace, education, lifetime number of female sex partners, history of sex with men,
condom use, and history of genital warts, uncircumcised men were significantly less
likely to clear any HPV (HR=0.59, 95% CI: 0.36-0.98), oncogenic HPV (HR=0.36 95%
CI: 0.14-0.91), and nononcogenic/undetermined risk status HPV (HR=0.50, 95%CI:0.250.98). Significant differences by circumcision status were only observed in samples from
the glans/coronal sulcus of the penis and not from the penile shaft, scrotum, or all sites
combined.
Finally, Giuliano et al. (2011)4 followed 1,159 men aged 18-70 residing in
southern Florida, USA, São Paulo, Brazil, or Cuernavaca, Mexico. Men underwent a
clinical examination where samples of penile and scrotal cells were collected for HPV
DNA testing at each study visit. Participants returned for follow-up visits every 6 months
over 4 years, for a total of up to 10 visits. Increasing age was significantly associated
with increased clearance of oncogenic HPV (AHR=1.02, 95% CI: 1.01-1.03). Men from
Brazil were significantly less likely to clear any HPV (AHR=0.69, 95% CI: 0.58-0.83),
oncogenic HPV (AHR=0.71, 95% CI: 0.56-0.91) and non-oncogenic HPV (AHR=0.81,
95% CI: 0.81-0.96) compared to men from the USA. Men from Mexico were
significantly less likely to clear oncogenic HPV (AHR=0.73, 95% CI: 0.57-0.94)
compared to men from the USA. Men with a higher number of lifetime female partners
were less likely to clear oncogenic HPV (AHR for 2-9 partners=0.70, 95% CI: 0.55-0.90;
AHR for 10-49 partners=0.64, 95% CI: 0.51-0.82; AHR for ≥ 50 partners=0.49, 95% CI:
0.31-0.76) compared to men with 0 or 1 partner. Men who were HPV-positive at
baseline were less likely to clear any HPV (AHR=0.85, 95% CI: 0.76-0.96) and non-
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oncogenic HPV (AHR=0.81, 95% CI: 0.70-0.93) compared to men who were HPVnegative at baseline.
To date, the only factors associated with HPV clearance in men are circumcision
status, lifetime number of sex partners, infection with multiple HPV types, age, and
country of residence. Other factors that influence HPV persistence remain to be
identified. Determining modifiable behavioral factors associated with HPV clearance
will be important in secondary prevention efforts to decrease the burden of HPV-related
diseases.
Psychoneuroimmunology
Psychoneuroimmunology (PNI) is the study of the bidirectional links between the
central nervous system (CNS), immune system, and endocrine system and the
implications of these interactions for health and disease.5,6 Psychological factors may
play a role in the development and course of a range of diseases including infectious
diseases and several cancers.6,7 The aim of psychoneuroimmunology is to discover how
behaviors and health are related111. One focus of this field is the influence of stress on
immune function5.
The theoretical model of how stress can affect immune function proposes that
stress triggers cognitive, emotional, and affective responses which lead to the activation
of the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic-adrenalmedullary
(SAM) axis inducing a release of hormones that can affect immune function7. The
nervous, endocrine, and immune systems are able to communicate by means of shared
hormones, neuropeptides, and cytokines. The brain is able to communicate with the
immune system through the autonomic nervous system and from neuroendocrine outflow
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from the pituitary112. Both primary and secondary lymphoid organs are innervated with
sympathetic nerves which release an array of neuropeptides and can influence the
immune system112. Release of corticotropin-releasing hormone (CRH) during stress may
down regulate immune responses through it's effect on the secretion of glucocorticoids
(GCs) and catecholamines (CAs)111,113. In experiments on animals, stress has been
associated with an increase in the susceptibility to a range of infectious diseases and
experimental tumors112. Subsequent research in patients with conjugal bereavement,
severe life stress, and major depression found negative effects on immunity111.
The effects of stress on immune function have varied in direction and magnitude
in previous research. When examining the affects of stress and immune outcomes, host
factors (e.g. age, sex, etc.), nature of the stimulus (e.g. intensity and duration), and the
type of immune response measured are important factors which may interact and
influence immune responses differentially.
Of particular concern is the effect of stress on the balance between Th1 and Th2
immune responses and neurogenic inflammation in peripheral tissues113. GCs and CAs
induce a shift towards Th2 immunity by up regulation of Th2 cytokine production and
suppression of Th1 cytokine production.
Stressful and uncontrollable life events, lack of social support, and having a
passive or helpless coping style may have a negative impact on immune functioning, thus
contributing to persistence of viral infections such as HPV. Biobehavioral research such
as psychoneuroimmunology may be important in furthering the understanding of HPV
persistence and could “form the basis of interventions aimed at reducing the risk of HPV
persistence” and subsequent malignancies8.
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Stress
Psychological stress is a factor that may play a role in the course of health and
disease. Stress can impact immune function; evidence suggests that stress can increase
the severity and duration of infectious diseases, promote reactivation of latent viruses,
and affect vaccine response.21 Effects are seen in numerous immune cells and substances
including B and T cells, Natural Killer cells, and cytokines. The immune response may
differ depending on the duration of the stress, with brief stressors causing a shift from
specific immunity to natural immunity and chronic stressors leading to broad immune
impairment and a shift from a Th1 to a Th2 immune response 7,11
Stress has been defined in a variety of ways14. The classical definition of stress is
when environmental demands exceed the perceived ability to meet those demands
resulting in the perturbation of homeostasis7. There is no universal definition of what
constitutes psychological stress, however recent definitions focus on the cause (such as
life events) or effect (appraisal and emotional responses)114. Over 300 articles have been
published examining the association of psychological stress and immune parameters in
humans. Overall, they have shown that stress is able to modify immune response11.
Measurement of Stress
Several different approaches have been used to measure stress in humans. Many
studies have assessed major life events. In these instruments, participants self-report life
events which are assumed by the investigator to be stressful. These life events checklists
suffer from several limitations. Studies comparing life event checklists with interviewbased measures have found that checklist methods are prone to errors in accurately
measuring life events. Self-reported events may be consistent with the life events
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investigators are measuring less than 50% of the time. Subjects may interpret questions
in different ways, leading to reporting on events that do not correspond with the life
events investigators are attempting to measure14.
Scales based on checklists may miss chronic stress due to other life
circumstances, stress from the events in the lives of family or close friends, expectations
of future events, or other events not listed in the checklist16. There are also issues in how
well subjects can recall past events and report them to investigators and defining what
constitutes a life event14. In studying the effect of stress in relation to health, illness may
be affected by global stress level and not merely responses to particular events16.
Assessing life events is best attained through interview-based methods with guidelines
for defining life events14.
Other studies have compared immune outcomes among persons who are
experiencing a severe chronic stressor, such as caregiving for a family member with a
chronic illness, with controls who are not experiencing the stressor115,116. These types of
studies are measuring the effect of the stressor rather than the stress response on
immunity. Stressors are selected based on the researcher's belief that most people would
consider the event as stressful. However, the perception of an event as stressful and
psychological reaction is moderated by individual differences7.
Perceived stress attempts to measure perceptions or appraisals of stress14. The
most common instrument used to measure perceived stress is the perceived stress scale
(PSS)14 developed by Cohen et al. (1983)15. This scale attempts to measure the degree to
which situations are appraised as stressful and was designed to determine how
unpredictable, uncontrollable, and overloaded subjects consider their lives16. The scale
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was designed for use in populations which possess at least a junior high school education
level with questions that are easy to comprehend and response alternatives that are easy
to understand16. Response categories are a 5-point likert scale ranging from never to very
often16. Unlike check lists of life events, it is sensitive to nonoccurrence of events,
ongoing life circumstances, stress in the lives of family or close friends, and expectations
of future events16. There are 14-item (PSS-14), 10-item (PSS-10), and four-item (PSS-4)
versions of the scale. All three versions have been shown to have satisfactory reliability
and construct validity16,117. The two shorter scales have been reported to be as reliable
and valid as the original PSS-14, though the reported Cronbach's α for the PSS-4 is lower
that for the longer versions117. The PSS-4 is recommended for situations that require a
very brief survey instrument16. Construct validity of the PSS has been assessed by
correlating scores with other measures of stress. Correlation coefficients were higher for
depressive symptoms (range 0.65-0.76), anxiety scores (0.48-0.81), and physical
symptoms (0.52-0.70) than for life events (0.17-0.38). Discriminate validity has been
demonstrated by significantly different mean values in populations expected to
experience different levels of stress114.
Cohen and Williamson 198816 assessed differences in PSS score by demographic
characteristics among 2,387 U.S. residents 18 and older who completed a telephone
interview. There were significant differences in PSS scores by sex, age, household
income, education, race, household composition, marital status, and employment status16.
Cronbach’s alpha for each of the demographic groups was not reported.
The items included in the original PSS inquire about stress in the past month.
Because the scale is influenced by daily hassles, major life events, and changes in coping,
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the predictive validity of the scale is expected to decline rapidly after approximately one
to two months16. The one month time frame is suitable for cross-sectional research or
prospective designs which re-assess stress every one to two months. However, in casecontrol studies where the relevant etiologic time window includes time before the past
month or in prospective studies where participants are not re-assessed every one to two
months, the scale may miss important measures of stress. For example, in a prospective
study that re-assess participants annually, perceived stress will only be measured for the
previous month, which may not accurately reflect perceived stress during the other 11
months of the year.
Pbert et al. (1992)43 assessed both perceived stress and psychosocial dysfunction
in two clinical samples; 59 were participants in an employee health promotion program
and 41 were participants in a 12-week outpatient cardiac rehabilitation program. The
original PSS-14 was administered as well as a version modified to ask about the previous
six months. Other measures included were the Life Experience Scale (LES) to assess
events experienced in the past 6 months, the Inventory to Diagnose Depression (IDD) to
assess the range of symptoms used to diagnose depression, the Sate Anxiety Inventory to
assess feelings of apprehension, worry, tension, and nervousness, and the CohenHoberman Inventory of Physical Symptoms (CHIPS) to assess 39 common physical
symptoms and how much each symptom bothered or distressed the participant in the past
two weeks on a 5-point Likert scale. No significant group differences in stress and
dysfunction were found, therefore all participants were combined for analyses.
The correlation between the 1-month PSS and 6-month PSS was 0.76. Both
versions of the PSS were moderately correlated (0.24 to 0.44) with the total number of
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life events, number of negative life events, and impact scores on the LES; only the 6month PSS was correlated with the negative impact score. Correlations with the LES
scores were higher for the 6-month PSS than the 1-month PSS. Both the 1-month PSS
and the 6-month PSS were significantly correlated with the IDD, SAI, and CHIPS.
Correlations between the 6-month PSS with symptom measures (IDD, SAI, and CHIPS)
and the 1-month PSS with symptom measures were nearly identical.
Levenstein et al. (1993)118 developed a 30-item scale to assess perceived stress,
the Perceived Stress Questionairre (PSQ). Responses to 30 items were collected among
in-patients, outpatients, healthcare workers, and students with regard to both recent stress,
'during the past month', and stress in general, 'in general, during the past year or two'.
Both were correlated with the PSS; Spearman's r=0.56 with the General PSQ and 0.73
with the Recent PSQ. The correlation between the Recent and General forms
administered in a single sitting was 0.71. Ten ulcerative colitis patients completed the
Recent form monthly four to six times at home and returned them at their next clinic
visit. The mean coefficient of variation within individuals was 0.22, confirming that
there are temporal fluctuations in reporting of stress within the past month.
Among students, a generally healthy population, both the General and Recent
forms correlated with somatic symptoms assessed by Kellner's Symptom Questionnaire
(r=0.50 and 0.58, respectively). Among asymptomatic ulcerative colitis patients, visible
mucosal inflammation of the rectum was associated with scores on the General and
Recent PSQs (p=0.005 and 0.03 respectively). While the Recent scale had a higher
correlation with the PSS, life events, and somatic symptoms, the General scale had a
higher correlation with hospitalization status and rectal inflammation in the populations
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studied. Thus, the authors concluded that the General scale which assessed stress 'in the
long run' may be a better predictor of health status.
Stress and Immunity
Theories on how stress is related to immune function have evolved over time. In
early models, stress was believed to be broadly immunosuppressive. Later models
proposed that acute stress enhanced immune response whereas chronic stress was
suppressive. Neither of these theories explained why chronic stress was associated with
both diseases of inadequate immunity, such as infectious diseases and cancers, and
diseases characterized by excessive immune response, such as allergies and autoimmune
diseases. More recently, models have focused on how chronic stress may induce a shift
from a Th1 to a Th2 profile. Chronic stress may actually both enhance and suppress the
immune system by altering cytokine secretion. Th1 cytokines may be suppressed while
production of Th2 cytokines is enhanced without changing overall immune function. A
meta-analysis with studies of stress and immune parameters supports this hypothesis 11.
Thus, this model reconciles the seemly conflicting results of previous work as a shift
from a Th1 to Th2 profile may increase susceptibility to infectious disease and cancer and
increase vulnerability to allergies and autoimmune diseases.
Segerstrom and Miller (2004)11 conducted a meta-analysis of published studies on
immune response and stress. Stress studies were categorized as acute time-limited (brief
laboratory experiments such as public speaking), brief naturalistic (real-life short term
challenges such as academic exams), stressful event sequences (a focal event such as
death of a spouse or natural disaster), chronic stress (circumstances that pervade a
person's life such as traumatic injury or care giving), distant stress (traumatic events that
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occurred in the past such as sexual assault or being a prisoner of war), life events
checklists (number of life events occurring over a specified time frame), and perceived
stress or intrusive thoughts.
Acute time limited stressors were associated with increases in immune
parameters, particularly number of NK cells and granular lymphocytes. Brief naturalistic
stress in healthy adults was associated with functional immune parameters including
changes in cytokine production indicating a shift from Th1 to Th2 immunity. Stressful
event sequences were associated with increased numbers of NK cells and Epstein-Barr
virus antibodies. Chronic stress was associated with declines in functional measures of
immune response, however no reliable changes in immunity were found for chronic
stressors. Life events were not significantly associated with immune measures; however
there was an association with lymphocyte-proliferative responses to PHA and NK cell
cytotoxictiy in older populations and number of NK cells in participants with HIV/AIDS.
Stress appraisals were not significantly associated with immune parameters in this
analysis, however only 3 or 4 studies reported data for each of the immune parameters
examined and there may have been limited power to detect a significant association.
Though not significant, modest effect sizes (r of 0.10 to 0.20) were found for number of
T lymphocytes, T-helper lymphocytes, number of NK cells and NK cell cytotoxicity.
Not only may chronic stress directly influence immunity, but it may also have
effects on acute stress responses. Chronically stressed individuals may have greater
reactivity to acute stress. Accumulated stress may result in a state where even a minor
stressor could result in immune changes. High numbers of daily hassles have been
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associated with decreases in T cell and NK cell counts during acute experimental stress
tasks 119.
Though significant relationships were not found in the meta-analysis of perceived
stress and immune parameters, many individual studies have found a significant
relationship between stress and both immune parameters and clinical outcomes. Table
A.2 presents a summary of immune responses and clinical outcomes that have been
associated with measures of perceived stress.
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Table A.2. Immune Parameters and Perceived Stress
Immune parameter
IgG

Study

Design

N

Time frame

Theorell 1990120
Söderfeldt
2000121

prospective
crosssectional
crosssectional

49

12 to 16
months

Yang 2002122
Hapuarachchi
2003123

case-control

132

Past 6 months

case-control

43

Stone 1994124

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Past month
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks

Söderfeldt 2000

Exposure

Outcome

P value

Population

job strain

No significant ass.

p>0.05

workers

103

quantitative job strain

No significant ass.

p>0.05

workers

103

emotional job strain

No significant ass.

p>0.05

workers

Professional Stress
Scale

↑stress ass. ↓IgA

p<0.01

PSS-14

↑stress ass. ↓IgA

p<0.05

Nurses
University
employees

Daily desirable
events

↑ desirable events
ass. ↑ sIgA

p<0.05

men in the
community

No significant ass.

p>0.05

men in the
community

No significant ass.
↑ undesirable
work events ass. ↓
sIgA

p>0.05

men in the
community

p<0.01

men in the
community

p<0.01

men in the
community

IgA

sIgA

97

Daily undesirable
events
Daily desirable work
events
Daily undesirable
work events
Daily desirable
leisure events

↑ desirable events
ass. ↑ sIgA
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Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks

98

Daily undesirable
leisure events

↑ undesirable
work events ass. ↓
sIgA

p>0.05

men in the
community

Daily desirable
friends events

No significant ass.

p>0.05

men in the
community

Daily undesirable
friends events

No significant ass.

p>0.05

men in the
community

Daily desirable
spouse events

No significant ass.

p>0.05

men in the
community

Daily undesirable
spouse events

No significant ass.

p>0.05

men in the
community

Daily desirable
children events

No significant ass.

p>0.05

men in the
community

Daily undesirable
children events

No significant ass.

p>0.05

men in the
community

ass. ↑ sIgA

p<0.01

men in the
community

Daily undesirable
household events

No significant ass.

p>0.05

men in the
community

Daily desirable
financial events

No significant ass.

p>0.05

men in the
community

Daily desirable
household events

↑ desirable events
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Stone 1994

prospective

96

Stone 1994

prospective

96

Stone 1994

prospective

96

assessed
daily for 12
weeks
assessed
daily for 12
weeks
assessed
daily for 12
weeks

Yang 2002

case-control

132

Song 1999125

prospective

38

De Gucht 1999126

crosssectional

De Gucht 1999

soluble IL-2R

soluble IL-6R
gp 130

Daily undesirable
financial events

No significant ass.

p>0.05

men in the
community

Daily desirable self
events

No significant ass.

p>0.05

men in the
community

Daily undesirable
self events

No significant ass.

p>0.05

men in the
community

Past 6 months

Professional Stress
Scale

↑stress ass.
↓lysozyme

p<0.01

Nurses

43±6 days

PSS-14

No significant ass.

p>0.05

students taking
exams

60

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Nurses

crosssectional

60

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Song 1999

prospective

38

43±6 days

PSS-14

No significant ass.

p>0.05

Nurses
students taking
exams

Song 1999

prospective

38

43±6 days

PSS-14

No significant ass.

p>0.05

students taking
exams

0.008

students taking
exams

Lysozyme secretion

IL-1
IL-1RA
IL-2

IL-2 R

IL-6

↑ high stress group
Song 1999

prospective

38

43±6 days

99

PSS-14

compared to low
stress
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CC16
PSS-14

No significant ass.

p>0.05

students taking
exams

job strain index

No significant ass.

p>0.05

blue-collar
workers

43±6 days

PSS-14

↑ change PSS ↑
CD2+

past 7 days
1 day before
to 7 days
after surgery

IES intrusion scale

↑ IES ass. ↓T cells

p<0.01

change in IES
intrusion scale

↑IES ass. ↓T cells

p<0.05

job strain index

No significant ass.

p>0.05

43±6 days

PSS-14

↑ change PSS ↑
leukocytes

0.003

98

past 7 days

IES intrusion scale

No significant ass.

p>0.05

students taking
exams
breast cancer
patients

change in IES
intrusion scale

No significant ass.

p>0.05

breast cancer
patients

PSS-14

No significant ass.

0.09

Song 1999

prospective

38

Kawakami
1997127

crosssectional

65

Maes 1999128
Tjemsland
1997129

prospective
crosssectional

38
98

Tjemsland 1997

prospective
crosssectional

98

prospective
crosssectional

38

43±6 days

Total T cells
Number

Percentage
Leukocytes
Number

Kawakami 1997

Maes 1999
Tjemsland 1997

65

Tjemsland 1997

prospective

98

1 day before
to 7 days
after surgery

Maes 1999

prospective

38

43±6 days

0.01

students taking
exams
breast cancer
patients
breast cancer
patients
blue-collar
workers

Lymphocytes
Number

100

students taking
exams
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Tjemsland 1997

crosssectional

98

past 7 days

IES intrusion scale

↑ IES ass.
↓lymphocytes

p<0.01

breast cancer
patients

change in IES
intrusion scale

↑IES ass.
↓lymphocytes

p<0.05

breast cancer
patients

0.002

students taking
exams

0.3

students taking
exams

Tjemsland 1997

prospective

98

1 day before
to 7 days
after surgery

Maes 1999

prospective

38

43±6 days

PSS-14

↑ change PSS ↑
neutorphils

prospective

38

43±6 days

PSS-14

No significant ass.
↑ burnout ass.
↑LAA

p<0.05

University
employees

p>0.05

students taking
exams

Neutrophils
Number
Monocytes

Number
Maes 1999
Leukocyte adhesiveness/aggregation (LAA)
Lerman 1999130

case-control

179

Past month

Shirom-Melamed
Burnout
Questionnaire

Song 1999

prospective

38

43±6 days

PSS-14

No significant ass.

Number
CD2+HLA-DR+

Maes 1999

prospective

38

43±6 days

PSS-14

↑ change PSS ↑
CD2+CD26+

0.01

students taking
exams

Number
B lymphocytes

Maes 1999

prospective

38

43±6 days

PSS-14

↑ change PSS ↑
CD2+HLA-DR+

0.01

students taking
exams

Number

Maes 1999

prospective

38

43±6 days

PSS-14

No significant ass.

0.1

students taking
exams

CD 14

CD2+CD26+
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Tjemsland 1997

Tjemsland 1997

crosssectional

prospective

98

past 7 days

IES intrusion scale

↑ IES ass. ↓ B
lymphocytes

p<0.01

breast cancer
patients

98

1 day before
to 7 days
after surgery

change in IES
intrusion scale

No significant ass.

p>0.05

breast cancer
patients

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

IES intrusion scale

No significant ass.

p>0.05

Nurses
breast cancer
patients

change in IES
intrusion scale
Nurse Stress Index
(high v. low stress)

No significant ass.
High stress ass. ↓
NK cells

p>0.05

breast cancer
patients

p<0.05

Nurses

NK cells (CD3-CD56+ )
Number

De Gucht 1999
Tjemsland 1997

Tjemsland 1997
Percentage
CD57-CD16+ (NK subset)
Number
CD57+CD16+ (NK subset)
Number
CD57+CD16- (NK subset)
Number
NK cell activity

crosssectional
crosssectional

60
98

past 7 days

98

1 day before
to 7 days
after surgery

De Gucht 1999

prospective
crosssectional

Nakamura
1999131

crosssectional

42

Past month

PSS-14

No significant ass.

p>0.05

office workers

Nakamura 1999

crosssectional

42

Past month

PSS-14

No significant ass.

p>0.05

office workers

42

Past month

PSS-14

No significant ass.

p>0.05

office workers

42

Past month

PSS-14

No significant ass.

p>0.05

office workers

Nakamura 1999
Nakamura 1999

crosssectional
crosssectional

60

102
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Vitaliano 1998132

crosssectional

165

Past month

Hassles and Uplifts
scales - Time 1

No significant ass.

p>0.05

Vitaliano 1998

crosssectional

165

Past month

Hassles and Uplifts
scales - Time 2

No significant ass.

p>0.05

Wilcox 2000133

crosssectional

23

Past month

PSS-14

No significant ass.

p>0.05

dementia
caregivers,
cancer
survivors, and
controls
dementia
caregivers,
cancer
survivors, and
controls
caregivers in
physical
activity trial

High stress ass. ↑
CD25+

p<0.05

Nurses

60

Nurse Stress Index
(high v. low stress)
Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Nurses

crosssectional

60

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Nurses

crosssectional

60

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Nurses

CD25+ (activated T cells)
Number

De Gucht 1999

Percentage
De Gucht 1999
CD3+CD25+ (activated T-cells)
Number

De Gucht 1999

Percentage
De Gucht 1999
CD3+CD16CD56+ (cytotoxic T cells)

crosssectional
crosssectional

60

Number

De Gucht 1999

crosssectional

60

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Nurses

Percentage

De Gucht 1999

crosssectional

60

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Nurses
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Helper T cells (CD4+)
Number

High stress ass. ↑
CD4+CD25+

p<0.05

65

job strain index

No significant ass.

p>0.05

Kawakami 1997
Scanlan 1998134

crosssectional

168

past month

Hassles Scale
(baseline)

No significant ass.

p>0.05

prospective

168

15 to 18
months

Hassles Scale

↑ hassles ass. ↓
CD4 count

p<0.05

crosssectional

98

IES intrusion scale

↑ IES ass. ↓T cells

p<0.01

breast cancer
patients

↑IES ass. ↓CD4 T
cells

p<0.05

breast cancer
patients

60

change in IES
intrusion scale
Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

65

job strain index

No significant ass.

p>0.05

Tjemsland 1997

Tjemsland 1997
De Gucht 1999
Kawakami 1997

Scanlan 1998

Scanlan 1998
CD9+CD11b+ (suppressor T cells)
Number

Nurse Stress Index
(high v. low stress)

Nurses
blue-collar
workers
older
caregivers and
controls
older
caregivers and
controls

Scanlan 1998

Percentage

60

crosssectional
crosssectional

De Gucht 1999

De Gucht 1999

prospective
crosssectional
crosssectional

98

past 7 days
1 day before
to 7 days
after surgery

crosssectional

168

past month

Hassles Scale
(baseline)

No significant ass.

p>0.05

prospective

168

15 to 18
months

Hassles Scale

No significant ass.

p>0.05

Nurses
blue-collar
workers
older
caregivers and
controls
older
caregivers and
controls

crosssectional

60

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Nurses

104
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crosssectional

60

Nurse Stress Index
(high v. low stress)

No significant ass.

p>0.05

Kawakami 1997

crosssectional

65

job strain index

No significant ass.

p>0.05

Maes 1999

prospective

38

43±6 days

PSS-14

0.08

crosssectional

168

past month

Hassles Scale
(baseline)

No significant ass.
↑ hassled ass. ↑
CD* count (men
only)

p<0.05

prospective
crosssectional

168

15 to 18
months

Hassles Scale

No significant ass.

p>0.05

IES intrusion scale

No significant ass.

p>0.05

prospective
crosssectional

98

change in IES
intrusion scale

↑IES ass. ↓CD8 T
cells

p<0.01

job strain index

No significant ass.

p>0.05

p<0.05

Percentage
De Gucht 1999
Suppression/cytotoxic T cells (CD8+)
Number

Scanlan 1998

Scanlan 1998
Tjemsland 1997

Tjemsland 1997
Percentage

Kawakami 1997

98

past 7 days
1 day before
to 7 days
after surgery

65

Scanlan 1998

crosssectional

168

past month

Hassles Scale
(baseline)

↑ hassled ass. ↑
CD*8 percent

Scanlan 1998

prospective

168

15 to 18
months

Hassles Scale

No significant ass.
↑ high stress group

soluble CD8
Song 1999
Helper/inducer T cells (CD4+CD29+)

prospective

38

43±6 days

PSS-14

105

compared to low
stress

Nurses
blue-collar
workers
students taking
exams
older
caregivers and
controls
older
caregivers and
controls
breast cancer
patients

p>0.05

breast cancer
patients
blue-collar
workers
older
caregivers and
controls
older
caregivers and
controls

0.009

students taking
exams
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Number

Kawakami 1997

Percentage
Kawakami 1997
Suppressor/inducer T cells (CD4+CD45RA+)
Number
Percentage
CD4+/CD8+ ratio
Number

crosssectional

65

job strain index

No significant ass.

p>0.05

blue-collar
workers

crosssectional

65

job strain index

↑ job strain ↓ % T
cells

p<0.05

blue-collar
workers

65

job strain index

No significant ass.

p>0.05

65

job strain index

No significant ass.

p>0.05

Kawakami 1997

crosssectional
crosssectional

Maes 1999

prospective

Kawakami 1997

Scanlan 1998
Tjemsland 1997

Tjemsland 1997

crosssectional
crosssectional

blue-collar
workers
blue-collar
workers

38

43±6 days

PSS-14

↓ change PSS ↑
CD4+/CD8+ ratio

0.002

168

past month

Hassles Scale
(baseline)

↑ hassled ass. ↑
CD4/CD*

p<0.05

98

past 7 days

IES intrusion scale

↑ IES ass. ↓ratio

p<0.01

students taking
exams
older
caregivers and
controls
breast cancer
patients

No significant ass.

p>0.05

breast cancer
patients

↑stress ass.
↑URTI episodes

p<0.01

1 day before
to 7 days
change in IES
prospective
98 after surgery
intrusion scale
Clinical Outcomes and Perceived Stress

Num. URTI episodes
Koh 2002135

case-control

132

Past 6 months

Professional Stress
Scale

Cobb 1996136

prospective

107

15 weeks

PSS-10

Cobb 1996

prospective

107

15 weeks

Hassles Scale

106

↑ stress in those with
UTTI

p<0.001

↓ stress in those with
UTTI

p<0.001

Nurses
Parents in a
study of stress
in children
Parents in a
study of stress
in children
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Absence due to URTI
Koh 2002
URTI (Upper respiratory tract infection)
(PSS) Perceived stress scale
IES (Impact of Events Scale)
sIgA (secretory IgA)
IL-1RA (interleukin-1 receptor antagonist)
IL (interleukin)
IL-2R (IL-2 receptor)
gp 130 (glycoprotein 130)
CC16 (Clara cell protein)

case-control

132

Past 6 months

107

Professional Stress
Scale

↑stress ass.
↑URTI absences

p<0.01

Nurses

Two studies of upper respiratory tract infections (URTI) found that increased job
or perceived stress were associated with increases in the number of URTIs and work
absence related to URTIs. In a case-control study by Koh et al. (2002)135, higher scores
on the Professional Stress Scale were associated with significant increases in the number
of URTI episodes and number of absences due to URTI in the past six months. A
prospective study by Cobb et al. (1996)136 followed 107 adults participating in a study of
stress in children for 15 weeks. Perceived stress and hassles were measured by the
Hassles Scale and PSS-10 weekly. Interestingly, daily hassles were lower in participants
that did not have a clinically verified URTI, whereas perceived stress was significantly
higher in participants who experienced a URTI during follow-up.
Of the numerous immune parameters studied, IgA, lysozyme secretion, gp 130,
leukocyte number, Neutrophil number, leukocyte adhesiveness/aggregation (LAA),
CD2+, CD19+, CD25+, NK cells, CD4+, CD8+, and the CD4/CD8 ratio were found to
be significantly associated with a measure of perceived stress in at least one research
study. Many of these studies had small numbers of participants and may lack adequate
power to detect associations. Indeed, of the three studies with at least 100
subjects122,130,134 all had significant findings. These studies also suggest that perceived
stress is associated with both immune parameters and occurrence of URTI, however
further prospective research with adequate sample sizes is needed to examine these
relationships.
While some studies examining the relationship between stress and response to
immunization have found significant associations with measures of perceived stress,
stressful life events, and in chronically stressed populations65,137-142, others have not143-145.
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Though results have from these studies been mixed, they suggest that stress may have a
negative impact on secondary antibody response (function of antigen-specific T and B
cells after re-exposure to an antigen), but not primary response (the first time the immune
system encounters the antigen)146. The relationship with stress is most pronounced for
thymus-dependent vaccines and when outcomes are measured an extended time after
vaccination. More research is still needed in this area to clarify the suggested effects of
stress on vaccination responses147.
Studies examining immune parameters, clinical outcomes, and responses to
vaccination all suggest a relationship between psychosocial stress and the immune
system. Results reported by Scanlan (1998) suggest that men may be more vulnerable to
the influence of psychosocial stress on the immune system than women134. Further
research is still needed in this area.
Stress, HPV, and Cervical Cancer
If psychosocial factors such as stress can modify the immune response, then such
factors may influence HPV persistence and progression to cervical precancerous lesions
and cancers. Although no published study has evaluated psychosocial variables and HPV
viral persistence, a cross-sectional study examined perceived stress and stressful life
events in relation to T-cell proliferative responses to HPV 16 among 74 women with CIN
I and II. Stressful life events during the past six months were assessed via a modified and
shortened version of the Holmes-Rahe Social Readjustment Rating Scale; a checklist of
12 events. Perceived stress was measured by the PSS-14. In a multivariate logistic
regression including marital status, detection of HPV-16 DNA, and smoking status,
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higher perceived stress, but not number of life events, was significantly associated with
non-response to HPV 16, OR=0.91, 95%CI: 0.85-0.98148.
Chronic stress has been associated with a shift from a Th1 to a Th2 cytokine
profile148. Th1 response has been shown to be a factor in HPV persistence and
progression. Thus, the stress induced shift from a Th1 to Th2 profile could be the
biological pathway by which stress can promote HPV persistence and development of
cervical lesions.
A search of pubmed including variable combinations of the terms HPV, stress,
psychosocial, cervical, cervix, lesion, neoplasia, and cancer resulted in the identification
of eight studies reporting on the association between measures of stress and cervical
disease. Of these studies, five found a significant association between psychosocial
variables and cervical lesions or cancer28-32, whereas three failed to identify a significant
association149-151. Only one study measured perceived stress using the PSS-14.
Controlling for HPV. Among these studies of psychosocial variables and cervical
lesions, five controlled for the presence of HPV. If it is the effect of stress on the
immune system which leads to decreased immune response and decreased regulation of
HPV, then these studies could be adjusting for an intermediate factor. Immune function
would be important in both clearing the HPV infection and clearing the cervical lesion.
The studies that controlled for HPV could be looking at the association of stress and
cervical cancer apart from the effect of stress on immune function in relation to HPV.
Research that did not control for HPV may be including the effect of psychosocial
variables on HPV persistence. Determining at what point stress has an effect in the
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course of cervical disease may only be possible with a prospective study in which followup begins prior to lesion development.
Tiersma et al. (2004)150 did not find a significant relationship in an analysis of
cervical disease grade and negative life events in the past year among 342 women with
no CIN, CIN I-CIN III, and invasive carcinoma. The relevant etiologic time window
may be different for participants with advanced disease versus low grade disease such as
CIN I. Whereas one year is appropriate for lower grade disease, invasive cancers could
take years to develop and measuring stress for the previous five to ten years may be
useful in examining these associations. Interestingly, when not adjusting for birthplace,
HPV group, age, and hospital site, the p-value for total number of negative life events is
0.08.
Using participants from their previous study who had CIN I or II, Tiersma et al.
(2005)149 examined the association between number of negatively rated life events and
time until progression [those who regressed (n=51) or had stable CIN I or II (n=22)
compared to those who progressed (n=20)] and time until regression (progression or
stable CIN compared to those who regressed) among 92 women followed for a mean of
2.25 years. Including women with stable disease with both those who progressed and
who regressed may obscure differences between women who progressed compared to
women who experienced regression. Comparing each of the three groups may have been
more informative, although the small sample size may have prevented this.
Coker et al. (2003)29 examined differences in the number of stressful life events
and the number of stressful life events participants reported as very upsetting (highimpact SLE) during the past 5 years in low-income women with HSIL (n=59) or LSIL
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(n=163) and controls with normal cytology (n=160). Both the total SLE score and highimpact SLE score were associated with SIL among white women, OR=1.20, 95%CI:
1.04-1.38 and OR=1.30, 95%CI: 1.10-1.55, respectively, but not among AfricanAmerican women. When subscales were examined, only the relationship subscale was
significantly associated with SIL; the loss, financial, and violence/legal subscales were
not. White women had significantly higher total SLE, high impact SLE, and relationship
subscale scores compared to African American women. The authors speculate that
African America women may have been less willing to disclose stressful life events to an
interviewer they did not know and was not of the same race or socioeconomic status.
This could result in an underestimation of stress in African Americans and account for
the null association between SLE and SIL in this group of participants.
Two studies were conducted among HIV positive women. Pereira et al. (2003)30
abstracted SIL diagnoses at study entry and 1 year later from medical charts of 32 HIV
infected women. Women completed a 10-item abbreviated version of the Life
Experience Survey (LES) which assessed stressful life events in the past year and their
impact, extremely negative (-3) to extremely positive (+3). An average impact score for
negative events in the past 6 months was used in analysis. Higher negative life stress
impact scores were associated with progression/persistence of SIL one year later
adjusting for presence of HPV16/18, decline in CD4+CD3+, and antiretroviral use,
OR=8.58, 95%CI: 1.07-69.08.
Antoni et al. (2008)28 examined the effect of a 10-week Cognitive behavioral
stress management (CBSM) intervention compared to a 1-day CBSM seminar on cervical
neoplasia among 39 HIV+ African-American, Caribbean, and Hispanic women with a
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history of CIN I. The intervention group had significantly lower odds of cervical
neoplasia at 9-month follow-up adjusting for cervical disease at study entry, presence of
HR-HPV, HIV viral load, CD4+CD3+ cell count decline, and substance use, OR=0.04,
95%CI: 0.002-0.62. Differences in cervical neoplasia risk by experimental condition
were found among the subgroup of women who reported residual life stress at follow-up,
but not among the subgroup of women who reported no life stress at follow-up.
Studies that did not control for HPV. Goodkin et al (1986)32 found a significant
correlation between negative life events in the past six months and CIN grade among 73
women with CIN I-III or invasive cancer and benign illness (leiomyoma). Although this
study measured negative life events over 20 years (0 to 6 months, 7 months to 1 year, 1 to
5 years, 5 years 1 month to 10 years, and 10 years 1 month to 20 years time blocks), the
correlations were over the same time period for each group of disease grade.
In a study of intimate partner violence (IPV), Coker et al. (2000)31 found that ever
experiencing IPV was significantly associated with self-reported invasive cervical cancer,
RR=4.28, 95% CI: 1.94-18.39. Increasing number of years in a violent relationship, IPVassociated injuries, physical IPV scores, and sexual IPV scores were associated with
increasing risk of cervical cancer. Experiencing physical or both physical and sexual IPV
and a higher number of years in a violent relationship were significantly associated with
self-reported treatment for an abnormal Pap smear. All measures in this study were selfreported and diagnosis was not confirmed with cervical cytology or biopsy results.
Recently, Wilkerson et al. (2009)151 reported that among 265 women they found
no significant association between perceived stress or life events and cervical cytology.
Cases were patients attending a colposcopy clinic who had a history of abnormal Pap
113

smear. However, 35% of cases had normal cytology at the time of the interview.
Including these women who no longer had cervical lesions at the time of the study may
have obscured associations between women with normal cytology and those with current
cervical lesions. Except for age, cervical cancer risk factors and demographic factors
were also not significantly associated with disease in regression analysis. This study
measured perceived stress in the past month using the PSS-14. This may not include the
relevant etiologic time window as most lesions may take more than 1-2 months to
progress to CIN II or III. Failure to identify significant associations may be due to the
methodological limitations of this study.
Comparison of these studies is difficult because they used different study designs,
measures of stress, control variables, populations, outcomes, and observed participants
over different time periods. There is evidence that different types of psychosocial
variables and stress may impact the immune system differently, with some measures of
stress showing a significant association with immune outcomes while others do not
within the same study population152.
Overall, these studies indicate that there is an association between cervical lesions
and psychosocial variables, however well designed prospective studies are needed to
confirm these associations. Table A.3 presents a summary of these eight studies.
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Table A.3. Studies of Cervical Cancer and Stress

Cervical Cancer and Stress
Controlled for HPV
Study

Antoni et
al. 200828

Exposure(s)

Assessment

Cognitive
behavioral
stress
management
(CBSM)
intervention

NA

Negatively
rated life
events

Life
Experience
Survey (LES)

Social support

Social Support
Questionnaire

Tiersma
et al.
2005149

Tiersma
et al.
2004150

Coping style

Dutch Utrecht
Coping List

Total number
negative life
events

Life
Experience
Survey (LES)

Outcome(s)

Assessment

Life stress

10-item LES

Cervical
neoplasia

Cervical
biopsy

Distress

Profile of
Mood States

Progression,
stable disease,
regression of
CIN

CIN grade

Study
Design

Control Variables

Methods

Results

Time
Period

Sig

Clinical
Trial

cervical neaoplasia at
study entry, HRHPV infection, HPV
viral load, decline in
CD4+ CD3+,
substance use

39 HIV+
minority women.
10-week CBSM
intervention or 1day CBSM
workshop. 9
month follow-up.

Intervention group
reported decreased
perceived life stress and
had significantly lower
odds of cervical
neoplasia, p=0.03

9 months

Yes

Prospective

age, HPV HR/LR/-,
medical center

93 patients with
CIN 1 or 2
followed 2.25
years with halfyearly
colposcopy and
cytology.
Survival
analysis- time till
progression
versus no
progression and
time till
regression versus
no regression.

20 progressed, 51
regressed, and 22 had
stable disease. No
association between
progression or
regression of CIN and
negatively-rated life
events, lack of social
support, coping style,
and distress.

Past year at
baseline
and time
since last
visit at
follow- up

No

Casecontrol

Coping, social
support,
socioeconomic
status, age, HPV
high/low risk, Dutch
born

393 patients
from two
teaching
hospitals

When adjusted for
control variables
p=0.73. Without
adjustment p=0.08

Past year

No

Histology

Biopsy
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Coker et
al. 200329

Pereira et
al. 200330

Stressful Life
Events

Stressful Life
Events

17 negative life
events. SLE
score=sum of
number of
events in past 5
years. High
impact
SLE=sum of
events
participants
reported as
being very
upset by the
event.

10-item version
of the LES

Cases: HSIL
or LSIL on
Pap smear

Controls:
normal Pap
smear

developing
progressive/
persistence
SIL

Pap smear
with follow-up
biopsy for
cases

Medical chart
review to
follow SIL
diagnosis for 8
to 16 months

Case
control

Stratified by race and
adjusted for age, HRHPV+, and lifetime
number of male sex
partners

59 cases of
HSIL, 163 cases
of LSIL, and 160
controls. Among
whites 101 cases
and 68 controls
and among
African
Americans 119
cases and 90
controls.

HR-HPV associated
with higher SLE score,
OR=1.81, 1.00-3.28.
SLE score sig.
associated with SIL
among whites (SLE
OR=1.2, 1.04-1.38;
high impact SLE
OR=1.3-, 1.1-1.55), but
not among African
Americans. Sig. was in
the relationship stress
subscale; all 5 questions
associated with SIL
among whites.

Past 5 years

Yes

Prospective

Presence of HPV
16/18, decline in
CD4+CD3+,
antiretroviral use at
study entry

32 HIV-1+
women with a
previous
abnormal Pap
smear followed
for 8 to 16
months.

Negative Life events
sig. associated with
persistent/progressive
SIL, OR=8.58, 1.0769.08

Past Year
at baseline
with 6 to 18
month
follow up

Yes
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Did not control for HPV

Coker et
al. 200031

Goodkin
et al.
198632

Wilkerson
et al.
2009151

Current or
recent Physical
and sexual
Intimate
partner
violence (IPV)

Index of
Spouse AbusePhysical (12item version)

Battering

Women's
Experience
with Battering

Past physical,
sexual, and
psychological
IPV

Abuse
Assessment
Screen

Negatively
rated life
events

Perceived
Stress

Life
Experience
Survey (LES)

Perceived
Stress Scale

Self-reported
cervical
neoplasia with
medical record
review. Three
groups:
cervical cancer
(n=14),
cervical
dysplasia
(n=234), and
no reported
history of
cervical
neoplasia or
other cancer
controls
(n=847)

Modified
National
Health
Interview
Survey. Asked
if diagnosed
with a specific
cancer and if
had been
treated with
"cryotherapy,
laser therapy,
or any other
treatment for
abnormal Pap
smear"

uterine
leiomyomas
control group,
CIN I, II, III
and invasive
cervical cancer

Surgical
pathology
reports and
colposcopy

Abnormal
cervical
cytology

Cervical
cytology

Cross
sectional

CaseControl

Casecontrol
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Ever experienced IPV
associated with
increased risk of
cervical cancer,
adjusted RR=4.47,
1.07-19.07 and with
cervical dysplasia
adjusted RR=1.60,
1.18-2.15. Doseresponse with years in
violent relationship.

Ever
experienced
IPV, years
in violent
relationship

Yes

Yes

No

Age and pack-years
of smoking.

1152 women
recruited from
family practice
clinics.
Converted OR to
RR.

None

73 women
recruited from
UM Jackson
Department of
Gynecology

Significant correlation
between CIN promotion
and LES 0-6 months

0-6mon,
7mon-1yr,
1-5yrs,
5yr1mon10yrs,
10yr1mon20yrs

Unknown

Controls: 141
women with
normal Pap
results. Cases:
124 women
attending
colposcopy
clinic (35% had
normal Pap at
time of study)

No significant
association between
disease status and
perceived stress

Past month

Sleep
Sleep is a physiological state characterized by reduced consciousness, muscle
movement, and metabolism and alterations in the activity of the central nervous system34.
It is hypothesized to have a restorative function, but the exact functions of sleep are
unknown. Sleep is divided into rapid eye movement (REM) and non-rapid eye
movement (NREM), which is further divided into S1, S2, S3, and S4. A 90-minute cycle
in which sleep cycles through S1-S4 and REM sleep occurs five or six times per night.
Both quantity and quality of sleep are important. Chronic sleep loss results in excessive
drowsiness and diminished psychomotor performance. Short sleep duration, less than
five hours per night, and poor sleep quality have been associated with increased risks of
diabetes, hypertension, coronary heart disease, acute myocardial infarction, and
mortality34.
Previous research suggests that partial sleep deprivation (PSD) increases markers
of systemic inflammation, TNF-α and IL-1β production, and secretion of IL-6. The bidirectional communication between the brain and immune system suggests a route by
which sleep has the ability to influence the immune system34. Numerous cytokines and
other neuroendocrine substances have been associated with the sleep-wake cycle in
humans and animals. Studies have found evidence of alterations in several cytokines and
proliferation of T cells with the sleep-wake cycle12,153. Not only may sleep influence
cytokine expression, but cytokines may also influence sleep though a reciprocal
relationship154. Studies in both humans and animals have generally found increases in
sleep duration following infection153. Shared regulatory molecules between sleep and the
immune system may explain how sleep influences immunity153.
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Measurement of Sleep
Numerous instruments have been developed to measure sleep quality. Self-report
scales include both quantitative (sleep duration, sleep latency, and number of
awakenings) and qualitative aspects (restfulness, sleep satisfaction, mood, and daytime
functioning)155. In a systematic review of instruments used to assess sleep dysfunction in
adults, Devine et al.(2005)156 identified four domains of sleep that are of general interest
to measuring sleep: sleep initiation, sleep maintenance, sleep adequacy, and somnolence
or sleepiness.
Six were found to include all four domains (including the commonly used
Pittsburgh Sleep Quality Index (PSQI)44,156), however all included more than 5 items.
Four instruments included three of the four domains. The Jenkins Sleep Problems Scale
(JSPS) is an extremely brief questionnaire (3 or 4 items) that was developed for
epidemiological research17. Though it has not been widely used, it has been shown to be
reliable and valid156.
In a study of older adults and college students, Alapin et al.(2000)157 examined
participants who reported frequency of difficulty in concentrating during the day and how
distressed they were about their sleep problems on a 10-point scale ranging from not at
all to very much. Ability to concentrate during the day significantly differed between
good and poor sleepers and was significantly correlated with total sleep time, total wake
time, sleep efficiency, nocturnal tension, and distress about having sleep problems. The
single item which assessed ability to concentrate during the day was not stated. Distress
was assessed by asking, “How distressed are you by an insomnia problem?”.
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Sleep and Immunity
Sleep has been associated with immune function in both human and animal
studies.3,154,158-160 Previous research indicates that even small amounts of sleep loss can
impact immune measures154. Insufficient sleep can be attributed to inadequate duration
of sleep or poor qualitative sleep (proportion and duration of sleep stages and number of
awakenings). Though there is debate over how much sleep an individual needs, the
National Sleep Foundation recommends adults get seven to nine hours of sleep per
day161. Sleeping for 7 hours has been associated with the lowest rates of morbidity and
mortality; with both longer or shorter durations associated with increased risk153. In
modern society the average sleep duration has been declining. A study in San Diego
adults found that the average duration of sleep was only 6.2 hours per night, much less
than the 8 hour average self-reported duration found in the 1970's162.
Experimental sleep deprivation has been used to study the effects of altered sleep
patterns on immune responses in humans12. Total sleep deprivation (TSD) or continuous
wakefulness may have different effects on immune responses than partial sleep
deprivation (PSD) or a restriction from sleep for only part of the night163. Because PSD
may more closely approximate the sleep loss and disruption experienced by many people,
this review will focus on this type of sleep deprivation.
In observational studies of sleep, significant associations between NK cell
activity35,36 and NK cell number37 have been found (Table 4). In two experimental
studies of exposure to rhino virus38,39, sleep efficacy and sleep duration were associated
with illness. In experimental studies of PSD, IL-2, IL-6, TNF-α, neutrophils,
lymphocytes, NK cells, and Lymphokine-activated killer cell activity have been
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associated with sleep loss. Table A.4 presents a review of immune parameters and PSD
studies. All but the two studies which subjected volunteers to rhino virus had fewer than
50 subjects and may have been underpowered to detect small to moderate associations.
Redwine et al. (2000)164 found that the normal increase in IL-6 levels observed during
baseline sleep was delayed in men deprived of sleep during the early night (until 3 a.m.).
Evidence from Shakhar et al. (2007)36 suggests that the association between NK
cell activity and sleep may be masked by within subject variability in cross-sectional
studies. Self-reported sleep duration over the past three nights was assessed at two time
points. In cross-sectional analyses, NK cell activity was associated with sleep duration
the previous night for the second time point, but not the first. Changes in NK cell activity
were significantly associated with changes in sleep duration the previous night.
Therefore some of the reported studies may be limited by their cross-sectional design.
Table 4 presents a summary of the associations between immune parameters and selfreported sleep or experimental PSD.
In a study of immune responses to influenza vaccination, Spiegel (2002)52
compared 11 healthy men who were subjected to PSD to 14 control subjects. Men in the
experimental group were only allowed to sleep from 1-5AM over the first six nights. The
morning following the fourth night of PSD they were administered the influenza vaccine.
After the initial six nights of PSD they were allowed to sleep 12 hours per night. Antiinfluenza IgG antibody titers were assessed before vaccination and at 10 days and 21 to
30 days post vaccination. At 10 days post vaccination mean antibody titers in the PSD
group were significantly lower than the control group (p=0.03). At 21 to 30 days there
were no significant differences in antibody titer, indicating that antibody titers may
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recover after sleep is restored. This suggests that patients who are chronically sleep
deprived may have poorer responses to influenza vaccination. A similar study in 19
healthy men and women found that one night TSD before administration of Hepatitis A
vaccine was associated with (p=0.18) lower antibody titers up to 28 days post
vaccination165.
Sleep may have an impact on the Th1 to Th2 ratio. In a study of one night TSD in
14 healthy men, Dimitrov (2004)166 found that compared to wakefulness, sleep in the
early part of the night shifted the Th1/Th2 ratio towards increased Th1 responses
(measured by INF-γ/IL-4 ratio). This ratio then shifted towards Th2 activity in the later
part of the night. None of the PSD or observational studies reported results for the
Th1/Th2 ratio.
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Table A.4. Immune Parameters and Associations with Sleep.

Immune parameter

Study

Time
Design
N frame
Exposure
Partial Sleep Deprivation Experimental Studies

Outcome

P
value

Population

IL-2
Con-A stimulated
production
IL-6

IL-6 concentration
stimulated
production of IL-6
TNF-α
stimulated
production of TNFα
Total White blood cells

Irwin 1996167

PSD-E
compared to
baseline

↓ compared to
baseline

experimental 26 1 night

PSD-E
compared to
baseline
PSD-E
compared to
baseline

↓ IL-6
compared to
baseline
↑ IL-6
compared to
baseline

experimental 26 1 night

PSD-E
compared to
baseline

↑ TNF-α
compared to
baseline

experimental 42 1 night

PSD-E
compared to
baseline

No significant
ass.

p>0.05 healthy men

experimental 42 1 night

PSD-E
compared to
baseline

No significant
ass.

p>0.05 healthy men

experimental 42 1 night

Redwine 2000164 experimental 31 1 night
Irwin 2010168

Irwin 2010

Irwin 1996

p<0.01 healthy men

p<0.05 healthy men

p<0.01 healthy adults

p<0.01 healthy adults

Neutrophils

number

Irwin 1996
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percent
Lymphocytes

Irwin 1996

experimental 42 1 night

number

Irwin 1996

experimental 42 1 night

percent
NK cells

Irwin 1996

experimental 42 1 night

Number

Irwin 1996

experimental 42 1 night

Irwin 2008169 experimental 14 1 night
Percentage

Irwin 1996

experimental 42 1 night

NK cell activity

Irwin 1996

experimental 42 1 night

Irwin 1994158 experimental 23 1 night
Lymphokine-activated killer cell activity
NF-κB activation

PSD-E
compared to
baseline

↓ compared to
baseline

p<0.01 healthy men

PSD-E compared
to baseline
PSD-E compared
to baseline

↑ compared to
baseline
↑ compared to
baseline

PSD-E compared
to baseline
PSD-E compared
to baseline
PSD-E compared
to baseline
PSD-E compared
to baseline
PSD-L compared
to baseline

↓ compared to
baseline

↓ compared to
baseline

p<0.01 healthy men

No significant ass.
↓ compared to
baseline
↓ compared to
baseline
↓ compared to
baseline

p<0.01 healthy men
p<0.01 healthy men

p<0.01 healthy men
healthy men
p>0.05 and women
p<0.01 healthy men
p<0.05 healthy men
p<0.01 healthy men

Irwin 1996

experimental 42 1 night

PSD-E compared
to baseline

Irwin 2008

experimental 14 1 night

PSD-E compared
to baseline

↑ compared to
baseline

healthy men
p<0.01 and women

Irwin 2008

experimental 14 1 night

PSD-E compared
to baseline

No significant ass.

healthy men
p>0.05 and women

CD3
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CD4
Irwin 2008

experimental

1
4

1 night

PSD-E compared to
baseline

No significant ass.

p>0.0
5

healthy men and
women

Irwin 2008

experimental

1
4

1 night

PSD-E compared to
baseline

No significant ass.

p>0.0
5

healthy men and
women

Irwin 2008

experimental

1
4

1 night

PSD-E compared to
baseline

No significant ass.

p>0.0
5

healthy men and
women

Irwin 2008

experimental

1
4

1 night

No significant ass.

p>0.0
5

healthy men and
women

Hall
199837

crosssectional
crosssectional
crosssectional
crosssectional
crosssectional
crosssectional

2
9
2
9
2
9
2
9
2
9
2
9

3
nights
3
nights
3
nights
3
nights
3
nights
3
nights

p<0.0
5
p>0.0
5
p>0.0
5
p>0.0
5
p>0.0
5
p>0.0
5

Depressed
patients
Depressed
patients
Depressed
patients
Depressed
patients
Depressed
patients
Depressed
patients

CD8

CD19

CD14

NK cells
Numbe
r

Hall 1998
Hall 1998
Hall 1998
Hall 1998
Hall 1998

PSD-E compared to
baseline
Observational Studies

Time awake in NREM- ↑time awake ass.
1
↓NKC
Sleep quality

No significant ass.

sleep latency

No significant ass.

REM latency

No significant ass.

Total delta NREM-1

No significant ass.

sleep maintenance

No significant ass.
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Irwin 1992

crosssectional
crosssectional
crosssectional
crosssectional
crosssectional
crosssectional
crosssectional
crosssectional

2
9
2
9
2
3
1
7
2
3
1
7
2
3
1
7

Shakhar
200736

crosssectional

4
5

prospective
crosssectional
crosssectional

4
5
2
9
2
9

Hall 1998

NKCA

Hall 1998
Irwin
199235
Irwin 1992
Irwin 1992
Irwin 1992
Irwin 1992

Shakhar
2007
NK %
lysis

Hall 1998
Hall 1998

3 nights

Total NREM

3 nights
1 or 2
nights
1 or 2
nights
1 or 2
nights
1 or 2
nights
1 or 2
nights
1 or 2
nights

Total delta all night
Sleep latency
Sleep latency
Total sleep time
Total sleep time
Sleep efficiency
Sleep efficiency

3 nights

Self-reported sleep
duration over past 3
nights
Self-reported sleep
duration over past 3
nights
Time awake in
NREM-1

3 nights

Sleep quality

3 nights

1 months
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No significant
ass.
No significant
ass.
No significant
ass.
↑sleep lat.
↓NKCA
↑sleep time
↑NKCA
↑sleep time
↑NKCA
↑sleep eff.
↑NKCA
↑sleep eff.
↑NKCA
↑sleep time ass.
↑NKCA (2nd
time point, but
not 1st)

p>0.0
5
p>0.0
5
p>0.0
5
p<0.0
5
p<0.0
1
p<0.0
5
p<0.0
5
p<0.0
5

Depressed
patients
Depressed
patients
depressed
patients
community
controls
depressed
patients
community
controls
depressed
patients
community
controls

p<0.0
5

healthy women

↑Δsleep time ass.
↑ΔNKCA
No significant
ass.
No significant
ass.

p<0.0
5
p>0.0
5
p>0.0
5

healthy women
Depressed
patients
Depressed
patients
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Hall 1998

cross-sectional

29

3 nights sleep latency

Hall 1998

cross-sectional

29

3 nights REM latency

Hall 1998

cross-sectional

29

3 nights Total delta NREM-1

Hall 1998

cross-sectional

29

3 nights sleep maintenance

Hall 1998

cross-sectional

29

3 nights Total NREM

Hall 1998 cross-sectional
Occurrence of cold after experimental exposure

29

3 nights Total delta all night

Infection
and illness

Cohen
199738

experimental

276

past
month

Sleep efficacy
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No
significant
ass.
No
significant
ass.
No
significant
ass.
No
significant
ass.
No
significant
ass.
No
significant
ass.
sleep eff.
≤0.80 ass.
↑colds

p>0.05

Depressed patients

p>0.05

Depressed patients

p>0.05

Depressed patients

p>0.05

Depressed patients

p>0.05

Depressed patients

p>0.05

Depressed patients

OR=2.8 healthy men and
(1.2-4.8) women
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Infection
<7 hrs
and
sleep ass.
objective
14 days
↑ colds
signs of
prior to
compared OR=2.9
illness
Cohen 200939 experimental 153 baseline Average sleep duration to ≥8 hrs (1.2-7.3)
Infection
sleep eff.
and
<0.92 ass.
objective
14 days
↑colds
OR=5.58
signs of
prior to
compared
(2.1illness
Cohen 2009
experimental 153 baseline Sleep efficacy
to >0.98
14.5)
Note: All tests of significance are of adjusted tests if reported.
EEG (Electroencephalograph)
PSD-E (Early night partial sleep deprivation - awake until 0300)
PSD-L (Late night partial sleep deprivation - awake 0300 to 0700)
Con A (Concanavalin-A)
NF-κB (nuclear factor-κB - transcription control pathway of cellular expression of proinflammarotry genes
NKCA (Natural killer cell activity)
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healthy men and
women

healthy men and
women

Poor sleep quality and sleep loss are common and the prevalence has been
increasing162. Like stress, acute sleep deprivation may actually increase immune
responses, whereas if sleep loss becomes chronic it can negatively impact immune
function153. If chronic partial sleep loss does indeed affect immunity, the public health
implications are vast, as this is the type of sleep alteration that prevails in modern society
due to factors such as shift work, pressured lifestyles, and other stresses153. Despite their
limitations, these studies provide evidence that sleep can affect the immune system. The
effects of sleep deprivation on clinical outcomes requires further research154.
Sleep and Cervical Cancer
There are no published studies of sleep and cervical cancer. One study examined
sleep quality and depression on immunocompetence in women at risk for cervical cancer.
Sleep satisfaction was significantly associated with the number and percentage of helper
T cells and percentage of cytotoxic T cells, even after controlling for depression.3
Sleep and Stress
Results of several studies suggest that sleep and stress may interact. Sleep
measures have been shown to mediate the relationship between stress and number of NK
cells37,170. Among 57 HIV-positive patients, Impact of Events Scale (IES) scores (a
measure of intrusive and avoidant thoughts) and PSQI scores were significantly
associated with CD3+CD8+ cell counts. In a path analysis of IES and PSQI scores, the
direct association between IES and CD3+CD8+ was no longer significant. PSQI scores
remained significant, with 23% of the variance in CD3+CD8+ cells accounted for in the
full model with IES and PSQI.
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In a study of 29 patients seeking treatment for bereavement related depression,
time awake during NREM sleep accounted for 12% of the variance in NK cell number
while IES accounted for 7%. When time spent awake during NREM sleep was entered
into a regression model with IES scores, the association of intrusive thoughts and
avoidant behaviors was no longer significant. The small sample size may have limited
the ability to detect significant effects for IES accounting for sleep37. In a study of an
acute laboratory stressor in 39 health women, NK cell mobilization was significantly
reduced in women with a high amount of time awake after sleep onset171. Therefore
including a measure of sleep may be important in assessing the role of stress with regard
to immune or clinical outcomes.
Summary
HPV causes genital warts and is associated with anogenital and oro-pharangeal
cancers. Most individuals will be infected with HPV at some point, but will mount an
effective immune response and clear the infection. Persistence of HPV infection is an
important step in the pathway to neoplastic lesions and cancer. Factors that influence
persistence of HPV remain to be elucidated. It is a common belief that high stress and
sleep loss can cause an increased susceptibility to infection. Stress and sleep have been
associated with changes in immune response in many scientific studies. Specifically,
stress may induce a shift from a Th1 type immune response towards Th2 type immunity.
A Th1 type response may be important in successful clearance of HPV. If stress and
sleep affect immunity this could have implications for the host's ability to successfully
respond to an HPV infection. Since the immune system protects against both infection
and malignancies, behaviors such as increased stress and decreased sleep duration could
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affect both the persistence of the HPV infection and the lesions resulting from a persistent
HPV infection. Identifying the relationship between stress, sleep and immunity is an
important public health endeavor.
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Appendix B. Parent Studies

Data for this analysis was drawn from two parent studies conducted at the
University of South Florida and Moffitt Cancer Center.
The Natural History of HPV in Men Study
The Natural History of HPV in Men (HIM) Study is a prospective natural history
study of HPV in men. A convenience sample of over four thousand men ages 18 to 70
were recruited from the Central Florida area, as well as Sao Paulo, Brazil and the state of
Morelos, Mexico. Eligibility criteria for inclusion in the study were: (a) aged 18-70
years; (b) residents of one of the three sites - central Florida, US, Sao Paulo, Brazil, or
Morelos, Mexico; (c) no self-reported prior diagnosis of penile or anal cancers; (d) never
diagnosed with genital or anal warts; e) have not participated in an HPV vaccine study; f)
no self-reported prior diagnosis with AIDS or HIV; g) no reported current penile
discharge or burning during urination; h) not currently being treated for an STI; i) have
not been imprisoned or homeless during the last 6 months; j) have not been in drug
treatment during the last 6 months; k) no plan to relocate in the next 4 years; and l)
willingness to comply with 10 scheduled visits every six months for four years. The
proposed research will use data from men in the US cohort.
Men in the US cohort were recruited from the University of South Florida
(students, faculty, and staff) and the general population of the greater Tampa
metropolitan area using multiple strategies including: face-to-face recruitment in
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classrooms and workplace settings; publicity at mass events through Brochures and
posters with tear off phone numbers; targeted mailings via e-mail and hard mail; radio
and newspaper advertisements targeting men; word of mouth; and peer leaders of groups
with a predominately male membership. A total of 1,427 men were enrolled into the
HIM study at the U.S. site.
The HIM study protocol includes a total of ten visits: a pre-enrollment run-in visit
including informed consent, a baseline enrollment visit, and eight follow-up visits
scheduled every 6 months. At each visit a sexual history computer-assisted self interview
(CASI) questionnaire is administered, a visual inspection of the skin and external
genitalia is conducted, and blood and penile skin samples are collected. Penile samples
are collected to detect genital HPV. First, any warts or lesions on the penis are sampled
by wetting a Dacron applicator with sterile normal saline, swabbing the penis, and
placing the swab in buffered preservative solution designed to preserve DNA, RNA, and
protein (Specimen Transport Medium - STM). After sampling any warts or lesions, a
new wet swab is used to sweep 360° around the coronal sulcus and then another 360°
around the glans penis. This swab is then placed into a separate collection vial with STM
labeled by anatomic site. Another wet swab is used to sample the entire skin surface of
each of the four quadrants of the shaft of the penis (left and right ventral, and left and
right dorsal) and placed into a vial of STM. All HPV samples are stored in a –20oC
freezer until transfer to the University of South Florida laboratory where they are stored
at –70 oC until PCR analyses and genotyping is performed.
Exfoliated penile cell samples are tested for HPV DNA using polymerase chain
reaction (PCR) amplification of a fragment of the L1 gene. To determine specimen
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adequacy, GH20/PC04 human ß-globin target is co-amplified. For every 20 samples a
negative control (H2O) and a positive control (CaSki Cells) are run for accuracy and to
control for possible contamination. One randomly re-sampled clinical sample is included
for every 20 samples as a blinded quality control. HPV genotyping is conducted on all
samples regardless of results by PCR using the reverse line blot method. The HPV
genotype strip contains 40 probe lines, 37 for detecting individual HPV genotypes (6, 11,
16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51 to 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73,
81, 82, 83, 84, IS39, and CP6108) and two concentrations of the ß-globin control probe.
(Roche Molecular Diagnostics, Alameda, CA).
There is no FDA approved test for HPV in men; HPV testing in this study is for
research purposes only and is not available in regular clinical care. At every study visit a
nurse practitioner provides each participant general oral and written materials about
HPV. Materials explain that HPV can be sexually transmitted and is associated with
certain cancers and genital warts. Participants are told their HPV test results from the
previous visit at each 6-month follow-up visit and are counseled on what the results mean
by the nurse practitioner. They are also reminded that the results are not FDA-approved
for men and are for research purposes only.
Strategies to retain participants in the study for four years include: a preenrollment run-in visit, updating contact information at each visit (phone numbers, e-mail
addresses, mailing addresses), reminder calls and/or e-mails the day prior to scheduled
appointments, monetary compensation of $540 over the ten visits, empathetic and warm
staff who can establish a rapport with participants to encourage disclosure of sexual
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conduct and minimize embarrassment during the genital exam, and a retention specialist
to identify participants who are lost to follow-up.
The Cognitive and Emotional Responses to an HPV Test Result (CER) Study
The Cognitive and Emotional Responses (CER) Study is the behavioral arm of the
larger HIM Study conducted in the US cohort of men. This research assesses men’s
cognitive and emotional responses to receiving an HPV test result. After completing the
third HIM visit, the first time they are given HPV test results, all HIM participants are
invited to participate in the CER study. After providing informed consent, men complete
a CASI approximately two to four weeks after they receive their previous HPV test result
through the HIM study (Figure 1). At each of the four CER visits, participants complete
the CER CASI questionnaire on a private computer workstation at the HIM study
location. This survey takes approximately 30 minutes to complete. Instrument items
assess a range of variables including HPV knowledge, attitudes and beliefs about HPV,
sexual behavior, sexual partnership status, information-seeking behavior, preventative
behaviors, emotional responses to receiving HPV test results, perceived threat of genital
warts and cancers, and HPV vaccine intentions. Participants are compensated with $130
for completing four study visits. The amount of compensation increases with each
subsequent visit; $25, $30, $35 and $40 at visits 1 though 4, respectively. A total of 565
men were recruited into the CER study and completed the first study visit from March
2007 to March 2010. An estimated 489 participants will complete the second visit for a
retention rate of 87% from the first visit to the second.
Because the CER study is an ongoing research study examining psychosocial
factors in a cohort of men tested for HPV every six months, it provides an excellent
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opportunity to gather data on psychosocial factors which may be associated with
persistence of an HPV infection.
Figure B.1. Timeline of HPV in Men (HIM) and Cognitive and Emotional Responses to
an HPV Result (CER) Studies

Associations of HPV and Stress and Sleep (HASS) Study
The proposed research will utilize a sub-sample of the CER cohort to examine the
associations of HPV and stress and sleep (HASS). Items concerning perceived stress and
sleep were added to the CER CASI in June 2009, midway through participant
recruitment. There were 55 participants who completed their last CER survey prior to
initiation of the stress and sleep items. Other participants first received the additional
items at their first, second, third, or forth CER visit. Eligibility for inclusion into the
HASS study will be (a) participants must have completed the stress and sleep items on
the CER CASI at least one time and (b) participants must have completed the CER CASI
within 45 days of their previous HIM study visit. CER study visits which occur after 45
days following a HIM study visit will be excluded because a longer time window will not
measure the appropriate time for exposure. Figure B.2 provides a diagram of the HIM,
CER, and HASS study structure.
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Figure B.2. Structure of the HIM, CER, and HASS Studies.
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Appendix C. Measures of Stress and Sleep

On each CER survey (administered every 6 months), all participants are asked
about their perceived stress and sleeping habits during the time since they last took the
survey. These additional questions were added in June 2009, about mid-way through
participant recruitment. Of the 565 men recruited into the CER study, 445 responded to
the additional items at least one time. Of the 445 who responded to the additional items,
426 (96%) completed the survey within 45 days of their most recent HIM study visit.
There are a total of 997 eligible visits among 426 CER participants. Of the 997 visits, 109
26% of the men) had 1 eligible visit or approximately 6 months of follow-up, 120 (28%)
had 2 eligible visits or 12 months of follow-up, 140 (33%) had 3 eligible visits or 18
months of follow-up, and 57 (13%) had 4 eligible visits or approximately 2 years of
follow-up time.
Data from the baseline visit was used in the analysis of HPV prevalence (Aim 1).
The persistence analysis (Aim 2) was limited to men who tested positive for HPV. There
were a total of 500 infections among 222 men. Among HPV positive men, perceived
stress and sleep problems were compared between those who test negative (clearance)
and those who continue to test positive for the same HPV type (persistence) at their next
study visit. It was hypothesized that perceived stress and sleep will have an impact on
immune function and this will result in decreased clearance of HPV infection among
participants with higher stress and sleep problems, Figure C.1.
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Figure C.1. Hypothesized Interactions between Perceived Stress, Sleep, and HPV
persistence.

Stress
Though there is no gold standard for assessing stress, however perceived stress
has commonly been assessed by the Perceived Stress Scale developed by Cohen and
Williamson (1998)16. All three versions have been found to possess good psychometric
qualities14, with the 4-item version having a reported reliability coefficient of 0.60117.
Because the questions are general, the scale can be used in diverse populations114. The 4item version has been suggested for studies where there is time constraints such as in the
present study117. These four questions can be completed in just a few minutes114.
Therefore, this research study uses a modified version of the four-item PSS. Because
participants in the HIM study are assessed every 6 months, using the original time frame
of one month will not measure stress during the entire period between visits and may not
be predictive of health outcomes. Therefore, the items in the PSS-4 were modified to
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assess stress in the past six months as reported in a comparison study of the one month
and 6 month PSS and a life events scale by Pbert et al. (1992)43. The General PSQ
developed by Levenstein et al. (1993)118 had a higher correlation with hospitalization and
rectal inflammation than the Recent PSQ. Thus, assessing stress in the past 6 months
may be a better predictor of HPV status than stress experienced in the past month. Table
5 contains a list of the four questions added to the CER CASI.
Sleep
Due to time constraints, a very limited number of items could be used to assess
sleep quality. No existing sleep questionnaire was both brief and included at least one
item to measure all aspects of sleep which may be relevant to this research. The threeitem version of the JSPS, a brief reliable scale17, assess trouble falling asleep, trouble
staying asleep, and waking up feeling tired. This three-item scale was included in the
added items. However, this scale does not include items which assess the duration or
quality of sleep. The Pittsburgh Sleep Quality Index (PSQI) is a validated instrument that
has been used extensively in the literature, however the entire 19-item scale is too long
for inclusion in the CER survey156. Of these19-items encompassing 7 domains44,
subjective sleep quality and sleep duration, may be associated with immune status and are
of interest for this research. Therefore, these two items were included in the questions
added to the CER survey. The subjective sleep quality question asks participants to rate
their sleep quality overall and has four responses ranging from very good to very bad.
The sleep duration question asks participants how many hours and minutes of sleep they
get at night.44,156
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Alapin et al. (2000)157 showed that both the ability to concentrate during the day
and sleep problem distress may be import aspects of sleep disturbance. Alapin et al.
(2000)114 did not report the item used to assess ability to concentrate. The item used to
assess distress asked, "How distressed are you by an insomnia problem?". This question
was modified as this survey will not be administered in a clinical population. To assess
these two aspects of sleep in the CER questionnaire, two four-point likert questions:
“Does not sleeping affect your ability to concentrate or get things done during the day?”
and “How bothered are you by your sleep problems?” were included.
HPV Status
This analysis will look at the prevalence of HPV in the entire cohort of men and
subsequent detection of an HPV infection of the same type among participants testing
positive for any of the 37 types of HPV included in the HIM study. For HPV prevalence,
men who are negative for all HPV types will be the comparison group in all analyses.
HPV clearance will be defined as a negative HPV test result following a positive HPVtest. HPV persistence will be defined as HPV infection of the same type detected at two
or more consecutive clinical visits. Men will be followed from 6 to 24 months from the
date of testing positive for HPV. Length of time followed will depend on date of entry
into the study and date of HPV acquisition.
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Appendix D. Stratification Brief

Abstract
Human papillomavirus (HPV) is the most common sexually transmitted infection
in the US and is associated with genital warts, ano-genital cancers, and oropharyngeal
cancers. We previously reported associations between HPV prevalence with perceived
stress and self-reported sleep problems among men. To further investigate these
associations, we examined the relationships between these factors within subgroups of
demographic factors. Generalized estimating equations using all 997 study visits among
426 men were employed to calculate odds ratios (OR) and 95% confidence intervals
(95% CI). Associations between perceived stress and HPV prevalence differed by age
category and marital status. Among men aged 50 and older and single men, those with
high stress were significantly more likely to be infected with oncogenic HPV compared
to those with low stress, Adjusted OR (AOR)=3.66 (95% CI: 1.25-10.67) and AOR=2.03
(95% CI: 1.29-3.22). Associations between self-reported sleep problems and HPV
prevalence differed by age category, education, and marital status. Among men 30 to 49
participants with low self-reported sleep problems were significantly more likely to be
infected with any HPV type, AOR=2.34 (95% CI: 1.19-4.62), compared to men with
moderate sleep problems. Among college educated men, participants with low sleep
problems were more likely to be infected with any HPV, AOR=1.70 (95% CI: 1.06-2.73),
and oncogenic HPV, AOR=1.74 (95% CI: 1.04-2.90) and men with high sleep problems
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were significantly more likely to be infected with oncogenic HPV, AOR=2.44 (95% CI:
1.32-4.50). Results suggest that associations between perceived stress and sleep problems
may be moderated by demographic factors.
Introduction
Infection with one or more of the 40 ano-genital types of human papillomavirus
(HPV) is the most common sexually transmitted infection (STI) in the US 1. A review of
HPV prevalence in men 172 found that estimates of prevalence ranged from 26% to 65%
in North American populations. Infection with oncogenic HPV types is associated with
cervical intraepithelial neoplasia and cervical cancer in women. These types have also
been associated with other ano-genital cancers, such as penile, anal, and vulvar cancer, as
well as a portion of oropharyngeal cancers. Infection with non-oncogenic types is
associated with condylomata (genital warts) 173.
In a previous publication, we reported associations between perceived stress and selfreported sleep problems among a sample of men tested for HPV at the baseline study
visit. In this cross-section study, men with high perceived stress were significantly more
likely to be infected with any HPV type and any oncogenic HPV type compared to men
with low perceived stress. Men with high self-reported sleep problems were significantly
more likely to be infected with any oncogenic HPV type compared to men with moderate
sleep problems. To further investigate relationships between perceived stress, selfreported sleep problems, HPV prevalence, and demographic factors, stratified analyses
were conducted utilizing all study visits.
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Methods
Participants
Details of this study can be found in Kolar et al. (2013). In brief, men are tested
for 37 individual HPV genotypes every 6 months as part of a large natural history study
of HPV in men (the HIM Study) conducted in the US, Mexico, and Brazil 41. A subset of
these men participating in the US cohort were invited to participate in a behavioral study
(the CER study) which collected additional behavioral and psychosocial information on
HIM Study participants 42.
Men participating in the HIM study were invited to participate in the CER at their third
HIM study visit. CER study participants completed the additional questionnaire
approximately 2 to 4 weeks after each 6-month HIM study visit. CER participants
completed the survey 4 times over 2 years. Midway through CER study recruitment,
items to assess perceived stress and self-reported sleep problems were added to the
survey. Men who completed these additional items within 45 days of their corresponding
HIM study visit were eligible for inclusion in the present analysis.
Measures
The 4-item Perceived Stress Scale 16 was modified to assess perceived stress in
the past 6 months. We previously found that men in the highest quartile of stress scores
had a higher prevalence of HPV and dichotomized stress as high (highest 25% of stress
scale scores) and low (lower 75% of stress scale scores.
Self-reported sleep problems were assessed with 7 items including the three-item
version of the Jenkins sleep problems scale (JSPS) which assessed trouble falling asleep,
trouble staying asleep, and waking up feeling tired 17 and 4 additional items which
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assessed sleep duration, subjective sleep quality, daytime functioning, and sleep distress.
All response options were on a 4-point likert scale. Self-reported sleep problems were
categorized as low (lower 25% of sleep scale scores), moderate (middle 50%), and high
(top 25%). Men in the moderate category were the reference category because they had
the lowest prevalence of HPV.
Men were considered positive for 'Any HPV' if they tested positive for any of the
37 HPV genotypes in the study protocol. Men were considered positive for 'Oncogenic
HPV' if they tested positive for any oncogenic HPV type (regardless of also testing
positive for a non-oncogenic HPV type) and positive for 'Non-oncogenic HPV' if they
only tested positive for one or more non-oncogenic HPV genotypes. Men PCR negative
for the 37 types and men who were only positive for unclassified HPV types were the
reference group in this analysis.
Statistical Analysis
Population-averaged generalized estimating equation models with an
autoregressive correlation structure were employed to include all eligible visits 69,174. This
method allows for the correlation between repeated measures of each subject to be taken
into account. Analyses were conducted within each category of demographic factors that
had significant interaction terms with perceived stress and self-reported sleep problems in
multivariable models. Univariate and adjusted odds ratios (AOR) and 95% confidence
intervals (95% CI) are reported. The proc genmod procedure in SAS version 9.3 (Cary,
NC) was used to conduct analyses.
Multivariable analyses for perceived stress were adjusted for age, health insurance
status, education, marital status, and number of vaginal sex partners in the past six
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months. Multivariable analyses for self-reported sleep problems were adjusted for age,
health insurance status, education, marital status, lifetime number of sex partners,
smoking status, and alcohol consumption. We did not further adjust models for both
perceived stress and self-reported sleep problems because in our previous analysis of
these factors with HPV prevalence adjustment for the second exposure did not affect
estimates. The majority of men were white (68%) and were circumcised as determined by
a HIM study physician (79%). These factors were not significantly associated with HPV
prevalence in this sample of men, therefore they were not included in multivariable
models.
Results
A total of 997 visits among 426 men were eligible for analysis. Of these visits,
HPV genotyping was available for 995. Greater than 99% (992) of visit surveys had all
stress items completed and 98% (974) had all sleep problems items completed.
Perceived Stress and HPV Prevalence
Perceived stress was significantly associated with oncogenic HPV infection in the
total sample (table D.1), AOR=1.48 (95% CI: 1.06-2.07). Interactions with perceived
stress were significant for age category and marital status. Among men aged 50 and
older, those with high stress were significantly more likely to be infected with oncogenic
HPV, AOR=3.66 (95% CI: 1.25-10.67). Among men 18 to 29 and 30 to 49, differences in
HPV prevalence were smaller and were not statistically significant. Among men who
were single, those with high stress were significantly more likely to be infected with
oncogenic HPV, AOR=2.03 (95% CI: 1.29-3.22).
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Self-reported Sleep Problems and HPV Prevalence
Self-reported sleep problems was associated with infection of any HPV type and
oncogenic HPV in the total sample, although differences were only significant among
men with low self-reported sleep problems compared to men with moderate sleep
problems (table D.2), any HPV AOR=1.42 (95% CI: 1.04-1.94) and oncogenic HPV
AOR=1.48 (95% CI: 1.08-2.05). Interactions with self-reported sleep problems were
significant for age category, education, and marital status. Due to small numbers, we
were unable to estimated adjusted odds ratios for all categories of these demographic
variables. Among men 30 to 49, men with low self-reported sleep problems were
significantly more likely to be infected with any HPV type, AOR=2.34 (95% CI: 1.194.62). Differences among men with low sleep problems were significant in univariate
analysis for non-oncogenic HPV among men 30 to 49, OR=.31 (1.22-4.39), and for any
HPV type among men 50 and older, OR=2.09 (1.01-4.32). Among men with a college
degree (2-year, 4-year, or graduate), those with low sleep problems were more likely to
be infected with any HPV type, AOR=1.70 (95% CI: 1.06-2.73), and oncogenic HPV,
AOR=1.74 (95% CI: 1.04-2.90) and men with high sleep problems were significantly
more likely to be infected with oncogenic HPV, AOR=2.44 (95% CI: 1.32-4.50),
compared to men with moderate sleep problems. Among married men, those with low
self-reported sleep problems were more likely to be infected with any HPV type,
OR=2.05 (95% CI: 1.06-3.97) and non-oncogenic HPV, OR=2.25 (95% CI: 1.10-4.59),
in univariate analyses.
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Discussion
This analysis found evidence for effect modification in the relationship between
HPV prevalence with perceived stress and self-reported sleep problems. Estimates of the
association between stress and HPV prevalence were higher among men who were older
or single and estimates of the association between sleep problems and HPV prevalence
were higher among men who were older, were college educated, or were married.
Immune function declines with age and it has been hypothesized that stress may
result in greater immunological changes among older individuals 64. In a study comparing
immune response to influenza vaccination among caregivers and controls, Kiecolt-Glaser
et al. (1996)65 found that differences in antibody titers were greater among participants
>70 years old. Among men 50 and older in this study, the estimate of the association
between perceived stress and oncogenic HPV prevalence was higher than for younger
men. Estimates of the association between self-reported sleep problems with any HPV
and non-oncogenic HPV were higher for men 30 to 49 and men 50 and older. However,
the small number of men over 50 in this sample limits the ability to examine the effects
of older age on perceived stress and self-reported sleep problems with HPV prevalence.
There are several limitations other to the present analysis. This was a sample of
men who were mostly white and were participating in a longitudinal study of HPV
infection in men, therefore the sample may not be representative of all men with HPV or
of women with HPV. Measures of stress, sleep problems, and demographic
characteristics were all self-reported by study participants and information on specific
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immune parameters, biological indicators of stress, and drug/medication use was not
available for inclusion into the analysis.
This analysis adds to our previous report of the association between perceived
stress and self-reported sleep problems with HPV prevalence. In this analysis, perceived
stress was only associated with oncogenic HPV, which are the types of HPV associated
with cancers of the ano-genital and aerodigestive tracts. Self-reported sleep problems was
associated with oncogenic and non-oncogenic HPV types. Odds ratios were higher for
men 50 and older for both perceived stress and sleep problems. These differences by
demographic factors may be important aspects to consider in future research to ensure
adequate sample sizes.
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Table D.1. Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV infection
among participants with high perceived stress to participants with low perceived stress stratified by demographics and sexual
behavior.

Any HPV Type
Perceived stress
Total sample
Low
High
Age
18 to 29
Low
High
30 to 49
Low
High
≥50
Low
High

Univariate
OR (95% CI)

Any Oncogenic HPV Type
a

Multivariable
OR (95% CI)

Univariate
OR (95% CI)

Any Non-oncogenic HPV Type
a

Multivariable
OR (95% CI)

Univariate
OR (95% CI)

Multivariablea
OR (95% CI)

1.00
1.33

(0.96-1.84)

1.00
1.40

(0.99-1.98)

1.00
1.40

(1.02-1.93)

1.00
1.48

(1.06-2.07)

1.00
1.17

(0.80-1.72)

1.00
1.14

1.00
1.03

(0.70-1.51)

1.00
1.06

(0.71-1.57)

1.00
1.17

(0.77-1.77)

1.00
1.38

(0.88-2.18)

1.00
1.06

(0.61-1.84)

1.00
NE

1.00
1.26

(0.76-2.09)

1.00
1.26

(0.74-2.16)

1.00
1.37

(0.73-2.58)

1.00
1.41

(0.73-2.75)

1.00
1.21

(0.64-2.28)

1.00
1.19

(0.60-2.34)

1.00
1.74

(0.73-4.14)

1.00
1.82

(0.64-5.13)

1.00
2.48

(1.03-5.96)

1.00
3.66

(1.25-10.67)

1.00
1.13

(0.43-3.01)

1.00
1.11

(0.36-3.45)
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(0.78-1.68)

Table D.1 continued
Marital Status
Unmarried, Single
Low
1.00
High
1.38 (0.90-2.11)
Unmarried, living with partner
Low
1.00
High
0.95 (0.41-2.17)
Married
Low
1.00
High
0.84 (0.47-1.49)
Separated/ Divorced, widowed
Low
1.00
High
1.81 (0.95-3.44)
a

1.00
1.48

(0.96-2.27)

1.00
1.73

(1.11-2.71)

1.00
2.03

(1.29-3.22)

1.00
1.26

(0.70-2.25)

1.00
1.23

(0.68-2.21)

1.00
1.11

(0.41-3.01)

1.00
0.56

(0.17-1.81)

1.00
0.52

(0.14-1.88)

1.00
1.78

(0.63-5.06)

1.00
1.55

(0.42-5.70)

1.00
0.86

(0.45-1.64)

1.00
0.81

(0.42-1.56)

1.00
0.84

(0.31-2.26)

1.00
0.95

(0.49-1.86)

1.00
1.00

(0.48-2.08)

1.00
1.76

(1.05-2.93)

1.00
1.79

(0.80-4.02)

1.00
1.99

(0.96-4.12)

1.00
1.40

(0.76-2.57)

1.00
NE

Multivariable model adjusted for age, insurance, education, marital status, number of vaginal sex partners in the past 6 months, and prevalence of HPV infection
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Table D.2. Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV infection
among participants with low and high sleep problems compared to those with moderate sleep problems stratified by demographics and
sexual behavior.

Any HPV Type
Sleep problems
Total sample
Low
Moderate
High
Age
18 to 29
Low
Moderate
High
30 to 49
Low
Moderate
High
≥50
Low
Moderate
High

Univariate
OR (95% CI)
1.29
1.00
1.14

(0.99-1.68)

1.01
1.00
0.92

(0.72-1.41)

2.00
1.00
1.43

(1.14-3.51)

2.09
1.00
1.62

Any Oncogenic HPV Type
a

Multivariable
OR (95% CI)
1.42
1.00
0.97

(1.04-1.94)

1.02
1.00
0.71

(0.66-1.56)

(1.19-4.62)

(0.77-2.65)

2.34
1.00
1.48

(1.01-4.32)

NE

(0.81-3.22)

NE

(0.85-1.54)

(0.61-1.38)

(0.69-1.37)

(0.45-1.10)

(0.69-3.17)

Univariate
OR (95% CI)
1.36
1.00
1.37

(1.04-1.78)

1.21
1.00
1.05

(0.87-1.68)

1.60
1.00
1.89

(0.91-2.80)

2.28
1.00
1.97

Any Non-oncogenic HPV Type
a

Multivariable
OR (95% CI)
1.48
1.00
1.20

(1.08-2.05)

1.11
1.00
0.84

(0.71-1.75)

(0.87-3.18)

(0.85-4.18)

1.67
1.00
2.00

(0.90-5.77)

NE

(0.85-4.59)

NE

(0.97-1.94)

(0.69-1.60)
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(0.80-1.80)

(0.49-1.42)

(0.72-5.60)

Univariate
OR (95% CI)

Multivariablea
OR (95% CI)

1.22
1.00
0.98

(0.86-1.72)
(0.65-1.47)

1.36
1.00
0.82

0.82
1.00
0.86

(0.51-1.32)

NE

(0.47-1.56)

NE

2.31
1.00
1.11

(1.22-4.39)

NE

(0.51-2.41)

NE

1.68
1.00
1.12

(0.74-3.81)

NE

(0.49-2.56)

NE

(0.89-2.06)
(0.52-1.29)

Table D.2 continued
Education
HS Diploma/GED or less
Low
1.48
Moderate
1.00
High
1.50
Some college, no degree
Low
1.11
Moderate
1.00
High
0.95
2-yr/4-yr/Graduate degree
Low
1.57
Moderate
1.00
High
1.31

(0.70-3.16)

NE

(0.69-3.27)

NE

(0.74-1.65)

1.10
1.00
0.67

(0.68-1.77)

1.70
1.00
1.39

(1.06-2.73)

(0.60-1.50)
(1.05-2.35)
(0.82-2.10)

(0.41-1.11)

(0.81-2.41)

1.35
1.00
1.12

(0.53-3.46)

NE

(0.48-2.60)

NE

1.16
1.00
1.04

(0.76-1.77)

1.12
1.00
0.83

(0.65-1.93)

1.50
1.00
2.03

(1.01-2.23)

1.74
1.00
2.44

(1.04-2.90)

(0.61-1.75)

(1.16-3.58)
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(0.46-1.52)

(1.32-4.50)

1.49
1.00
1.41

(0.67-3.32)

NE

(0.52-3.81)

NE

1.10
1.00
0.95

(0.62-1.96)
(0.47-1.95)

1.32
1.00
0.59

1.39
1.00
0.91

(0.86-2.26)

NE

(0.50-1.66)

NE

(0.69-2.52)
(0.22-1.55)

Table D.2 continued
Marital Status
Unmarried, Single
Low
1.20 (0.86-1.69)
Moderate
1.00
High
1.09 (0.70-1.71)
Unmarried, living with a partner
Low
0.83 (0.36-1.93)
Moderate
1.00
High
1.48 (0.59-3.74)
Married
Low
2.05 (1.06-3.97)
Moderate
1.00
High
0.79 (0.39-1.61)
Separated/ Divorced, widowed
Low
1.49 (0.73-3.01)
Moderate
1.00
High
1.49 (0.72-3.08)

1.21
1.00
0.88

(0.80-1.82)

1.23
1.00
1.39

(0.35-4.25)

NE
NE
NE
NE

(0.54-1.42)

(0.39-4.96)

1.44
1.00
1.30

(1.07-1.94)

1.40
1.00
1.08

(0.97-2.02)

0.73
1.00
0.88

(0.28-1.90)

(0.10-2.20)

(0.34-2.29)

0.47
1.00
0.32

1.57
1.00
1.68

(0.74-3.32)

NE

(0.77-3.67)

NE

1.45
1.00
1.39

(0.55-3.82)

NE

(0.53-3.38)

NE

(0.81-2.07)

a

(0.63-1.86)

(0.06-2.06)

0.90
1.00
1.02

(0.54-1.49)

0.89
1.00
0.86

(0.48-1.65)

0.70
1.00
1.61

(0.23-2.09)

(0.29-4.49)

(0.46-5.70)

1.14
1.00
1.15

2.25
1.00
0.43

(1.10-4.59)

NE

(0.18-1.03)

NE

1.84
1.00
1.87

(0.79-4.24)

NE

(0.68-5.14)

NE

(0.53-1.95)

(0.41-1.80)

(0.15-8.66)

Multivariable model adjusted for age, insurance, education, marital status, smoking status, alcohol consumption, lifetime number of sex partners, and prevalence
of HPV infection
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Appendix E. Additional Tables

Tables E.1 and E.2 present the continuous perceived stress and self-reported sleep
problems scale scores by demographics and sexual behaviors.

Table E.1. Stress and Sleep Scale Scores by Demographic Factors.
N
Marital Status
Single
Unmarried, living with a partner
Married
Separated/divorced/widowed
Education
HS Diploma/GED or less
Some college, no degree
2-yr/4-yr/Graduate degree
Age
18 to 20
21 to 22
23 to 31
32 to 49
≥50
Health insurance
No
Yes
Race
Non-white
White
Ethnicity
Non-Hispanic
Hispanic
Main sex partner
No
Yes
Physician determined circumcision
No
Yes

249
51
75
49
49
195
181
93
81
94
99
58
108
312
138
287
346
74
169
250
90
328

Stress Scale
mean (std) p-value
0.11
4.7 (2.6)
4.9 (2.9)
4.4 (2.6)
5.6 (3.1)
<0.01
5.7 (2.3)
4.6 (2.9)
4.7 (2.7)
0.59
4.3 (2.4)
4.6 (2.6)
4.9 (2.7)
5.0 (3.0)
5.0 (3.1)
0.78
4.9 (3.0)
4.7 (2.7)
0.58
4.8 (2.8)
4.7 (2.7)
0.85
4.7 (2.8)
4.7 (2.5)
0.42
4.8 (2.9)
4.6 (2.6)
0.90
4.7 (2.8)
4.8 (2.7)
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N
246
50
72
48
45
191
181
93
80
93
96
55
107
305
133
284
337
75
166
246
90
320

Sleep Scale
mean (std) p-value
0.20
7.2 (3.8)
6.9 (4.3)
7.8 (4.9)
8.8 (4.9)
0.07
7.9 (4.7)
6.9 (4.1)
7.9 (4.3)
0.11
6.4 (3.0)
7.3 (3.7)
7.2 (4.1)
8.6 (5.0)
7.8 (5.3)
0.72
7.5 (4.7)
7.5 (4.1)
<0.01
6.8 (4.7)
7.7 (4.0)
0.91
7.4 (4.3)
7.3 (3.8)
0.70
7.6 (4.2)
7.4 (4.3)
0.14
6.8 (3.9)
7.7 (4.4)

Table E.1 continued
Alcohol
No alcohol
≤1 drink per day
>1 drink per day
Smoking status
Never
Former
Current

0.23
76
172
164

4.7 (2.6)
4.9 (2.7)
4.5 (2.8)

243
94
87

4.5 (2.7)
4.8 (2.6)
5.3 (2.8)

0.03
70
170
163

6.4 (3.9)
7.4 (4.6)
7.9 (4.1)

238
94
84

6.9 (4.1)
8.1 (3.8)
8.2 (4.9)

0.03
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<0.01

Table E.2. Stress and Sleep Scale Scores by Sexual Behavior Factors.

N
Age at first sexual intercourse
≤15
16-17
18-19
≥20
Lifetime number of sex partners
0
1-3
4-9
10-20
≥21
Decline to answer
Any sex past 6 months
No
Yes
Vaginal sex past 6 months
No
Yes
Performed oral sex past 6 months
No
Yes
Received oral sex past 6 months
No
Yes
Insertive anal sex past 6 months
No
Yes
Number of female sex partner past 6 months
0
1
≥2
Condom use during vaginal sex past 6 months
Never
< 1/2 time, 1/2 time, > 1/2 time
Always

101
141
94
51
22
100
97
101
88
17
100
323
120
304
167
254
134
276
366
51
120
193
103
115
124
68

Stress Scale
mean (std) p-value
0.18
4.8 (2.8)
4.4 (2.7)
5.1 (2.8)
4.3 (2.8)
0.48
5.2 (2.1)
4.7 (2.5)
4.6 (2.8)
4.5 (2.5)
5.0 (3.3)
5.5 (2.5)
0.11
5.0 (2.6)
4.7 (2.8)
0.08
5.0 (2.6)
4.6 (2.8)
0.08
5.0 (2.9)
4.6 (2.7)
0.22
4.9 (2.9)
4.6 (2.7)
0.20
4.8 (2.8)
4.3 (2.4)
0.47
4.9 (2.6)
4.8 (2.9)
4.5 (2.6)
0.81
4.7 (2.8)
4.7 (2.5)
4.6 (3.2)
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N
99
140
92
50
21
100
96
100
84
16
97
318
116
300
161
252
130
274
358
51
115
190
103
113
125
65

Sleep Scale
mean (std) p-value
0.13
8.1 (4.7)
7.0 (3.8)
7.9 (4.4)
6.7 (4.2)
<0.01
5.7 (3.9)
6.9 (4.0)
7.0 (3.8)
7.5 (4.2)
9.2 (4.9)
6.1 (3.4)
0.94
7.6 (4.6)
7.4 (4.2)
0.87
7.6 (4.4)
7.4 (4.2)
0.47
7.3 (4.3)
7.6 (4.3)
0.61
7.3 (4.5)
7.5 (4.1)
0.14
7.6 (4.3)
6.6 (4.1)
0.77
7.6 (4.5)
7.2 (4.3)
7.6 (4.1)
0.70
7.8 (4.7)
7.1 (3.8)
7.3 (4.0)

For the baseline prevalence analysis PRs were calculated comparing quartiles of
perceived stress and sleep problems. Results did not differ from the categorized analysis.

Table E.3. Associations between quartiles of perceived stress and sleep problems with
prevalence of any HPV type, any oncogenic HPV type, and any non-oncogenic HPV
type.

Any HPV Type
Multivariable 1
PR (95% CI)

Univariate
Multivariable 2
PR (95% CI)
PR (95% CI)
Perceived Stress Score Quartiles
1st
1.00
1.00
1.00
2nd
1.09 (0.80-1.49)
1.08 (0.80-1.46)
1.11
(0.82-1.50)
3rd
0.92 (0.65-1.29)
0.94 (0.67-1.32)
0.96
(0.68-1.35)
4th
1.32 (0.98-1.79)
1.38 (1.03-1.86)
1.37
(1.01-1.87)
Self-reported Sleep Problems quartiles
1st
1.30 (0.94-1.81)
1.37
(1.01-1.86)
1.36
(1.01-1.84)
2nd
1.00
1.00
1.00
3rd
1.12 (0.79-1.58)
1.16 (0.84-1.58)
1.13
(0.83-1.55)
4th
1.49 (1.08-2.06)
1.31 (0.97-1.77)
1.25
(0.91-1.70)
Any Oncogenic HPV Type
Univariate
Multivariable 1
Multivariable 2
PR (95% CI)
PR (95% CI)
PR (95% CI)
Perceived Stress Score Quartiles
1st
1.00
1.00
1.00
2nd
0.98 (0.61-1.55)
0.96 (0.61-1.50)
1.00
(0.62-1.60)
3rd
0.74 (0.44-1.25)
0.69 (0.40-1.18)
0.72
(0.42-1.24)
4th
1.31 (0.84-2.05)
1.40 (0.90-2.19)
1.38
(0.84-2.26)
Self-reported Sleep Problems quartiles
1st
1.45 (0.87-2.44)
1.66 (1.02-2.70)
1.66
(1.02-2.70)
2nd
1.00
1.00
1.00
3rd
1.00 (0.57-1.77)
1.16 (0.68-1.97)
1.11
(0.65-1.89)
4th
1.89 (1.16-3.09)
1.73 (1.07-2.79)
1.58
(0.97-2.59)
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Table E.3 continued
Any Non-oncogenic HPV Type
Univariate
Multivariable 1
Multivariable 2
PR (95% CI)
PR (95% CI)
PR (95% CI)
Perceived Stress Score Quartiles
1st
1.00
1.00
1.00
2nd
1.34 (0.78-2.32)
1.31 (0.78-2.19)
1.33
(0.80-2.22)
3rd
1.14 (0.64-2.02)
1.18 (0.67-2.06)
1.2
(0.68-2.10)
4th
1.64 (0.95-2.84)
1.65 (0.98-2.79)
1.66
(0.97-2.84)
Self-reported Sleep Problems quartiles
1st
1.35 (0.79-2.29)
1.34 (0.81-2.20)
1.31
(0.80-2.16)
2nd
1.00
1.00
1.00
3rd
1.29 (0.76-2.17)
1.25 (0.77-2.01)
1.22
(0.76-1.97)
4th
1.43 (0.83-2.46)
1.08 (0.64-1.83)
1.01
(0.59-1.75)
a
Multivariable 1 model adjusted for age, insurance, education, marital status, and number
of vaginal sex partners in the past 6 months, Multivariable 2 model additionally adjusted
for sleep category
b
Multivariable 1 model adjusted for age, insurance, education, marital status, smoking
status, alcohol consumption and lifetime number of sex partners, Multivariable 2 model
additionally adjusted for perceived stress category
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An additional table of perceived stress by category of sleep problems and sleep problems by category of perceived stress was
also calculated for the baseline prevalence analysis.

Table E.4. Unadjusted Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV
infection among participants with high perceived stress to participants with low perceived stress stratified by age category and sexual
behavior.

Any HPV
Perceived
Stress
Sleep Category
Low
Moderate
High

Low
High
Low
High
Low
High
Sleep

Perceived Stress Category
Low
Low
Moderate
High
High
Low
Moderate
High

N

Univariate
PR (95% CI)
1.00
(0.67-1.98)
1.00
1.32 (0.91-1.90)
1.00
1.24 (0.87-1.76)
Univariate
PR (95% CI)
1.15

1.26

(0.94-1.69)
1.00
1.35 (0.97-1.87)
1.10 (0.61-2.00)
1.00
1.27 (0.86-1.88)

Oncogenic HPV
Multivariate
PR (95% CI)

1.36
1.45
1.23

1.32
1.25
0.97
1.07

Perceived
Stress

1.00
(0.79-2.36)
1.00
(1.003-2.10)
1.00
(0.86-1.76)

Low
High
Low
High
Low
High
Sleep

(1.004-1.72)
1.00
(0.93-1.67)
(0.60-1.56)
1.00
(0.62-1.84)

Low
Moderate
High
Low
Moderate
High
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Non-Oncogenic HPV

Univariate
PR (95% CI)

Perceived
Stress

1.00
(0.38-2.70)
1.00
1.43 (0.75-2.70)
1.00
1.32 (0.79-2.21)
Univariate
PR (95% CI)

Low
High
Low
High
Low
High
Sleep

1.01

1.56
1.79
1.11
1.67

(0.99-2.47)
1.00
(1.09-2.96)
(0.38-3.25)
1.00
(0.87-3.18)

Low
Moderate
High
Low
Moderate
High

Univariate
PR (95% CI)
1.00
(0.61-3.31)
1.00
1.41 (0.80-2.46)
1.00
1.36 (0.68-2.74)
Univariate
PR (95% CI)
1.42

1.15
1.15
1.16
1.12

(0.72-1.85)
1.00
(0.65-2.06)
(0.47-2.85)
1.00
(0.57-2.21)

Full tables of stress and sleep stratified by all variables included in multivariable models for the gee prevalence analysis were
also created.

Table E.5. Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV infection
among participants with high perceived stress to participants with low perceived stress stratified by demographics and sexual
behavior.

Any HPV Type
Perceived stress
Total sample
Low
High

Univariate
OR (95% CI)

Any Oncogenic HPV Type
a

Multivariable
OR (95% CI)

Univariate
OR (95% CI)

Any Non-oncogenic HPV Type
a

Multivariable
OR (95% CI)

Univariate
OR (95% CI)

Multivariablea
OR (95% CI)

1.00
1.33

(0.96-1.84)

1.00
1.40

(0.99-1.98)

1.00
1.40

(1.02-1.93)

1.00
1.48

(1.06-2.07)

1.00
1.17

(0.80-1.72)

1.00
1.14

1.00
1.03

(0.70-1.51)

1.00
1.06

(0.71-1.57)

1.00
1.17

(0.77-1.77)

1.00
1.38

(0.88-2.18)

1.00
1.06

(0.61-1.84)

1.00
NE

1.00
1.26

(0.76-2.09)

1.00
1.26

(0.74-2.16)

1.00
1.37

(0.73-2.58)

1.00
1.41

(0.73-2.75)

1.00
1.21

(0.64-2.28)

1.00
1.19

(0.60-2.34)

1.00
1.74

(0.73-4.14)

1.00
1.82

(0.64-5.13)

1.00
2.48

(1.03-5.96)

1.00
3.66

(1.25-10.67)

1.00
1.13

(0.43-3.01)

1.00
1.11

(0.36-3.45)

(0.78-1.68)

b

Age
18 to 29
Low
High
30 to 49
Low
High
≥50
Low
High
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Table E.5 continued
Education
HS Diploma/GED or less
Low
1.00
High
1.54
Some college, no degree
Low
1.00
High
0.91
2-yr/4-yr/Graduate degree
Low
1.00
High
1.55
Health insurance
No
Low
1.00
High
1.20
Yes
Low
1.00
High
1.30

(0.61-3.90)

1.00
1.42

(0.50-4.04)

1.00
1.46

(0.47-4.50)

1.00
1.20

(0.34-4.25)

1.00
1.28

(0.41-3.99)

1.00
1.08

(0.27-4.28)

(0.63-1.33)

1.00
0.90

(0.60-1.36)

1.00
1.18

(0.74-1.87)

1.00
1.26

(0.74-2.13)

1.00
0.77

(0.44-1.34)

1.00
0.72

(0.41-1.29)

(0.97-2.47)

1.00
1.66

(1.03-2.67)

1.00
1.44

(0.99-2.08)

1.00
1.60

(1.01-2.52)

1.00
1.73

(0.96-3.13)

1.00
1.70

(0.94-3.09)

(0.64-2.24)

1.00
1.28

(0.66-2.50)

1.00
1.45

(0.66-3.23)

1.00
2.03

(0.87-4.74)

1.00
1.00

(0.49-2.05)

1.00
0.98

(0.47-2.04)

(0.96-1.76)

1.00
1.32

(0.97-1.81)

1.00
1.42

(1.01-1.99)

1.00
1.51

(1.05-2.17)

1.00
1.25

(0.83-1.89)

1.00
1.22

(0.81-1.86)
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Table E.5 continued
Marital Statusb
Unmarried, Single
Low
1.00
1.00
High
1.38 (0.90-2.11) 1.48
Unmarried, living with partner
Low
1.00
1.00
High
0.95 (0.41-2.17) 1.11
Married
Low
1.00
1.00
High
0.84 (0.47-1.49) 0.86
Separated/ Divorced, widowed
Low
1.00
1.00
High
1.81 (0.95-3.44) 1.76
Number of vaginal sex partners in the past 6 months
0
Low
1.00
1.00
High
1.67 (0.92-3.03) 1.48
1
Low
1.00
1.00
High
1.15 (0.81-1.65) 1.12
≥2
Low
1.00
1.00
High
1.63 (0.81-3.27) 1.71

(0.96-2.27)

1.00
1.73

(1.11-2.71)

1.00
2.03

(1.29-3.22)

1.00
1.26

(0.70-2.25)

1.00
1.23

(0.68-2.21)

(0.41-3.01)

1.00
0.56

(0.17-1.81)

1.00
0.52

(0.14-1.88)

1.00
1.78

(0.63-5.06)

1.00
1.55

(0.42-5.70)

(0.45-1.64)

1.00
0.81

(0.42-1.56)

1.00
0.84

(0.31-2.26)

1.00
0.95

(0.49-1.86)

1.00
1.00

(0.48-2.08)

(1.05-2.93)

1.00
1.79

(0.80-4.02)

1.00
1.99

(0.96-4.12)

1.00
1.40

(0.76-2.57)

1.00
NE

(0.77-2.83)

1.00
1.99

(1.06-3.73)

1.00
1.98

(0.98-4.01)

1.00
1.60

(0.71-3.60)

1.00
1.08

(0.44-2.65)

(0.76-1.64)

1.00
1.45

(0.94-2.22)

1.00
1.44

(0.91-2.27)

1.00
1.07

(0.69-1.66)

1.00
0.99

(0.63-1.56)

(0.85-3.45)

1.00
1.49

(0.74-3.01)

1.00
1.55

(0.76-3.18)

1.00
2.00

(0.83-4.81)

1.00
2.17

(0.4-5.62)

a

Multivariable model adjusted for age, insurance, education, marital status, smoking status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV infection

b

Interaction with stress significant in multivariable model for any HPV, oncogenic HPV, or non-oncogenic HPV model
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Table E.6. Odds Ratios comparing prevalence of any HPV Infection, oncogenic HPV infection, and non-oncogenic HPV infection
among participants with low and high sleep problems compared to those with moderate sleep problems stratified by demographics and
sexual behavior.

Any HPV Type
Sleep problems
Total sample
Low
Moderate
High

Univariate
OR (95% CI)
1.29
1.00
1.14

(0.99-1.68)

1.01
1.00
0.92

(0.72-1.41)

2.00
1.00
1.43

(1.14-3.51)

2.09
1.00
1.62

Any Oncogenic HPV Type
a

Multivariable
OR (95% CI)
1.42
1.00
0.97

(1.04-1.94)

1.02
1.00
0.71

(0.66-1.56)

(1.19-4.62)

(0.77-2.65)

2.34
1.00
1.48

(1.01-4.32)

NE

(0.81-3.22)

NE

(0.85-1.54)

(0.69-1.37)

Univariate
OR (95% CI)
1.36
1.00
1.37

(1.04-1.78)

1.21
1.00
1.05

(0.87-1.68)

1.60
1.00
1.89

(0.91-2.80)

2.28
1.00
1.97

Any Non-oncogenic HPV Type
a

Multivariable
OR (95% CI)
1.48
1.00
1.20

(1.08-2.05)

1.11
1.00
0.84

(0.71-1.75)

(0.87-3.18)

(0.85-4.18)

1.67
1.00
2.00

(0.90-5.77)

NE

(0.85-4.59)

NE

(0.97-1.94)

(0.80-1.80)

Univariate
OR (95% CI)

Multivariablea
OR (95% CI)

1.22
1.00
0.98

(0.86-1.72)
(0.65-1.47)

1.36
1.00
0.82

0.82
1.00
0.86

(0.51-1.32)

NE

(0.47-1.56)

NE

2.31
1.00
1.11

(1.22-4.39)

NE

(0.51-2.41)

NE

1.68
1.00
1.12

(0.74-3.81)

NE

(0.49-2.56)

NE

b

Age
18 to 29
Low
Moderate
High
30 to 49
Low
Moderate
High
≥50
Low
Moderate
High

(0.61-1.38)

(0.45-1.10)

(0.69-3.17)

(0.69-1.60)
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(0.49-1.42)

(0.72-5.60)

(0.89-2.06)
(0.52-1.29)

Table E.6 continued
Educationb
HS Diploma/GED or less
Low
1.48 (0.70-3.16)
Moderate
1.00
High
1.50 (0.69-3.27)
Some college, no degree
Low
1.11 (0.74-1.65)
Moderate
1.00
High
0.95 (0.60-1.50)
2-yr/4-yr/Graduate degree
Low
1.57 (1.05-2.35)
Moderate
1.00
High
1.31 (0.82-2.10)
Health insurance
No
Low
1.69 (0.97-2.94)
Moderate
1.00
High
1.59 (0.91-2.78)
Yes
Low
1.07 (0.79-1.46)
Moderate
1.00
High
1.01 (0.70-1.46)

NE
NE
1.10
1.00
0.67

(0.68-1.77)

1.70
1.00
1.39

(1.06-2.73)

1.88
1.00
1.13

(0.87-4.05)

1.19
1.00
0.89

(0.83-1.71)

(0.41-1.11)

(0.81-2.41)

(0.54-2.34)

(0.59-1.34)

1.35
1.00
1.12

(0.53-3.46)

NE

(0.48-2.60)

NE

1.16
1.00
1.04

(0.76-1.77)

1.12
1.00
0.83

(0.65-1.93)

1.50
1.00
2.03

(1.01-2.23)

1.74
1.00
2.44

(1.04-2.90)

1.43
1.00
1.47

(0.79-2.61)

1.56
1.00
1.11

(0.67-3.61)

1.17
1.00
1.33

(0.87-1.58)

1.30
1.00
1.27

(0.90-1.89(

(0.61-1.75)

(1.16-3.58)

(0.70-3.09)

(0.90-1.95)
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(0.46-1.52)

(1.32-4.50)

(0.42-2.97)

(0.81-1.97)

1.49
1.00
1.41

(0.67-3.32)

NE

(0.52-3.81)

NE

1.10
1.00
0.95

(0.62-1.96)
(0.47-1.95)

1.32
1.00
0.59

1.39
1.00
0.91

(0.86-2.26)

NE

(0.50-1.66)

NE

1.70
1.00
1.24

(0.89-3.25)

NE

(0.64-2.40)

NE

1.05
1.00
0.87

(0.67-1.64)

1.13
1.00
0.74

(0.50-1.53)

(0.69-2.52)
(0.22-1.55)

(0.67-1.91)
(0.40-1.38)

Table E.6 continued
Marital Statusb
Unmarried, Single
Low
1.20 (0.86-1.69)
Moderate
1.00
High
1.09 (0.70-1.71)
Unmarried, living with a partner
Low
0.83 (0.36-1.93)
Moderate
1.00
High
1.48 (0.59-3.74)
Married
Low
2.05 (1.06-3.97)
Moderate
1.00
High
0.79 (0.39-1.61)
Separated/ Divorced, widowed
Low
1.49 (0.73-3.01)
Moderate
1.00
High
1.49 (0.72-3.08)

1.21
1.00
0.88

(0.80-1.82)

1.23
1.00
1.39

(0.35-4.25)

NE
NE
NE
NE

(0.54-1.42)

(0.39-4.96)

1.44
1.00
1.30

(1.07-1.94)

1.40
1.00
1.08

(0.97-2.02)

0.73
1.00
0.88

(0.28-1.90)

(0.10-2.20)

(0.34-2.29)

0.47
1.00
0.32

1.57
1.00
1.68

(0.74-3.32)

NE

(0.77-3.67)

NE

1.45
1.00
1.39

(0.55-3.82)

NE

(0.53-3.38)

NE

(0.81-2.07)
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(0.63-1.86)

(0.06-2.06)

0.90
1.00
1.02

(0.54-1.49)

0.89
1.00
0.86

(0.48-1.65)

0.70
1.00
1.61

(0.23-2.09)

(0.29-4.49)

(0.46-5.70)

1.14
1.00
1.15

2.25
1.00
0.43

(1.10-4.59)

NE

(0.18-1.03)

NE

1.84
1.00
1.87

(0.79-4.24)

NE

(0.68-5.14)

NE

(0.53-1.95)

(0.41-1.80)

(0.15-8.66)

Table E.6 continued
Lifetime number of sex partners
0
Low
3.65 (0.58-22.94)
Moderate
1.00
High
3.94 (0.30-52.20)
1 to 3
Low
1.01 (0.49-2.10)
Moderate
1.00
High
0.13 (0.01-1.32)
4 to 9
Low
1.09 (0.64-1.85)
Moderate
1.00
High
1.02 (0.58-1.81)
10 to 20
Low
1.18 (0.66-2.09)
Moderate
1.00
High
1.20 (0.68-2.12)
≥21
Low
2.31 (1.01-5.31)
Moderate
1.00
High
0.94 (0.50-1.78)

NE

NE

NE

NE

NE

NE

1.92
1.00
9.31

NE

2.02
1.00
0.53

(0.74-5.56)

NE

NE

NE

(0.08-3.56)

NE

NE

NE

1.08
1.00
1.09

(0.63-1.86)

NE

(0.46-2.28)

NE

(0.57-2.08)

NE

1.02
1.00
1.37

(0.56-3.40)

NE

1.15
1.00
1.33

(0.66-1.98)

1.22
1.00
1.44

(0.68-2.20)

1.31
1.00
0.83

(0.64-2.69)

1.23
1.00
0.60

(0.55-2.77)

1.78
1.00
1.08

(0.79-4.00)

1.22
1.00
0.90

(0.52-2.86)

2.46
1.00
0.83

(0.87-6.94)

2.45
1.00
0.96

(0.78-7.72)

NE
1.10
1.00
1.10

(0.61-1.97)

1.26
1.00
1.18

(0.68-2.34)

2.03
1.00
0.88

(0.80-5.16)

(0.65-1.84)

(0.62-2.22)

(0.44-1.74)

(0.69-2.57)

(0.52-2.26)
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(0.74-2.79)

(0.39-2.09)

(0.10-38.17)

NE

(0.39-223.47)

NE

(0.44-1.57)

(0.36-1.92)

(0.27-1.33)

(0.41-2.22)

Table E.6 continued
Smoking status
Never
Low
Moderate
High
Former
Low
Moderate
High
Current
Low
Moderate
High
Alcohol
No alcohol
Low
Moderate
High
≤1 drink per day
Low
Moderate
High
>1 drink per day
Low
Moderate
High

1.29
1.00
1.11

(0.90-1.85)

1.39
1.00
1.00

(0.91-2.13)

1.14
1.00
1.10

(0.65-2.02)

(0.54-1.97)

(0.60-2.00)

1.03
1.00
0.87

1.65
1.00
1.28

(0.77-3.56)

NE

(0.69-2.37)

NE

0.85
1.00
1.24

(0.47-1.55)

NE

(0.81-1.91)

NE

1.23
1.00
1.24

(0.81-1.88)

1.14
1.00
0.91

(0.71-1.82)

1.51
1.00
0.96

(0.94-2.43)

2.05
1.00
0.94

(1.19-3.52)

(0.71-1.73)

(0.80-1.93)

(0.56-1.63)

(0.61-1.65)

(0.44-1.71)

(0.52-1.58)

(0.51-1.72)

1.46
1.00
1.44

(1.02-2.09)

1.61
1.00
1.34

(1.03-2.51)

1.05
1.00
1.17

(0.55-2.01)

(0.45-2.07)

(0.61-2.26)

0.97
1.00
1.42

1.53
1.00
1.42

(0.71-3.32)

NE

(0.66-3.09)

NE

0.77
1.00
1.28

(0.51-1.19)

NE

(0.78-2.09)

NE

1.38
1.00
1.49

(0.88-2.17)

NE

(0.86-2.59)

NE

1.55
1.00
1.25

(0.90-2.69)

2.13
1.00
1.25

(0.85-2.43)

(0.68-2.30)

a

(0.72-2.47)

(0.67-3.02)

(1.14-3.96)
(0.64-2.43)

1.07
1.00
0.83

(0.69-1.68)

NE

(0.49-1.39)

NE

1.27
1.00
1.00

(0.59-2.77)

NE

(0.39-2.52)

NE

1.81
1.00
1.15

(0.72-4.57)

NE

(0.53-2.47)

NE

0.91
1.00
1.20

(0.39-2.10)

NE

(0.67-2.18)

NE

1.05
1.00
1.01

(0.66-1.66)
(0.61-1.66)

0.91
1.00
0.66

1.43
1.00
0.69

(0.77-2.66)

NE

(0.32-1.50)

NE

(0.47-1.77)
(0.34-1.27)

Multivariable model adjusted for age, insurance, education, marital status, smoking status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV infection
Interaction with stress significant in multivariable model for any HPV, oncogenic HPV, or non-oncogenic HPV model

b
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Associations between self-reported sleep problems were further examined by
categorizing sleep problems the same as perceived stress with the top 25% as high and
the bottom 75% as low. Results were similar when 3 categories are used, although only
multivariable model 2 for any HPV type and any oncogenic HPV type was significant.

Table E.7. Associations between HPV clearance and self-reported sleep problems
categorized as high and low.

Sleep problemsb
Low
High
Sleep problemsb
Low
High

Univariate
Multivariable 1
HR (95% CI)
HR (95% CI)
Any HPV type

Multivariable 2
HR (95% CI)

1.00
1.00
0.84 (0.63-1.10)
0.78 (0.57-1.06)
Any Oncogenic HPV type

1.00
0.68 (0.50-0.93)

1.00
1.00
0.95 (0.75-1.22)
0.65 (0.40-1.05)
Any Non-oncogenic HPV type

1.00
0.56 (0.32-0.99)

Sleep problemsb
Low
1.00
1.00
1.00
High
0.91 (0.64-1.30)
0.87 (0.60-1.27)
0.75 (0.49-1.15)
a
Multivariable 1 model adjusted for age, insurance, education, marital status, number of
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable
2 model additionally adjusted for sleep category
b
Multivariable 1 model adjusted for age, insurance, education, marital status, smoking
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV
infection, Multivariable 2 model additionally adjusted for perceived stress category
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Associations between perceived stress and self-reported sleep problems with
incidence of HPV infection are presented below. Per infection incidence was analyzed,
therefore men can contribute multiple infections to the analysis.
Table E.8 . Associations between perceived stress and self-reported sleep problems with
incidence of any HPV type, any oncogenic HPV type, and any non-oncogenic HPV type
among men tested for HPV every 6 months.

Any HPV Type (n=336)
Univariate
Multivariable 1
HR (95% CI)
HR (95% CI)
Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

Perceived Stressa
Low
High
Sleep problemsb
Low
Moderate
High

1.00
0.95 (0.68-1.33)

Multivariable 2
HR (95% CI)

1.00
1.01 (0.72-1.41)

1.00
1.02 (0.74-1.42)

0.97 (0.67-1.39)
0.96 (0.67-1.36)
1.00
1.00
0.85 (0.57-1.28)
0.75 (0.49-1.16)
Oncogenic HPV (n=156)
Univariate
Multivariable 1
HR (95% CI)
HR (95% CI)

0.96 (0.67-1.38)
1.00
0.74 (0.49-1.13)

1.00
0.86 (0.56-1.34)

1.00
0.97 (0.62-1.50)

1.00
0.90 (0.57-1.43)

0.91 (0.57-1.46)
1.00
1.07 (0.66-1.72)

0.80 (0.49-1.31)
1.00
0.90 (0.55-1.46)

0.81 (0.49-1.32)
1.00
0.91 (0.56-1.47)

Non-oncogenic HPV (n=180)
Univariate
Multivariable 1
HR (95% CI)
HR (95% CI)

Multivariable 2
HR (95% CI)

Multivariable 2
HR (95% CI)

1.00
1.01 (0.69-1.49)

1.00
1.04 (0.71-1.53)

1.00
1.11 (0.76-1.62)

1.01 (0.65-1.56)
1.00
0.71 (0.45-1.13)

1.05 (0.70-1.59)
1.00
0.65 (0.39-1.07)

1.05 (0.69-1.61)
1.00
0.63 (0.39-1.02)
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Table E.8 continued
a

Multivariable 1 model adjusted for age, insurance, education, marital status, number of
vaginal sex partners in the past 6 months, and prevalence of HPV infection, Multivariable
2 model additionally adjusted for sleep category
b
Multivariable 1 model adjusted for age, insurance, education, marital status, smoking
status, alcohol consumption, lifetime number of sex partners, and prevalence of HPV
infection, Multivariable 2 model additionally adjusted for perceived stress category
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Table E.9. Associations of categorized sleep duration with HPV prevalence in the total sample and HPV clearance among HPV-positive men.

Any HPV Type
Univariate
OR (95% CI)
Sleep time category
Less than 5 hours
5 to 6 hours
6 to 7 hours
7 to 9 hours
9 or more hours

1.35
0.97
1.31
1.00
1.28

(0.72-2.55)
(0.63-1.50)
(0.99-1.71)
(0.70-2.33)

Univariate
HR (95% CI)

Any Oncogenic HPV Type
GEE Analysis
Multivariablea
OR (95% CI)
1.31
1.53
1.23
1.00
1.40

(0.65-2.64)
(0.998-2.35)
(0.76-2.00)
(0.66-3.00)

Multivariable
HR (95% CI)

Univariate
OR (95% CI)
1.49
0.95
1.24
1.00
1.10

(0.66-3.34)
(0.56-1.62)
(0.91-1.68)
(0.58-2.10)

Clearance Analysis
Univariate
HR (95% CI)

Multivariablea
OR (95% CI)
1.09
0.82
1.18
1.00
0.96

(0.48-2.49)
(0.47-1.45)
(0.81-1.70)
(0.49-1.91)

Multivariable
HR (95% CI)

Any Non-oncogenic HPV Type
Univariate
OR (95% CI)
1.31
0.98
1.40
1.00
1.34

(0.61-2.80)
(0.58-1.67)
(0.98-2.01)
(0.63-2.88)

Univariate
HR (95% CI)

Multivariablea
OR (95% CI)
1.06
0.78
1.31
1.00
1.04

(0.45-2.53)
(0.42-1.46)
(0.87-1.96)
(0.42-2.54)

Multivariable
HR (95% CI)

Sleep time category
Less than 5 hours
0.95 (0.48-1.89) 1.03 (0.50-2.10)
0.92 (0.23-3.71)
1.31 (0.25-6.90)
0.92 (0.42-2.01) 0.84 ((0.39-1.80)
5 to 6 hours
0.88 (0.54-1.42) 0.84 (0.51-1.38)
1.06 (0.60-1.88)
1.18 (0.62-2.26)
0.77 (0.41-1.44) 0.65 (0.36-1.16)
6 to 7 hours
0.93 (0.69-1.27) 0.79 (0.57-1.09)
1.18 (0.79-1.76)
1.40 (0.88-2.23)
0.79 (0.54-1.16) 0.49 (0.32-0.75)
7 to 9 hours
1.00
1.00
1.00
1.00
1.00
1.00
9 or more hours
0.83 (0.49-1.41) 0.76 (0.43-1.36)
1.20 (0.63-2.28)_ 1.12 (0.45-2.78)
0.60 (0.28-1.29) 0.42 (0.19-0.95)
a
Multivariable model adjusted for age, insurance, education, marital status, smoking status, alcohol consumption, lifetime number of sex partners, and prevalence
of HPV infection.
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